Effects of L-Carnitine on Growth Performance, Apparent Nutrient Digestibility, and Whole Body Composition in Weanling Pigs by Rincker, Michael James
EFFECTS OF L-CARNITINE ON GROWTH
PERFORMANCE, APPARENT NUTRIENT
DIGESTIBILITY, AND WHOLE
BODY COMPOSITION IN
WEANLING PIGS
By
MICHAEL JAMES RINCKER
Bachelor of Science
Oklahoma State University
Stillwater, Oklahoma
1999
Submitted to the Faculty of the
Graduate College of the
Oklahoma State University
in partial fulfillment of
the requirements
for the Degree of
MASTER OF SCIENCE
August, 2001
EFFECTS OF L-CARNlTINE ON GROWTH
PERFORMANCE, APPARENT NUTRlENT
OIGESTIBrLITY, AND WHOLE
BODY COMPOSITION IN
WEANLING PIGS
Thesis Approved:
------.~-Ie-g-e----
II
ACKNOWLEDGEMENTS
The work of this thesis would not be complete without expressing my sincere
gratitude to several individuals. Without the support of my family and friends this
project would not have been attainable and for that I'm forever indebted to you. First, I
would like to thank the people that have been the most instrumental in my life, my
parents, Jim and Sharon. Everything that I havc become and everything that I have
accomplished is because of the life lessons you taught me as a child. As well, the support
and love that I have received in life from my brother and sister, Matt and Kim, have been
the greatest of inspirations in my accomplishments.
Next, I would like to thank everybody at Oklahoma State. These people have
made my educational experience an extremely enjoyable one and one that 1 wiH never
forget. My sincere appreciation goes out to my major advisor, Dr. Scott Carter, for the
care and understanding you have shown me. I would also like to thank you for your
knowledge of the swine industry that you have shared with me. Also, I would like to
extend my appreciation to my committee members, Dr. Bob Teeter, and Dr. Barbara
Stoecker. I would also like to thank Russell Fent, a true friend. I realize a person is only
blessed with a friendship like that a few times throughout their life. I am also extremely
grateful for all the help and knowledge that Brandon Senne, Allen Pettey, Jared Shriver,
and Jin-Seong Park provided. A guy couldn't ask for a better group of friends to work
with. Again, thank you to everyone.
111
Chapter
TABLE OF CONTENTS
Page
INTRODUCTION 1
1. REVIEW OF LITERATURE
History 4
Biosynthesis ofCamitine 7
Metabolism of Camitine 11
Functions of Carnitine 14
Role ofL-Carnitine in Human Nutrition 20
Role of L-Carnitine in Swine Nutrition
Dietary Sources of Camitine 24
Neonatal Nutrition 26
Weanling Pig Nutrition 29
GrowerlFinisher Pig Nutrition 32
Sow Nutrition 34
Conclusions 34
II. EFFECTS OF L-CARNITINE ON GROWTH PERFORMANCE OF
WEANLING PIGS
Abstract 36
Introduction 37
Materials and Methods 38
Results 42
Discussion 43
Implications 45
III. EFFECTS OF L-CARNITINE IN THE DIET OF WEANLING PIGS ON
APPARENT NUTRIENT DIGESTIBILITY, WHOLE BODY COMPSITION,
TISSUE ACCRETION, AND BLOOD METABOLITES
Abstract 47
Introduction 48
Materials and Methods 50
Results 56
Discussion 61
Implications 64
IV
Chapter Page
IV. EFFECTS OF L-CARNITINE AND SOYBEAN OIL ON GROWTH
PERFORMANCE IN WEANLING PIGS
Abstract 65
Introduction 66
Materi als and Methods 67
Results 72
Discussion 75
Implications 77
V. EFFECTS OF L-CARNITINE AND SOURCE OF DIETARY FAT ON
GROWTH PERFORMANCE OF WEANLING PIGS
Abstract 78
Introduction 79
Material s and Methods 81
Results 85
Discussion 88
Implications 90
VI. SUMMARY AND CONCLUSIONS 91
VII. LITERATURE CITED 96
APPENDIX 105
v
Table
LIST OF TABLES
CHAPTER I
Page
1.1 Camitine concentrations found in animal and plant products 25
CHAPTER II
2.1 Composition of control diets (as-is basis) 39
2.2 Chemical composition of control diets (as-is basis) .41
2.3 L-Carnitine concentration of diets .41
2.4 Growth performance ofweanling pigs 43
CHAPTER III
3.1 Growth performance of weanling pigs 56
3.2 Apparent energy digestibility of weanling pigs 57
3.3 Nitrogen balance of weanling pigs 58
3.4 Whole body composition and tissue accretion of weanling pigs 59
3.5 Blood metabolites of weanling pigs 60
CHAPTER IV
4.1 Composition of basal diets (as-is basis) 68
4.2 Chemical composition of basal diets (as-is basis) 70
4.3 L-Camitine concentration of diets 71
4.4 Growth performance ofweanling pigs 73
4.5 Blood metabolites of weanling pigs 74
CHAPTER V
5.1 Composition of control diets (as-is basis) 82
5.2 Chemical composition of control diets (as-is basis) 83
5.3 L-Camitine concentration of diets 84
5.4 Growth performance of weanling pigs 87
APPENDIX
1. Pen means for average daily gain, average daily feed intake, and gain:feed for
Phases 1 and 2 - Experiment 1 106
Vl
Table Page
2. Analysis of variance for average daily gain, average daily feed intake, and
gain:feed for Phases 1 and 2 - Experiment I 107
3. Pen means for average daily gain, average daily feed intake, and gain:feed for
Phase 3 and the entire 38-d period - Experiment 1 108
4. Analysis of variance for average daily gain, average daily feed intake, and
gain:feed for Phase 3 and the entire 38-d period - Experiment 1 109
5. Pen means for initial and final body weight, average daily gain, average daily feed
intake, and gain:feed for the entire 38-d period - Experiment 2 110
6. Analysis of variance for average daily gain, average daily feed intake, and
gain: feed for the entire 38-d period - Experiment 2 Ill
7. Pen means for average daily feed intake, gross energy intake, fecal energy
excretion, and digestible energy (kcal/d, kcal/kg) - Experiment 2 (Period 1) .... 11 ~
8. Analysis of variance for average daily feed intake, gross energy intake, fecal
energy excretion, and digestible energy (kcalld, kcal/kg) - Experiment 2 (Period
1) 113
9. Pen means for fecal excretion and urine excretion, urinary energy, and
metabolizable energy (kcal/d, kcal/kg) - Experiment 2 (Period 1) 114
10. Analysis of variance for fecal excretion and urine excretion, urinary energy and
metabolizable energy (kcal/d, kcal/kg) - Experiment 2 (Period 1) 115
11. Pen means for energy ratios - Experiment 2 (Period 1) 116
12. Analysis of variance for energy ratios - Experiment 2 (Period 1) 117
13. Pen means for average daily feed intake, gross energy intake, fecal energy
excretion, and digestible energy (kcal/d, kcallkg) - Experiment 2 (Period 2) .... 118
14. Analysis of variance for average daily feed intake, gross energy intake, fecal
energy excretion, and digestible energy (Kcal/d, kcallkg) - Experiment 2 (Period
2) 119
15. Pen means for fecal excretion and urine excretion, urinary, energy and
metabolizable energy (kcalld, kcallkg) - Experiment 2 (Period 2) 120
16. Analysis of variance for fecal and urine excretion, urinary energy, and
metabolizable energy (kcal/kg, kcal/kg) - Experiment 2 (Period 2) 121
vii
Table Page
17. Pen means for energy ratios - Experiment 2 (Period 2) 122
18. Analysis of variance for energy ratios - Experiment 2 (Period 2) 123
19. Pen means for average daily feed intake, gross energy intake, fecal energy
excretion, and digestible energy (kcal/d, kcal/kg) - Experiment 2 (Period 3) .... 124
20. Analysis of variance for average daily feed intake, gross energy intake, fecal
energy excretion, and digestible energy (kcal/d, kcal/kg) - Experiment 2 (Period
3) 125
21. Pen means for fecal and urine excretion, urinary energy and metabolizable energy
(kcal/d, kcal/kg) - Experiment 2 (Period 3) 126
22. Analysis of variance for fecal and urine excretion, urinary energy and
metabolizable energy (kcal/d, kca1/kg) - Experiment 2 (Period 3) 127
23. Pen means for energy ratios - Experiment 2 (Period 3) 128
24. Analysis of variance for energy ratios - Experiment 2 (Period 3) 129
25. Analysis of variance for average daily feed intake, gross energy intake, fecal
energy excretion, and digestible energy (kcalld, kcal/kg) - Experiment 2 (Period 2
& 3 pooled) 130
26. Analysis of variance for urinary energy and metabolizable energy (kcal/d,
kcal/kg) - Experiment 2 (Period 2 & 3 pooled) 13l
27. Analysis of variance for energy ratios - Experiment 2 (Periods 2 & 3 pooled) .. 132
28. Pen means for average daily feed intake, nitrogen intake, nitrogen excretion, and
nitrogen absorbed (g/d, %) - Experiment 2 (Period 1) 133
29. Analysis of variance for average daily feed intake, nitrogen intake, fecal nitrogen
excretion, and nitrogen absorbed (g/d, %) - Experiment 2 (Period 1) 134
30. Pen means for urinary nitrogen excretion, nitrogen retention (g/d, %), and
nitrogen retention:nitrogen absorption - Experiment 2 (Period 1) 135
31. Analysis of variance for urinary nitrogen excretion, nitrogen retention (g/d, %),
and nitrogen retention:nitrogen absorption - Experiment 2 (Period 1) 136
32. Pen means for average daily feed intake, nitrogen intake, nitrogen excretion, and
nitrogen absorbed (g/d, %) - Experiment 2 (Period 2) 137
Vlll
Table Page
33. Analysis of variance for average daily feed intake, nitrogen intake, fecal nitrogen
excretion, and nitrogen absorbed (gld, %) - Experiment 2 (Period 2) 138
34. Pen means for urinary nitrogen excretion, nitrogen retention (g/d, %), and
nitrogen retention:nitrogen absorption - Experiment 2 (Period 2) 139
35. Analysis of variance for urinary nitrogen excretion, nitrogen retention (gld, %),
and nitrogen retention:nitrogen absorption - Experiment 2 (Period 2) 140
36. Pen means for average daily feed intake, nitrogen intake, nitrogen excretion, and
nitrogen absorbed (g/d, %) - Experiment 2 (Period 3) 141
37. Analysis of variance for average daily feed intake, nitrogen intake, fecal nitrogen
excretion, and nitrogen absorbed (gld, %) - Experiment 2 (Period 3) 142
38. Pen means for urinary nitrogen excretion, nitrogen retention (g/d, %), and
nitrogen retention:nitrogen absorption - Experiment 2 (Period 3) 143
39. Analysis of variance for urinary nitrogen excretion, nitrogen retention (gld, %),
and nitrogen retention:nitrogen absorption - Experiment 2 (Period 3) 144
40. Analysis ofvariance for average daily feed intake, nitrogen intake, fecal nitrogen
excretion, and nitrogen absorbed (g/d, %) - Experiment 2 (Period 2
& 3 pooled) 145
41. Analysis of variance for urinary nitrogen excretion, nitrogen retention (g/d, %),
and nitrogen retention :nitrogen absorption - Experiment 2 (Period 2
& 3 pooled) 146
42. Pen means for initial and final body weight, and average daily gain - Experiment
2 147
43. Analysis of variance for initial and final body weight, and average daily gain -
Experiment 2 148
44. Pen means for percentage of protein, lipid, ash, and water - Experiment 2 ........ 149
45. Analysis of variance for percentage of protein, lipid, ash, and water - Experiment
2 150
46. Pen means for rates of protein, lipid, ash, water, and energy accretion -
Experiment 2 151
ix
Table Page
47. Analysis of variance for rates of protein, lipid, ash, water, and energy accretion -
Experiment 2 152
48. Pen means for albumin levels - Experiment 2 153
49. Analysis of variance for albumin levels - Experiment 2 154
50. Pen means for blood urea nitrogen levels - Experiment 2 155
51. Analysis of variance for blood urea nitrogen levels - Experiment 2 1S6
52. Pen means for C-reactive protein levels - Experiment 2 157
53. Analysis of variance for C-reactive protein levels - Experiment 2 158
54. Pen means for glucose levels - Experiment 2 159
55. Analysis of variance for glucose levels - Experiment 2 160
56. Pen means for non-esterified fatty acid levels - Experiment 2 161
57. Analysis of variance for non-esterified fatty acid levels - Experiment 2 162
58. Pen means for protein levels - Experiment 2 163
59. Analysis of variance for protein levels - Experiment 2 164
60. Pen means for triglyceride levels - Experiment 2 165
61. Analysis of variance for triglyceride levels - Experiment 2 166
62. Pen means for average daily gain, average daily feed intake, and gain:feed for
Phases 1 and 2 - Experiment 3 (Room A) 167
63. Analysis of variance for average daily gain, average daily feed intake, and
gain:feed for Phases 1 and 2 - Experiment 3 (Room A) 168
64. Pen means for average daily gain, average daily feed intake, and gain:feed for
Phase 3 and overall - Experiment 3 (Room A) 169
65. Analysis of variance for average daily gain, average daily feed intake, and
gain: feed for Phase 3 and overall- Experiment 3 (Room A) 170
x
Table Page
66. Pen means for average daily gain, average daily feed intake, and gain:feed for
Phases I and 2 - Experiment 3 (Room B) 171
67. Analysis of variance for average daily gain, average daily feed intake, and
gain:feed for Phases 1 and 2 - Experiment 3 (Room B) 172
68. Pen means for average daily gain, average daily feed intake, and gain:feed for
Phase 3 and overall - Experiment 3 (Room B) 173
69. Analysis of variance for average daily gain, average daily feed intake, and
gain:feed for Phase 3 and overall- Experiment 3 (Room B) 174
70. Analysis of variance average daily gain, average daily feed intake, and gain:feed
for Phases 1 and 2 - Experiment 3 (A and B pooled) 175
71. Analysis of variance average daily gain, average daily feed intake, and gain:feed
for Phase 3 and overaIl- Experiment 3 (A and B pooled) 176
72. Pen means for albumin levels - Experiment 3 177
73. Analysis of variance for albumin levels - Experiment 3 178
74. Pen means for blood urea nitrogen levels - Experiment 3 179
75. Analysis of variance for blood urea nitrogen levels - Experiment 3 180
76. Pen means for C-reactive protein levels - Experiment 3 181
77. Analysis of variance for C-reactive protein levels - Experiment 3 182
78. Pen means for glucose levels - Experiment 3 183
79. Analysis of variance for glucose levels - Experiment 3 184
80. Pen means for non-esterified fatty acids levels - Experiment 3 185
81. Analysis of variance for non-esterified fatty acid levels - Experiment 3 186
82. Pen means for protein levels - Experiment 3 187
83. Analysis of variance for protein levels - Experiment 3 .188
84. Pen means for triglyceride levels - Experiment 3 189
Xl
Table Page
85. Analysis of variance for triglyceride levels - Experiment 3 190
86. Pen means for average daily gain, average daily feed intake, and gain:feed for
Phases 1 and 2 - Experiment 4 (Room A) 191
87. Analysis of variance for average daily gain, average daily feed intake, and
gain:feed for Phases 1 and 2 - Experiment 4 (Room A) 192
88. Pen means for average daily gain, average daily feed intake, and gain:feed for
Phase 3 and overall - Experiment 4 (Room A) 193
89. Analysis of variance for average daily gain, average daily feed intake, and
gain:feed for Phase 3 and overall - Experiment 4 (Room A) 194
90. Pen means for average daily gain, average daily feed intake, and gain:feed for
Phases 1 and 2 - Experiment 4 (Room B) 195
91. Analysis of variance for average daily gain, average daily feed intake, and
gain :feed for Phases 1 and 2 - Experiment 4 (Room B) 196
92. Pen means for average daily gain, average daily feed intake, and gain:feed for
Phase 3 and overall- Experiment 4 (Room B) .197
93. Analysis of variance for average daily gain, average daily feed intake, and
gain:feed for Phase 3 and overall - Experiment 4 (Room B) 198
~4. Analysis of variance for average daily gain, average daily feed intake, and
gain:feed for Phases 1 and 2 - Experiment 4 (Rooms A and B pooled) 199
95. Analysis of variance for average daily gain, average daily feed intake, and
gain:feed for Phase 3 and overall- Experiment 4 (Rooms A and B pooled) ......200
XIl
Table
LIST OF FIGURES
CHAPTER I
Page
1.1 Chemical structure of camitine 5
1.2 Mammalian pathway of L-camitine biosynthesis 10
1.3 The carnitine acyltransferase system 16
Xlii
Introduction
The swine industry, similar to many industries, has undergone a technological
revolution during the last decade of the 20th century. Society has seen a change from the
small, family fann, where pigs were raised to satisfy a family's need, to large, vertically-
integrated swine fanns that supply enough pork for the world human food demand.
Because of these changes, producers are imposed with new challenges on a daily basis.
These challenges range from genetically advanced breeding stock and improved
management techniques and facilities, to genetically enhanced feed ingredients, new
environmental regulations, and new pharmaceutical drug policies. All of these
technological advancements have one common goal in the swine industry: to make swine
production economically feasible, allowing the producer to manage a profitable swine
operation.
Extensive research has been conducted in the area of feed ingredients and their
nutrient digestibility, and subsequent effects on growth performance of swine. This is
due to the fact that feed is the major economic input to the swine production system,
representing over 65% of all production expenses. The stage of production where
producers believe animals are hindered the most, and improvements in growth
performance are lost, as a result of poor nutrient digestibility, is immediately post-
weanmg.
Common practice in today's swine industry is weaning pigs at 21 days of age or
younger. As a result of implementing this early-weaning management strategy, a
detrimental effect on perfonnance of weanling pigs is conceivable. This unfavorable
dilemma, known as post-weaning lag, is the result of several factors. Upon weaning, the
baby pig's diet is being altered from a strictly liquid milk diet to a pelleted food diet. At
this early age of the animal, the gastrointestinal tract of the pig is immaturely developed
and enzyme activity is limited, resulting in inefficient utilization of added dietary plant
protein sources and fat sources. Another cause of post-weaning lag is environmental
stress. At weaning, animals are removed from their natural surrounding and grouped in
an unfamiliar nursery room with unknown animals. A third cause leading to post-
weaning lag is immunological stress and the exposure of newly weaned pigs to foreign
pathogens. Therefore, if the producer can make the transition into the nursery room as
comfortable as possible for the weanling pig, they can minimize post-weaning lag.
The greatest challenge during the early post-weaning period is maintaining feed
consumption in the young pig. The newly weaned pig, particularly during the first few
days, can not consume sufficient quantities of feed to meet their energy demands for
growth. Thus, complex weanling pig diets, consisting of nutrient-dense ingredients that
are highly digestible and appropriate for the pig's stage of physiological development, are
fonnulated and fcd. However, at this stage of development, the weanling pig is unable to
efficiently utilize and gain the beneficial effects from added dietary fat sources. The
inefficient utilization of these dietary fat sources could possibly be attributed to minimal
stores ofL-camitine in the newly weaned pig. Therefore, to meet the energy demands,
the feeding regime of newly weaned pigs must consist of readily available carbohydrate
sources that can provide a large portion of the energy supply. However, it is hypothesized
that altering the metabolic processes of beta-oxidation can gamer more efficient
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utilization of energy found in dietary fat sources; thus, improving growth perfonnance
and body composition of the young pig by partitioning more nutrients from lipid
deposition to protein accretion.
Thus, the objectives of this thesis were to evaluate the effects of supplementing L-
camitine, an intermediate in lipid metabohsrn, to the diet of weanling pigs and its
subsequent effects on growth, feed efficiency, nutrient digestibility, and whole body
composition of weanling pigs.
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CHAPTER 1
Literature Review
History
Camitine, a name derived from the Latin word carD or carnis, meaning flesh, was
discovered in muscle extract by two independent groups of scientists in 1905 (Gulewitsch
and Krimberg, 1905; Kutscher, 1905). In the same year that Gulewitsch and Krimberg
(1905) isolated carnitine from muscle extract and assigned it the empirical fonnula
C7H IsN03, another nitrogenous base was isolated from the same muscle extract by
Kutscher (1905). Kutscher termed this compound "Novain" and assigned it the empirical
formula C7H ISN02AuC4. In 1908, Krimberg (1908) was able to prove, using Kutscher's
isolation procedure for Novain, that a significant amount of camitine was obtained from
the original material. From this he concluded that Novain and camitine were the same
compound.
Twenty-two years would pass before scientific proof could validate that the
empirical formula C7H 1SN03, assigned to camitine by Gulewitsch and Krimberg, was
correct. In 1927, Tomita and Sendju were successful at separating the synthetic a- and p-
hydroxy isomers using brucine salts and found that the gold chloride and other
derivatives of the isomers melted at the same temperature as derivatives of the natural
compound. Additionally, by synthesizing natural camitine through the methylation of P-
hydroxy-y-aminobutyric acid, Tomita and Sendju (1927) succeeded in establishing the
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chemical structure (Figure 1.1) of camitine as y-trimethyl-~-hydroxy-butyrobetaine.
Furthennore, carnitine is also known as 3-hydroxy-4-trimethyl ammonium butyrate.
Figure 1.1. Chemica.) structure of carnitine.
H2 H2
H3C C H C O'
'-.... N+ /' '-.... d/' '-.... C/'
/' I IIH3C I
CH3 OH 0
The first indication of a requirement for carnitine arose in research evaluating the
nutritional requirements of the meal wonn, Tenebrio molitor (Fraenkel and Blewett,
1947). Larvae of the meal wonn failed to grow or survive on a synthetic diet consisting
of casein, glucose, cholesterol, a salt mixture, and nine B vitamins; however, optimal
growth ensued upon addition of small quantities of yeast or liver preparations to the
medium. The factor in yeast, which aided in the survival and growth of Tenebrio molitor,
was first named "vitamin B/' (Fraenkel, 1948; Fraenkel et aI., 1950) to indicate its place
in the B-group of vitamins, and the "T" standing for Tenebrio. Concentrations of the
vitamin BT were found to be present in yeast, milk, and many animal tissues (Fraenkel,
1951). The identity of vitamin BT as camitine was established in 1951. Carter et a1.
(1952) reported, similar to camitine, the pure crystalline fonn of vitamin BTwas highly
hygroscopic, was soluble in water and the lower alcohol's, gave only end absorption in
the ultraviolet, and had a specific rotation of[a]o22 = -23.5°. Furthennore, the empirical
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formula ofvitamin BT was C7H1SN03, and upon dehydration with sulfuric acid yields
crotonobetaine, like carnitine. Also, both carnitine and vitamin BT are present in muscle
extract to the extent of 1.5-3.0% (Carter et aI., 1952).
While the chemistry and physiology of carnitine had been determined, there was
still uncertainty as to the exact physiological function of carnitine. In 1957, the effects of
camitine on palmitic acid oxidation by liver tissue slices, skeletal muscle particulates, and
heart preparations were evaluated (Fritz, 1959). These authors proposed that the presence
of camitine in muscle and other tissues was to facilitate the transfer of long chain fatty
acids to the enzymatically active intra-mitochondrial sites for fatty acid oxidation.
Later, Fritz et a1. (1962) reported that altering the structure of the compound in
any of a number of ways terminates the catalytic action of carnitine on long-chain fatty
acid metabolism. Examples of altering the structure of camitine include, removal of the
hydroxy group attached to the p-carbon, replacement of the carboxyl group with a cyano,
an alcohol, or an amide grouping, or by substitution of a primary amino grouping for the
trimethyl-ammonium moiety of carnitine (Fritz et aI., 1962).
With the discovery that carnitine is synthesized from the essential amino acids
lysine and methionine, it was suggested that a carnitine deficiency may be a result of
marginal or deficient intake oflysine (Rebouche, 1992). Subsequent studies in rats
demonstrated that diets deficient in lysine resulted in the characteristic signs and
symptoms of a lysine deficiency; however, no abnormalities that could be attributed to a
carnitine deficiency were observed.
Scientist began to look at the role of camitine as a dietary nutrient in human
nutrition when Engel and Angelini (1973) reported the first instance of camitine
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deficiency in human skeletal muscle with associated lipid storage myopathy. Since this
first report, over 20 cases with systemic camitinc deficiency have been described (Kerner
and Hoppel, 1998). Because of this an abundance of research has been conducted
seeking to identify the nutritional aspects of carnitine in every human physiological stage
of development. The majority of research has focused on premature and full-term infants
(Rebouche, 1992).
Initial studies evaluating the role of carnitine and its importance in swine nutrition
were conducted in the late 1980's (Newton and Haydon, 1988, 1989; Weeden et al.,
1990, 1991). Current research in this area deals with determining the effects of dietary
camitine on growth performance, nutrient digestibility, and carcass characteristics in
various physiological stages of maturity of swine.
Biosynthesis of Carnitine
Two isomers of camitine exist, the D- and L- forms; however, only the L-form is
biologically active and occurs in nature (li, 1995). The first convincing evidence for
camitine biosynthesis in animals was obtained from chick embryos, which contained
significant amounts of camitine, whereas none was found in eggs (Fraenkel, 1953).
The key finding to establishing the pathway of camitine biogenesis lay in
discovering the origin ofy-butyrobetaine by Linneweh (1928). Two more significant
clues to the mechanism of camitine biosynthesis were discovered in 1961. It was shown
that the methyl groups of carnitine are donated by the amino acid methionine (Bremer,
1961; Wolf and Berger, 1961), and that y-butyrobetaine is converted to carnitine (Bremer,
1962; Lindstedt and Lindstedt, 1961). The next important discovery was made in 1971,
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when researchers showed that labeled lysine is converted to carnitine in the fungus,
Neurospora crassa (Horne and Broquist, 1973) and rats (Tanphaichitr and Broquist,
1973). This discovery resulted in the establishment of the origin of the carnitine four
carbon chain. These key findings were the foundation for several studies (Cox and
Hoppel, 1973; Hulse et aI., 1978) on the biosynthesis ofcarnitine in both animals and
microorganisms that resulted in the establishment of a metabolic pathway for the
synthesis of carnitine.
The initial precursors ofL-carnitine synthesis are the amino acids lysine and
methionine. In Neurospora crassa, the methylation of free lysine with S-
adenosylmethionine provides the three methyl groups (Rebouche and Broquist, 1976).
However, in mammals the pathway of carnitine biosynthesis is unique in that free lysine
is not subject to methylation, but rather, lysine residues contained in body proteins are the
substrates for S-adenosylmethionine-dependent methyltransferases which produce the
intermediate peptide-bound trimethyl-lysine (Odie et aI., 2000). The primary
intermediate, E-N-trimethyl-L-lysine, is synthesized only as a post-translational
modification ofprotein synthesis and the intermediate is released by normal processes of
protein turnover for carnitine synthesis. A number of proteins contain one or more E-N-
trimethyl-L-lysine residues, including histones, actin, myosin, and calmodulin
(Rebouche, 1992).
E-N-Trimethyl-L-lysine destined for carnitine biosynthesis undergoes four
enzymatic reactions. The first of these involves hydroxylation of the substrate to form ~­
hydroxy- E-N-trimethyl-L-lysine. This reaction is catalyzed by E-N-trimethyl-L-Iysine
hydroxylase, an a-ketoglutarate-requiring dioxygenase found in the mitochondria of
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liver, kidney, heart, skeletal muscle, and brain tissues. In the next step, p-Hydroxy-e -N-
trimethyl-L-Iysine undergoes aldol cleavage to glycine and y-
trimethylaminobutyraldehyde. A pyridoxal phosphate-requiring enzYme known as serine
hydroxymethyltransferase catalyzes this reaction. y-Trimethylaminobutyraldehyde is
oxidized to y-butyrobetaine by specific and nonspecific NAD+-requiring aldehyde
dehydrogenases. The final reaction is a second hydroxylation at the Pcarbon ofy-
butyrobetaine to form L-carnitine. The enzyme catalyzing this reaction, y-butyrobetaine
hydroxylase, also is an a-ketoglutarate-requiring dioxygenase (Rebouche, 1992). y-
Butyrobetaine hydroxylase is present only in a few tissues, and it also shows species
variations in tissue distribution. In all species, this enzyme is found in the liver.
However, the enzyme is also present in the kidney and brain of humans (Rebouche and
Engel, 1980). As well, the enzyme is present to a small extent in the testis of rats, but is
absent from all other tissues (Haigler and Broquist, 1974). The metabolic pathway of
camitine biosynthesis is detailed in Figure 1.2.
The pathway of camitine biosynthesis contains some rate-limiting steps that can
control the yield of carnitine synthesis. Olson and Rebouche (1987) reported that y-
butyrobetaine hydroxylase, a rate-limiting enzyme, varied with physiological stage of
maturity in rats and humans. The hepatic y-butyrobetaine hydroxylase activity in human
infants is about 25% of that in adults. Furthermore, determinations of e -N-trimethyl-L-
lysine content of various tissue proteins and their rates of turnover, and the rate of
carnitine biosynthesis, indicated that the availability of e-N-trimethyl-L-Iysine and the
rate of camitine biosynthesis were of the same order of magnitude (Rebouche, 1982).
Because the only endogenous source of e -N-trimethyl-L-lysine for camitine biosynthesis
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is through protein turnover containing this amino acid, studies involving the oral
supplementation of E -N-trimethyl-L-lysine to rats (Rebouche et aI., 1986) and humans
(Olson and Rebouche, 1987; Rebouche et aI., 1989) elicited an increase in the rate of
carnitine biosynthesis.
Figure 1.2. Mammalian pathway of L-carnitine biosynthesis&
13-Hydroxy- E-
N-trimethyl-lysine
L-Lysine
(Peptide-linked)
S-Adenosyl-
L-Methionine
~ • E-N-Trimethyl-Iysine
(Peptide-linked)
Succinate a-keIOglutarate\ I Prolein Hydrolysis I
+02 +02 - \~ E-N-Trimethyl-iysine
E-N-Trimethyl-Iysine
Hydroxylase
Glycin
P-HydroxY-E-N-
Trimethyllysine Aldolase
y-Trimethylamin -
butyraledhyde y-Trimethylamino-
butyraldehyde
Dehydrogenase
y-Butyrobetaine
a-ketoglutarate
+ O2
uccinate
+ O2
L-Carnitine
aAdapted from Rebouche (1992).
Carnitine is not degraded systemically in humans; therefore, the rate of carnitine
excretion provides a reasonable indirect estimate of carnitine synthesis. Measuring the
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steady-state rate of camitine excretion by strict vegetarian adults and children, the rate of
camitine biosynthesis in humans is estimated to be approximately 2 ~mol . kg body
weighr1 • day-I (Rebouche and Seim, ]998).
In biological systems camitine exists either as free camitine or as esters of short-,
medium-, or long-chain organic and fatty acids. Thus, when performing camitine assays,
diet, plasma, and tissue samples should be analyzed for both free camitine and
acylcamitine concentrations (Owen, 1996). Parvin and Pande (1977) describe the
preferred method for the determination of picomole amounts of total camitine and free
carnitine in the presence of short-chain acy1camitines. The method is based on the
conversion of radioactive acetyl-CoA to acetylcamitine in the presence of carnitine
acetyltransferase and oxidized glutathione or N-ethylmaleimide to pull the reaction to
near completion, so that linear standard curves are obtained over a wide range. The rapid
separation of acetylcamitine from acetyl-CoA is accomplished by selective absorption of
acetyl-CoA on charcoal in the presence of acid and ethanol. The charcoal separation
method also allows a direct and precise assay of camitine acetyltransferase, which is
particularly useful for studies requiring low levels of acetyl-CoA (Parvin and Pande,
1977).
Metabolism of Caroitine
Carnitine transport and carnitine absorption have been evaluated in a variety of
intestinal preparations ranging from rats and pigs to guinea pigs and humans. In rats
(Rebouche et al., 1984) and humans (Rebouche and Chenard, 1991), approximately 54-
87% of dietary carnitine is absorbed. Additionally, Gudjonsson and coworkers reported
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(1985) the rapid absorption of L-carnitine by the small intestinal mucosa ofrats in vivo
with subsequent release of carnitine slowly into the circulation. By the observations that
L-camitine was absorbed twice as rapidly as the 0 isomer and the process was saturable,
Gross and Henderson (1984) suggested the presence of a speci fic carrier for camitine in
the mucosal membrane. However, there is some discrepancy on the mode of transport in
camitine absorption. Gross et a1. (1986) reported facilitated diffusion of carnitine into
isolated guinea pig enterocytes, whereas Hamilton et a1. (1986) concluded that camitine
is taken up by active transport and passive diffusion in human intestinal biopsy
specimens. Using jejunal perfusions in vivo in human adults, Li et al (1992) concluded
that camitine is absorbed by active mechanisms during a normal meal, while
pharmacological doses of camitine are absorbed primarily by passive diffusion.
Whatever the mode of action in camitine absorption, mechanisms are present in
most tissues that establish and maintain concentration gradients between extracellular and
intracellular carnitine pools. As well, camitine concentrations typically are higher in
tissue than in extracellular fluid compartments, with human skeletal and cardiac
myocytes normally having over 50 times the concentration of camitine than that of
plasma (Rebouche and Seim, 1998).
The fate of absorbed carnitine in normal metabolic activities is the formation of
acylcamitine esters. Of the camitine taken up from the lumen into the intestinal mucosa
up to 50% is acetylated (Gudjonsson et al. , 1985). The predominant acylcamitine formed
both intracellularly and in circulation is acetyl-L-camitine, which participates in both
anabolic pathways and catabolic pathways in cellular metabolism. Intracellular long-
chain acylcamitine esters are produced to transport the fatty acyl moieties across the
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mitochondrial membrane into the mitochondrial matrix. Short- and medium-chain
acylcamitine esters are formed in mitochondria and peroxisomes, in part as a means of
removing organic acids from these organelles as high-energy compounds (Borum, 1986).
Carnitine that is not absorbed in the small intestine is almost totally degraded in
the large intestine by bacteria and primarily excreted in the urine as metabolites, but with
traces being evident in feces. Enzymes of mammalian origin do not degrade L-camitinc,
but microorganisms in the gastrointestinal tract are entirely responsible for metabolite
formation (Rebouche et al., 1984; Seim et al., 1985).
Whether it is endogenous or exogenous carnitine, there are a number of different
pathways of carnitine metabolism in microorganisms. During aerobic conditions, the
enzyme camitine dehydrogenase induces the reduction of L-camitine at carbon 3,
producing dehydrocarnitine (Aurich and Lorenz, 1959). Subsequently, dehydrocamitine
is cleaved to form glycine betaine by enzyme extracts and presumably acetate (Lindstedt
et al., 1967). Under anaerobic conditions enterobacteria do not assimilate the carbon and
nitrogen of camitine, but they do metabolize it via crotonobetaine to y-butyrobetaine in
the presence of other carbon and nitrogen sources. Escherichia coli isolated from the
intestinal lumen of a rat was first shown to reduce L-camitine to y-butyrobetaine (Seim et
al., 1979). Two enzymatic reactions, a dehydration and a reduction, are involved in the
transformation. Thus, the primary function of camitine in this pathway may be as an
electron acceptor during anaerobic growth of enterobacteria in the absence of preferred
substrates (Seim et aI., 1982).
Another metabolic pathway of carnitine degradation was first demonstrated in
Serratia marcescens by Unemoto et a1. (1966). It was shown that camitine is
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Co-ASH
metabolized initially by cleavage of the C4-N bond, forming trimethylamine and malate.
Although it is evident that the trimethylamine- and y-butyrobetaine forming pathways are
active in intestinal flora, it has not been demonstrated that complete degradation of
camitine occurs in this pathway.
A combination of absorption of carnitine from dietary sources, rate of carnitine
biosynthesis, and highly efficient re-absorption of camitine maintain homeostasis of
extracellular and intracellular carnitine concentrations in mammals.
Functions of Carnitine
Fritz (1959) first documented the idea that the function of carnitine was to
facilitate the transport of long-chain fatty acids across the mitochondrial membrane.
Since his discovery, it has become an established fact (Fritz and Yue, 1963; Bray and
Briggs, 1980) that the primary metabolic role of camitine is as a cofactor for enzymes
that shuttle long-chain fatty acids across the otherwise impermeable inner mitochondrial
membrane into the matrix of the mitochondria. Once in the mitochondrial matrix, long-
chain fatty acids are utilized in the production of adenosine triphosphate (energy) via p-
oxidation and oxidative phosphorylation. As well, camitine is involved in the facilitation
of activated medium- and short-chain organic acids from peroxisomes to mitochondria,
referred to as the camitine shuttle.
The functions of carnitine are mediated by one of three groups of camitine
acyltransferase (CAT) enzymes, which catalyze the reaction:
acyl-CoA + camitine ~ ~ acy1camitine +
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The three groups of enzymes include carnitine palmitoyltransferases, carnitine
octanoyltransferases, and carnitine acetyltransferases, all of which are freely reversible
enzymes (Rebouche and Seim, 1998).
The most investigated group of enzymes is camitine acetyltransferases, which are
widely distributed in nature, occurring in most if not all mammalian tissues, including
brain (Choi et aI., 1977) and spenn (Marquis and Fritz, 1965). Sperm are incapable of
oxidizing long-chain fatty acids, and therefore have short-chain camitine
acetyltransferase activity. Camitine octanoyltransferases and camitine
palmitoyltransferases are the enzymes that catalyze the reversible fonnation of medium-
and long-chain acylcamitines from medium- and long-chain acyl-CoAs and L-carnitine in
mitochondria (Bieber, 1988).
Prior to the transportation of long-chain fatty acids into the mitochondrial matrix,
synthetases located in the endoplasmic reticulum and in the outer membrane of the
mitochondria first activate the long-chain fatty acids to their CoA thioesters. The fatty
acyl-CoA may then be esterified via acyl-CoA transferases to fonn various triglycerides,
cholesterol esters, and phospholipids that are exported from the liver as lipoproteins or
stored in adipose tissue. Fatty acyl-CoA that does not undergo esterification is
transported into the matrix of the mitochondria. Three camitine dependent membrane
proteins coordinate the activity of fatty acyl-eoA transport. The first reaction is
catalyzed by camitine palmitoyltransferase I (CPT I), located in the outer mitochondrial
membrane, and involves the transfer of the fatty acyl moiety to join with the camitine
molecule located in the intennembrane space. Fatty acyl-camitine is derived from this
reaction. Translocase, located in the intermembrane space, catalyzes the exchange-
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diffusion of fatty acyl-carnitine for free carnitine from the matrix, across the inner
mitochondrial membrane. The enzyme carnitine palmitoyltransferase II (CPT II), located
on the matrix side of the inner membrane, completes the transfer process by exchanging
fatty acyl-carnitine for free camitine and producing fatty acyl-CoA within the matrix.
This shuttling process allows for the recycling of both camitine and free CoA-SH
between the intennembrane space and the cytosol, to begin the process anew. The
camitine acyltransferase system is detailed in Figure 1.3.
Fieure 1.3. The carnitine acyltransferase systemR•
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The idea is conceivable for tissue- and organ-specific regulation of the camitine
acyltransferase system through alterations in intracellular malonyl-CoA concentrations.
In the fed state, upregulation of fatty acid synthesis increases the concentration of
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malonyl-CoA, the first intennediate of fatty acid synthesis. Malonyl-CoA has a profound
inhibition on CPT I activity, resulting in esterification of endogenous and exogenous fatty
acids rather than transportation into the mitochondrial matrix for oxidation (Sugden and
Holness, 1994). Additionally, these authors suggested that the rates of oxidation of the
two major oxidative energy substrates, glucose and fatty acids, i.e., the pyruvate
dehydrogenase (PDH)2 complex and the camitine acyltransferase system (CAT), have
interactive regulation. The activation of the PDH2 system generates regulatory
metabolites that suppress the activity of the CAT system, and vice versa.
In addition to facilitating the transport of long-chain fatty acids, numerous studies
have established that camitine has other roles in intermediary metabolism. Bieber et a1.
(1982) reported that camitine has a more general facilitative effect on mitochondrial
metabolism via its buffering of the acyl CoA/CoA-SH ratio in the matrix of the
mitochondria. Utilization of all fuels by mitochondria is dependent on the availability of
reduced CoA (CoA-SH). The oxidation of pyruvate, a-ketoglutarate, fatty acids, and
branched-chain a-ketoacids utilize a common mitochondrial CoA-SH pool, thus, a
continuous replenishment of this pool is necessary. It has been proposed that camitine is
primarily responsible for the renewal of the CoA-SH pool by removing acyl- and acetyl-
CoA from the mitochondria as acetylcamitine (Bieber et aI., 1982). However, the rat is
unique in that the buffering capacity of camitine varies between the liver and heart. The
buffering capacity in the liver is limited due to the low amount of camitine
acetyltransferase present in mitochondria (Lysiak et aI., 1988).
Another beneficial function of camitine and its associated acyItransferases is the
elimination of toxic acyl residues (xenobiotics) arising from blockage of normal
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metabolic pathways (Bieber, 1988). The elimination of these selective acyl residues is
important in individuals who are deficient or seriously compromised in the enzymes
needed for metabolism of the activated acyls. This is also another means to modulate the
CoA-SH/acyl-CoA ratio
Camitine has a unique function in the flight muscles of certain insects. Particular
insect flight muscles are fatty acid oxidase-deficient; therefore, in the flight muscles of
blowflies and bees the primary function of camitine is not related to fatty acid oxidation.
Instead, camitine has a direct affect on carbohydrate utilization via pyruvate metabolism
(Childress et a1., 1966). During the initial phase of flight, pyruvate is generated at a rate
faster than is utilized via the Krebs cycle. Paralleling the increase in pyruvate is a 4-fold
increase in acetyl camitine concentration. Childress et a1. (1966) reported that acetyl
camitine is formed from pyruvate in mitochondria by working muscles of blowflies. By
serving as an acceptor for acetyl groups from acetyl-CoA, there is a decrease in the
acetyl-CoA to CoA ratio. This permits the continuous formation of acetyl-CoA from
pyruvate, part of which can then condense with oxaloacetate as the Krebs cycle becomes
available. Additionally, the conversion of pyruvate to acetyl camitine provides an
auxiliary store of active acetate, which can be readily transacetylated back to acetyl-CoA
for subsequent oxidation.
Hahn and Skala (1975) suggested that camitine is involved in non-shivering
thermogenesis, a physiological function for which brown adipose tissue is held largely
responsible. The concentration of camitine and the activity of camitine acetyltransferase
in brown adipose tissue increase soon after birth, and in the suckling rat are higher than in
any other organ. Camitine increases fatty acid oxidation, which is closely related to heat
18
production in brown adipose tissue, thereby helping to maintain thermoneutrality in the
suckling rat during instances of cold exposure. As well, Borum (1981) proposed that
during adequate nutrition of the human neonate, brown adipose tissue is mobilized as a
source of thermoregulatory heat production in response to cold environments. Whereas,
during undernutrition, both in the absence and in the presence of cold-induced
thermogenesis, white adipose tissue serves as a general reserve. Mobilization of either
brown or white adipose tissue for thermogenesis requires adequate amounts of camitine.
Genetic Defects of the Carnitine Acyltransferase System:
Deficiencies of specific enzymes in the camitine acyltransferase system can have
adverse affects on the oxidation of fatty acids. Although it is rare, a small number of
cases have reported a hepatic deficiency of the enzyme, camitine palmitoyltransferase I
(CPT I) (Kerner and Hoppel, 1998). These authors reported that in the liver isoform,
CPT I activity decreased by approximately 85-90%. Clinical symptoms of a CPT]
deficiency include hypoketotic hypoglycemia, typically precipitated by fasting in infancy,
but usually without myopathy or cardiomyopathy.
Carnitine palmitoyltransferase I deficiency involving the skeletal muscle isoform
of the enzyme has been reported in only a few patients. In all cases there was an
occurrence of rhabdomyolysis, which is the disintegration of striated muscle fibers and
subsequent excretion of myoglobin in the urine (Kerner and Hoppel, 1998).
A deficiency in the acy1camitine-camitine translocase enzyme results in defective
intramitochondrial transport of acy1camitines formed by CPT I. Again, this deficiency is
rare, but it is one of the most severe disorders of fatty acid oxidation. The disease
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exhibits autosomal recessive inheritance with very early onset and lethal outcome in the
perinatal and infantile period of life. Symptoms include hyperamrnonemia, hypoketotic
hypoglycemia, and elevation of plasma long-chain acylcamitines with very low free
carnitine levels (Kerner and Hoppel, 1998).
The occurrence of a CPT II deficiency has been reported more frequently and is
the most common disorder of lipid metabolism affecting skeletal muscle. The typical
adult muscle fonn is by far the most frequent. However, the disease manifests itself in
several clinical phenotypes, including affecting the hepatic enzyme isofonn. The
classical symptom in young adulthood is recurrent episodes of myoglobinuria induced by
exercise (Kerner and Hoppel, 1998).
Role of L-Carnitine in Human Nutrition
Carnitine is a naturally occurring compound that is synthesized in the liver and
kidney of humans from the essential amino acids lysine and methionine. Adult humans
are capable of synthesizing adequate amounts of endogenous carnitine for normal
facilitation of long chain fatty acids into the mitochondrial matrix to be used for energy
production. However, carnitine is a critically important nutrient for the human neonate.
Hepatic glycogen stores are rapidly depleted within the first 24 hours after birth.
Consequently, lipids become an essential source of energy for newborn infants during the
first few months of life. Utilization of these lipid sources requires adequate levels of
carnitine. Yet, because carnitine stores are minimal and biosynthetic capabilities are
reduced in the neonate compared with the adult, nutritionists have speculated that
camitine may be an essential nutrient for the human neonate (Borum, 1981).
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Exogenous sources of camitine are supplied to infants from breast milk, milk-
based formulas, or carnitine-supplemented soy-based formulas. Increases are observed in
the carnitine content of human breast milk during the first week postpartum from 39 to 63
runol per milliliter, followed by decreases in the carnitine content of the milk to 45 nmol
per milliliter after one month of lactation (Borum, 1981).
In 1972 the first report of a carnitine deficient patient appeared in the literature.
This finding was of special interest because it provided a metabolic explanation for a
muscle disease (Engel and Angelini, 1973). Human carnitine deficiency appears to be a
family of syndromes ranging from a defective carnitine biosynthetic pathway to an
inadequate transport of carnitine into muscle cells. Classical symptoms of a camitine
deficiency are progressive muscle weakness with lipid accumulation in Type I muscle
fibers. Also, it generally reveals a biphasic progression with many patients expressing
bouts of hypoglycemia or symptoms typical with hypoglycemia (Borum, 1981).
The greatest concern for a camitine deficiency is in preterm infants. Nakano et al.
(1989) reported that a positive correlation exists between concentrations of camitine in
skeletal muscle and gestational age at birth. In very premature infants the estimated level
of carnitine in skeletal muscle, in relation to whole-body weight, is approximately 10
times less than that of adults (Schmidt-Sommerfeld and Penn, 1990). In an experiment to
determine the effects of supplemental camitine to pretenn infants, Helms et a1. (1990)
observed increased nitrogen balance and weight gain for intravenously fed pretenn
infants (gestational age 32 ±5 wk) supplemented with camitine. The study was initiated
2 to 3 wk after birth when infants were administered 50 !-tmol . kg'l . day,l of camitinc,
after 7 days dosage levels of camitine increased to 100 j..!mol . kg'l . day'l.
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Contradictory to the results of Helms et a1. (1990), Sulkers et a1. (1990) reported
that carnjtine supplementation at the dosage level of 298 ~mol . kg-\ . day"1 to premature
infants was not beneficial. Differences in opinions may be caused by two major
differences in experimental designs. First, dosage levels varied between studies. Sulkers
and coworkers experiment was more representative of the normal clinical situation
because it is advised that fat emulsions should be infused continuously (Kao et aI., 1984).
Secondly, Sulkers and coworkers (1990) studied infants on d 4 to 7 after birth, in
comparison Helms et al. (1990) examined infants 2 to 3 wk after birth.
As the gestational age of infants' increases, the concern for inadequate carnitine
biosynthesis diminishes. However, concerns over insufficient carnitine stores still exist
for infants that receive a soy-protein-based formula instead of breast milk. In a study
conducted by Olson et a1. (1989), the effects of an exogenous source of carnitine fed with
formulas based on isolated soy protein on weight gain, serum concentrations of carnitine,
and excretion of medium-chain dicarboxylic acids of human infants were determined.
Normal male infants between the ages of 6 and 9 d were assigned to a diet containing
either 1.2 ~moVL or 86 ~moVL of L-carnitine. Increasing levels of dietary L-carnitine
did not affect growth or energy intake. However, infants fed 86 llmol/L ofL-carnitine
did have lower free, esterified, and total carnitine concentrations in serum samples when
compared with the control. Increases in serum free fatty acids suggest an inhibition of p-
oxidation due to low carnitine concentrations. Additionally, an increase in dicarboxylic
acids was observed which indicates fatty acids are metabolized within the cell by the
camitine-independent pathway ofmicrosomal-cytosolic (i)-oxidation (Olson et aI., 1989).
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Plasma carnitine concentrations in nonnal omnivorous children (age 1 to 17
years) generally are in the same range as adults (total camitine, 28 to 84 ~mol/l; free
camitine 22 to 66 ~moL/l) (Schmidt-Sommerfeld et aI., 1988). However, concerns about
adequate camitine stores in both strict vegetarians and lactoovovegetarians, who
habitually consume diets that are low in camitine, exist. In fruits and vegetables the
camitine concentration is less than 1% that of meats while the camitine concentration of
cereal products is less than 5% that of meats. Therefore, Lombard et al. (1989) compared
the plasma camitine concentrations and urinary camitine excretion levels of vegetarians
and individuals consuming mixed diets ofmeat, dairy products, and cereal products.
Although, the plasma camitine concentrations were somewhat lower and the urinary
camitine excretion levels were markedly lower, camitine levels of both groups were still
within the nonnal range. The results of Lombard et al. (1989) suggest that camitine
biosynthesis in conjunction with renal conservation is capable of maintaining adequate
carnitine stores, even when dietary camitine intake is minimal. Similar results were
published by Bowyer et al. (1989). The acute administration of camitine to patients on
long-term home parenteral nutrition with low carnitine concentrations had no affect on
rates of palmitate, ketone body, glucose, or leucine metabolism, also suggesting the rate
of camitine biosynthesis is sufficient to supply adequate levels of camitine for normal
metabolic functions.
Minimal literature is available concerning the camitine status of elderly people.
No clinical conditions have been identified in aging humans that are attributable to
nutritional camitine deficiencies. Borum et al. (1987) reported that the plasma carnitine
concentrations for women 40 years of age or older are higher than camitine
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concentrations for younger women. No differences were observed in circulating camitine
concentrations between older and younger males.
Some studies suggest that camitine may have beneficial effects in the treatment of
elderly humans with Alzheimer's disease. Although, the condition of patients that were
treated with acetyl-L-camitine did worsen with age, a slower rate of deterioration was
apparent when compared with a placebo group (Spagnoli et al., 1991). The mechanism
or mechanisms for the observed effects on patients with Alzheimer's disease are
unknown, but may be associated with a decrease in cholinergic neural deterioration.
The primary role of camitine in optimal mitochondrial fatty acid oxidation is well
established in human research. Additionally, research validates that camitine has other
significant roles in intermediary metabolism, including transportation of activated
medium- and short-chain organic acids from peroxisomes to mitochondria, buffering of
the acetyl-CoAJCoA-SH ratio, and detoxification of poorly metabolized acyl groups.
However, additional clinical trials integrating physiologic, biochemical, and
phannacological assessments are needed to definitively clarify any effects of carnitine on
perfonnance of individuals.
Role ofL-Carnitine in Swine Nutrition
Dietary Sources of Camitine:
Most animal products, including sow's colostrum and milk, are good sources of
camitine, whereas plant products are low in or devoid of camitine. Table 1.1 lists the
camitine concentrations of animal and plant sources used in swine diets.
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Table 1.1. Carnitine concentrations found in animal and plant products·
Product L-Carnitine, ppm
Animal sources
Blood meal
Feather meal
Fish bone meal
Fish meal
Meat bone meal (40%)
Skim milk powder
Whey powder
Whey powder (lactose extracted)
Cow's milk
Goat's milk
Sheep's milk
Sow's milk
Plant Products
Barley
Corn
Cottonseed
Milo
Rape seed
Soybean meal
Sunflower seed meal
Wheat
aAdapted from Owen (1996).
155
125
85
85-145
150
120-150
300-500
800-1000
6-50
15-20
130-320
25-60
10-38
5-10
20-25
15
10
0-10
2
3-12
L-Carnitine promotes the mitochondrial ~-oxidation of long-chain fatty acids by
facilitating their transfer across the irmer mitochondrial membrane. Ironically, research
suggests cereal grains and their by-products have minimal concentrations of carnitine
(Baumgartner and Blum, 1993). Because these feed ingredients usually constitute a
major portion of swine diets, the significance of dietary L-carnitine has received intensive
interest as oflate. Numerous studies with neonatal pigs (Blatzell et a1., 1987; Coffey et
a1., 1991; Hoffman et al., 1993; Kempen and OdIe, 1993, 1995) and weaned pigs
(Weeden et a1., 1990; Newton and Burtle, 1992; Owen et aI., 1996) have reported the
effects of L-carnitine when supplemented to the diet. As well, the effects of L-carnitine
on growth performance and carcass characteristics in growing-finishing swine have also
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been observed (Owen et a1., 1994; Smith et aI., 1994; Newton and Haydon, 1989).
Although research results are scarce, the effects of L-carnitine in sow diets have also
been investigated by Musser et a1. (1997a,b).
Neonatal Nutrition:
Carnitine and fatty acid metabolism are of critical importance in the neonate
because hepatic glycogen stores are depleted shortly after birth, and muscle glycogen
levels are minimal (Coffey et aI., 1991). As a result, utilization of lipids, which constitute
a majority of the energy in sow's milk, provides a large percentage of the energy to meet
the energy demand. Adequate levels of carnitine are found in sow's milk; however,
levels of carnitine in neonatal tissue are minimal suggesting carnitine is a critically
important nutrient for the neonatal piglet (Borum, 1981).
Because of ethical issues, research in the human neonate is limited. Therefore,
scientists have begun to utilize the neonatal pig as a model for human neonatal carnitine
metabolism. Comparisons between the neonatal pig and the human neonate are possible
because several characteristics are similar between the two groups (Blatzell et aI., 1987).
Similar attributes between the neonatal pig and the human neonate include anatomy and
physiology, as well as degree of maturity at birth. Furthermore, the capability to
investigate carnitine metabolism specifically is possible because both the animal model
and the human neonate are susceptible to hypothermia and hypoglycemia, disorders
associated with a carnitine deficiency. As well, both groups have the ability to adapt
from a sole energy source of carbohydrates at birth to the utilization ofhpids as an
important energy source postpartum. Additionally, the profile of tissue carnitine
concentrations of human neonates and neonatal pigs are similar during gestation (Blatzell
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et aI., 1987}. These authors reported that the plasma and red blood cell camitine
concentrations of neonatal piglets decrease around 90 d, corresponding with 30 wk
decreases observed in the plasma and red blood cell camitine concentrations ofhumans.
Similarly, increases in camitine concentrations of skeletal muscle from 60 « 26 wk
human gestation) to 112-d (38-wk human gestation) observed by Blatzell et al. (1987) are
comparable with those in humans.
However, the study by Blatzell et a1. (1987) did not answer the question, what
effects does feeding diets low in camitine have on camitine status or on utilization of
lipid sources? Therefore, Coffey et a1. (1991) conducted the first study to examine the
camitine status of piglets fed milk protein-based formulas compared with piglets reared
by the sow. All piglets were allowed to nurse the sow for 48 h to develop an immune
system. Pigs were then allotted to one of three diets: 1) fed by the sow; 2) fed a casein-
whey (high camitine) formula; or 3) fed an egg white protein (low camitine) formula.
Results indicate piglets fed a low camitine diet had reduced concentrations of camitine in
plasma and liver samples on d 7 of age and throughout the 21-d study when compared
with camitine concentrations of the other two groups. However, dietary treatments
resulted in minimal effects on carnitine concentrations in the heart and longissimus
muscle during the experiment.
Similar to milk protein-based formulas that are low in carnitine stores, the levels
of carnitine are also minimal in soy-protein based diets. Therefore, Hoffman et al. (1993)
conducted an experiment to determine whether the addition of L-camitine to a soy
protein-based diet containing soybean oil would improve performance and nitrogen and
energy utilization of neonatal pigs and performance of young pigs. The four dietary
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treatments were obtained from combining either aor 800 ppm L-camitine with either
1.18 or 12.31 % soybean oil. In Phases 1 and 2 soy-protein isolate served as the only
source of protein, while in Phase 3 soybean meal was the only protein source. The
addition of L-camitine did not affect any perfonnance criteria measured in all three
phases. As well, supplemental L-carnitine did not affect energy or nitrogen utilization in
Phase 1. Therefore, Hoffman et al. (1993) indicated that neonatal or young pigs do not
require a dietary source of L-camitine when a soy protein-based diet containing high
levels of crude soybean oil is fed. This suggests that the biosynthesis of carnitine in
neonatal and growing pigs is adequate for nonnal nutrient utilization and growth
performance, even when the diets are supplemented with high concentrations of crude
soybean oil to increase caloric density.
An alternative method to improving fat utilization in neonatal pigs is by
supplementing fat sources that are constituted primarily of medium-chain fatty acids.
Medium-chain fatty acids are capable of passive diffusion through the inner
mitochondrial membrane and subsequent intramitochondrial activation without the
assistance of camitine as a cofactor. However, in vitro evidence suggests camitine
stimulates the oxidation of medium-chain fatty acids in muscle (Otto, 1984). In
agreement with Otto (1984), Kempen and OdIe (1993) reported that camitine plays a role
in the oxidation of medium-chain fatty acids in the neonatal pig, suggesting camitine
should be included in the diet even when medium-chain fatty acids constitute a large
portion of the dietary fatty acid profile.
28
Weanling Pig Nutrition:
Efforts to maximize fann productivity within the commercial swine industry have
led to the practice of weaning pigs at 21 days of age or younger. Yet, because of this
early-weaning management strategy, producers are faced with the challenge of increased
post-weaning lag. In an effort to diminish post-weaning lag, complex, nutrient dense
diets are being developed and fed to early-weaned pigs (Tokach et a1., 1994). Milk
products (20 to 40%) and supplemental fat (5 to 10%) arc included within these complex
weanling pig diets to increase the caloric density. However, research by Mahan (1991),
Dove (1993), and Tokach et a1. (1995) suggest that the addition of soybean, com, and
coconut oils or tallow as a supplemental fat source does not improve average daily gain
(ADG) of pigs less than 28 d of age. Still, an improvement in ADG and feed efficiency
due to added dietary fat was observed from d 14 to 35 post-weaning (Mahan, 1991:
Tokach et aI., 1995). The period immediately post-weaning is when L-camitine synthesis
is lowest in weanling pigs (Kerner et aI., 1984). Therefore, given the role of L-carnitine
in lipid metabolism, these findings would suggest inadequate amounts of camitine are
available to utilize the supplemental fat provided in the diet for energy production via p-
oxidation in the mitochondrial matrix.
In early experiments dealing with L-camitine supplementation to weanling pigs,
Newton and Haydon (1988) reported that when L-camitine was included in the diet
(.60%) initially post-weaning, pigs grew faster and consumed more feed than pigs not fed
L-camitine. Weeden et a1. (1990) reported improvements in ADG from 22 to 36 d of age
due to added L-camitine, however, no improvements in ADG were noted from 3 to 5 wk
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post-weaning. As well, Weeden et al. (1990) suggested weanling pigs supplemented with
L-camitine accrued less carcass fat.
Because of the economic factors of supplementing maximal levels of L-camitine,
recent studies have evaluated whether smaller inclusion levels of carnitine can elicit the
same beneficial improvements in growth performance and carcass characteristics. As
well, current research has evaluated the effects of varying supplemental fat levels, various
supplemental fat sources, and varying dietary lysine levels on performance criteria and
carcass composition of swine.
Li et al. (1999) reported that the addition ofL-camitine (50 ppm) to diets with and
without added fat increased average daily gain and feed intake from 15 to 28 days post-
weaning. However, the increase in ADG due to L-camitine was greater in pigs fed diets
with soybean oil than in pigs fed diets containing lard. Additionally, data from the serum
chemical analysis indicated lower free camitine levels at weaning than at 14, 28 or 39
days after weaning. In both the L-camitine supplemented and unsupplemented pigs the
free camitine levels increased with age, indicating endogenous carnitine was being
synthesized after weaning (Li et al., 1999).
In comparison, Cho et al. (1999b) reported that ADG and F:G of weanling pigs
responded to supplemental L-carnitine better when coconut oil, which is mainly
comprised of medium-chain fatty acids, was included in the diet than when soy oil, a
long-chain fatty acid source, was added to the diet. Cho et al. (1999b) suggested these
improvements in growth performance were attributed to improvements in apparent
nutrient digestibility that were observed in pigs fed the combination of 1000 ppm added
L-carnitine and coconut oil.
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In another experiment conducted by Cho et at. (1999a), the effect of dietary L-
camitine with different lysine levels on performance of weanling pigs was evaluated.
Results suggested that during the first week after weaning the best perfonnance in growth
occurred when diets included 1.60% lysine and 1,000 ppm of L-carnitine. After the first
week, similar performance was observed between pigs fed diets containing 1.40% lysine
with 1,000 ppm L-camitine and pigs fed diets containing 1.60% lysine with 1,000 ppm L-
camitine. In this study, a dietary lysine level of 1.80% and added L-camitine did not
show any additional effect on the perfonnance of pigs.
These results are in contrast to Newton and Burtle (}992) who found high levels
of dietary lysine (1.50% total lysine) to be detrimental to growth performance when
supplemental L-camitine was fed to nursery pigs, 28 to 42 d of age.
Not all studies have reported positive results due to the supplementation ofL-
camitine, Ewan (1987) reported that the inclusion of 700 ppm L-camitine to diets fed to
pigs weaned at 22 days of age did not improve growth performance. As well, Hoffman et
al. (1993) reported that ADG and energy utilization in neonatal and young pigs were not
affected by added dietary L-camitine. However, the diets fonnulated by Hoffman et al.
(1993) contained 1.45 to 1.85% lysine from d 0 to 63 after weaning, suggesting dietary
lysine levels were in excess and agreeing with the findings of Newton and Burtle (1992).
Results published by Owen et al. (1996) agree with those of Kempen and Odie
(1995) that the absorption and uptake of carnitine within plasma, liver, heart, and whole
carcass increased with increasing levels of dietary L-carnitine. Also, weanling pigs fed
1,000 ppm L-camitine during Phase 1 (d 0 to 14) had less carcass lipid and daily lipid
accretion to d 35 post-weaning (Owen et al., 1996).
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Grower/ Finisher Pig Nutrition:
Recent marketing schemes in the commercial swine industry involve animals
being sold on a carcass merit system with premiums being offered for leaner, more
muscular animals. In an effort to reap larger economic rewards, producers have
developed animals with a greater genetic potential for lean growth. Also, producers have
begun to utilize feed additives that have a role in lean growth modulation of swine.
Speculation exists that supplemental L-camitine can improve dietary fat utilization
through increased 13-oxidation. Increased 13-oxidation can lead to a repartitioning of
nutrients for increased protein accretion and decreased lipid accretion in growing and
finishing swine.
Initial studies evaluating the effects of dietary L-camitine on growth performance
and carcass characteristics of growing and finishing swine were conducted by Newton
and Haydon (1989). Pigs were fed diets containing 0, 5, or 10 ppm added L-carnitine.
During the first 14 days, pigs fed 5 ppm L-camitine consumed less feed than pigs fed the
control diet; however, there were no differences in weight gain or feed efficiency.
During the last 14 days of the trial pigs fed L-camitine grew faster on the same amount of
feed compared with pigs fed the control diet. Unfortunately, supplemental L-carnitine
had no effect on backfat measurements. This study suggested camitine might have
beneficial effects during the latter stages of the finishing period.
Owen et al. (1993) reported that the dietary inclusion of 25 ppm L-camitine
during the growing-finishing phase did not affect growth performance of swine.
However, supplemental L-camitine during the growing-finishing phase did increase
longissimus muscle area and decrease fat accretion rate. A second experiment evaluating
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the effects of supplementing 0,25,50,75, or 125 ppm L-camitine to the diet of growing-
finishing pigs reported similar results (Owen et aI., 1994). Increasing levels of dietary L-
carnitine did not affect growth perfonnance~ yet, L-carnitine did elicit a response in
carcass characteristics. Dietary L-camitine reduced backfat and 10th rib backfat thickness
while increasing longissimus muscle area with 50 ppm providing the greatest response.
This is in agreement with data presented by Smith et a1. (1994). These authors
observed increases in carcass leanness due to supplemental L-camitine. Fifty ppm L-
camitine resulted in larger longissimus muscle area, lower 10th rib backfat thickness,
lower average backfat thickness, and greater percent muscle.
An interesting study was designed by Heo et al. (2000) to test the hypothesis that
dietary L-camitine can alter nutrient partitioning in young growing pigs, resulting in
changes in body composition. These authors formulated basal diets that were limiting in
metabolizable energy (ME) so that nitrogen retention and protein accretion responded to
ME. Basal diets were formulated in a 2 x 2 factorial arrangement of treatments to contain
either low or high protein concentrations and either 0 or 500 ppm added L-carnitine. As
well, all diets were fonnulated to contain 7% fat on the idea that added L-carnitine would
improve ME derived from fat. Supplemental L-carnitine increased ADO by 7.3% and
crude protein accretion rate by 9% in both protein levels. L-Camitine fed pigs had a 4.5
fold greater total-body carnitine accretion rate and almost a 100% greater total body
camitine concentration than unsupplemented pigs. Additionally, diets containing L-
camitine improved the efficiency of nitrogen retention and reduced urinary nitrogen
excretion by 14% in pigs. Carcass fat also was reduced in growing pigs when L-camitine
was added to their diet.
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Sow Nutrition:
The physiological role of carnitine is to facilitate the transport of long-chain fatty
acids across the mitochondrial membrane into the matrix of the mitochondrial for the
production of energy. As well, camitine has been shown to affect several key enzymes
involved in protein and lipid metabolism, suggesting an enhancement in the productivity
of gestating and lactating sows is conceivable. Therefore, Musser et a1. (1997a)
supplemented 50 ppm L-carnitine to gestating and lactating sows and determined the
effects on sow and litter performance. Gestating sows fed 50 ppm L-camitine had greater
weight gains and last rib fat depth during gestation. At farrowing, the sows supplemented
with 50 ppm L-camitine during gestation had increased pig and litter birth weights.
Subsequently, pig and litter weight gains tended to increase due to feeding L-camitine
during gestation. However, no differences were observed in sow and litter performance
as a result of feeding 50 ppm L-camitine during lactation.
In a subsequent study by Musser et a1. (1997b), 50 ppm L-camitine was
supplemented to first parity gilts during lactation and the effects on sow and litter
performance were determined. Supplemental L-camitine elicited no changes in litter
weaning weight or weight gain, or changes in sow weight and last rib fat depth during
lactation.
Conclusions:
Literature would suggest that beneficial responses are obtainable due to the
supplementation ofL-camitine in swine diets. Given the role ofL-carnitine in lipid
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metabolism, the greatest response attributed to L-camitine is in dietary fat utilization.
Enhancements in the utilization of dietary fat present many positive responses for swine
including an increased energy supply for growth and a repartitioning of nutrients from
lipid deposition towards protein accretion, resulting in improved body composition.
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Chapter II
Experiment 1
Effects ofL-Carnitine on Growth Performance of Weanling Pigs.
Abstract: An experiment was conducted to evaluate the effects of supplementing graded
levels ofL-camitine to the diet of weanling pigs on growth performance. One-hundred
twenty-eight weanling pigs (5.5 kg initial BW; 18 d) were randomly allotted by BW, sex,
and litter to four dietary treatments. There were 6 pens/trt of 4 to 6 pigs/pen. Dietary
treatments were the control diet with 25, 50, and 100 ppm L-camitine. Pigs were fed in
three dietary phases: (PI: d 0-10; P2: d 11-24; and P3: d 25-38 with 1.6, lA, and 1.2%
Lys, respectively). Phase 1 and 2 diets were complex com-soybean meal-dried whey
based containing lactose, animal plasma, blood meal, and fish meal, while diets for P3
were com-soybean meal based. Pigs were weighed and feed consumption was measured
weekly for the determination of ADG, ADFI, and G:F. For the 38-d study, ADG, ADFI,
and G:F were, respectively, 337,347,370, and 363 g; 503, 502, 516, and 523 g; and
0.669,0.692,0.717, and 0.693. Dietary L-camitine increased ADG (linear, P < 0.09) and
G:F (quadratic, P < 0.02) for d 0-38. However, this improvement in ADG and G:F
associated with L-camitine was greatest during Phase 2 (linear, P < 0.03). These results
suggest that the addition of L-camitine to the diet improved growth performance in
weanling pigs. The most effective level of L-camitine in improving growth performance
of weanling pigs was 50 ppm.
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Introduction
Carnitine is a naturally occurring compound that is synthesized from the essential
amino acids lysine and methionine. It also became known as vitamin BT, to indicate its
place in the B-group of vitamins (Fraenkel, 1948). The presence of carnitine in muscle
and other tissues is necessary to facilitate the transfer of long-chain fatty acids into the
enzymatically active intra-mitochondrial matrix, resulting in the production of adenosine
triphosphate (energy) via ~-oxidation and oxidative phosphorylation (Fritz and Vue,
1963; Bray and Briggs, 1980).
Kerner et al. (1984) reported that the biosynthesis ofcarnitine is limited in pigs
directly after weaning. This finding suggests that minimal carnitine stores in the
weanling pig may hinder the response to supplemental fat sources. Therefore, studies to
determine the effects of supplemental L-carnitine on weanling pig performance have
been conducted. Newton and Haydon (1988) reported that when 0.60% L-camitine was
added to the diet initially post-weaning, pigs grew faster and consumed more feed than
pigs not fed L-carnitine. Improvements in ADG and increases in feed intake from 22 to
36 days of age, due to added L-carnitine (1,000 ppm), were also reported by Weeden et
al. (1990). Heo et al. (2000), Li et al. (1999), and Owen et al. (1996) also reported
improvements in performance criteria of weanling pigs due to supplemental L-carnitine.
In contrast, Hoffman et al. (1993) and Owen et al. (2001) did not find any improvements
in growth performance of weanling pigs due to added L-camitine.
Because of increased dietary costs due to supplementing maximal levels of L-
camitine, the addition ofL-camitine to the diet of weanling pigs may not be
economically feasible for the producer. Recent studies by Real et al. (2001) have
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reported that the addition oflower supplemental levels ofL-camitine enhanced growth
perfonnance of weanling pigs. Therefore, the objective of our study was to detennine the
effects of lower dietary concentrations of L-camitine (0 to 100 ppm) on growth
perfonnance of weanling pigs.
Materials and Methods
One-hundred twenty-eight Yorkshire, Hampshire, and crossbred (Yorkshire x
Hampshire) pigs were weaned at 18 ± 4 d and placed in temperature-controlled nursery
rooms in a 38-d experiment. Initially averaging 5.5 kg, pigs were allotted randomly on
the basis of weight, sex, and litter to four dietary treatments in a randomized complete
block design. There were 6 pen replicates per treatment and pigs were grouped with 4 to
6 pigs per pen. Dietary treatments were fonnulated by supplementing the control diet
(Table 2.1) with 25, 50, and 100 ppm L-carnitine. The four dietary treatments were: 1)
control; 2) control + 25 ppm L-camitine; 3) control + 50 ppm L-camitine; and 4) control
+ 100 ppm L-camitine. Pigs were fed in three dietary phases: [Phase 1 (PI): d 0-10;
Phase 2 (P2): d 11-24; and Phase 3 (P3): d 25-38]. Complexity of the diet changed with
phases to satisfy the nutrient requirements (NRC, 1998) of the weanling pig. Phase I
(1.6% Lys) and Phase 2 (1.4% Lys) diets were complex com-soybean meal-dried whey
based diets containing lactose, spray-dried animal plasma, spray-dried blood meal, and
fish meal, while Phase 3 (1.2% Lys) diets were typical com-soybean meal based. All
diets were fed in pelleted fonn and contained 5.0% soybean oil as a dietary fat source.
Pigs were housed in temperature-controlled nursery rooms and grouped in
elevated pens with wire flooring. Each pen provided 1.72 square meters of space and
contained a five-hole, stainless steel feeder and one nipple waterer that allowed ad
38
libitum access to feed and water throughout the experiment. Room temperature was
maintained initially at 31°C, and decreased by 1.1 °C weekly until the room temperature
reached 25.5°C. Pig weights and feed consumption were recorded weekly for the
determination of average daily gain (ADG), average daily feed intake (ADFI), and
gain:feed (G:F).
Table 2.1. Composition of control diets (as-is basis).
Ingredient, % Phase 1 Phase 2 Phase 3
0.08
0.50
0.10
0.03
0.35
0.30
5.00
2.37
0.68
56.84
33.75
2.50
2.50
5.00
2.11
0.61
0.13
0.03
0.25
0.30
0.28
50.19
25.00
10.00
30.19
20.75
20.00
10.00
5.00
2.50
2.50
5.00
1.53
0.42
0.20
0.03
0.25
0.30
0.28
Com
SBM, (48%)
Whey,dried
Lactose
Plasma, spray-dried
Blood meal, spray-dried
Fish meal, menhaden
Soybean oil
Dicalcium phosphate
Limestone
DL-Methionine
Ethoxyquin
Salt
Trace min/Vit premixh
Zinc Oxide
Copper sulfate
AntibioticC 1.00 1.00
Comstarchd 0.05 0.10
aDiets formulated to contain 1.6, 1.4, and 1.2% total lysine for PI, P2, and P3,
respectively
bprovided the following per kg feed: Zn, 120 mg; Fe, 120 mg; Mn, 24 mg; Cu, 12 mg; I,
.36 mg; Se, .36 mg; vitamin A, 6,615 IU; vitamin D), 661 IU; vitamin E, 40 IU; vitamin
K (menadione activity), 4.4 mg; riboflavin, 6.6mg; d-pantothenic acid, 30 mg; niacin, 40
mg; vitamin B 12, 33 ug; d-biotin, 265 ug; choline, 144 mg; and folic acid, 2 mg.
cpl and P2 contained Neo-terramycin® (100 g/ton oxytetracycline & 140 g/ton neomycin
base) and P3 contained Lincomix® (200 g/ton lincomycin)
dL-camitine (Camiking 10, Lonza Inc., Fair Lawn, NJ) substituted at 0, 25, 50, and 100
ppm for cornstarch to obtain the four dietary treatments
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Chemical analysis:
Diets were analyzed for OM according to AOAC (1998) procedures. Gross
energy detelTI1inations were made by bomb calorimetry (Parr 1261 Isoperibol
Calorimeter, Moline, IL), and nitrogen determinations were performed by Kjeldahl
methodology (FOSS Tecator, 2400 Kjeltec Analyzer unit, 2020 Digestor, Hoganas,
Sweden). As well, diets were analyzed for L-camitine concentrations using methods
described by Parvin and Pande (1977). Chemical composition of the control diets is
shown in Table 2.2. The L-camitine concentration for the four dietary treatments for
each phase is detailed in Table 2.3.
Statistical analysis:
Data were analyzed as a randomized complete block design. Analysis of variance
was performed using GLM procedures of SAS (SAS Inst. Inc., Cary, NC) as described by
Steel et a1. (1997). The model included the effects of block (rep), treatment, and block x
treatment (error). The effects of increasing dietary L-camitine concentrations were
partitioned into linear and curvilinear components using orthogonal polynomial contrasts.
Due to unequally spaced dietary levels of L-camitine, coefficients were derived using the
integrative matrix language (PROC IML) procedures of SAS (Version 7.11). Pen served
as the experimental unit.
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Table 2.2. Chemical composition of control diets (as-is basis).
Item Phase 1 Phase 2 Phase 3
Calculated analysis
ME, kcal/kg
Crude protein, %
Total lysine, %
Digestible lysine, %
Digestible threonine, %
Digestible Met + Cys, %
Digestible tryptophan, %
Calcium, %
Phosphorus, %
Available phosphorus, %
Analyzed values
GE, kcallkg
Crude protein, %
3,364
22.58
1.60
1.36
0.80
0.80
0.25
0.90
0.80
0.62
4,125
20.47
3,373
21.70
1.40
1.18
0.70
0.70
0.23
0.90
0.80
0.56
4,170
20.01
3,402
21.19
1.20
1.00
0.61
0.56
0.21
0.90
0.80
0.51
4,186
19.68
Table 2.3. L-Carnitine concentration of dietsa•
Item:
Calculated
Concentration
Analyzed
Concentration
Supplemented
Levelb
a
25
50
100
o
25
50
100
Phase 1
Diet 1
Diet 2
Diet 3
Diet 4
Phase 2
Diet 1
Diet 2
Diet 3
Diet 4
Phase 3
Diet 1 0
Diet 2 25
Diet 3 50
Diet 4 100
L-camitine, ppm
37
62
86
117
19
41
71
106
1
28
51
101
a
25
49
80
o
22
52
87
o
27
50
lOa
aAnalysis reported on an as-is basis
bSupplemented level obtained by subtracting analyzed concentration from analyzed
concentration of unsupplemented diet (diet 1)
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Results
Supplemented levels of L-camitine (Table 2.3) were in agreement with calculated
levels, signifying proper diet mixing. Because of the inclusion of 5% soybean oil, all
diets had a caloric density (Table 2.2) between 4,125 and 4,206 kcal/kg. Analyzed values
of crude protein were approximately 1.75% lower than the calculated values for each
phase. However, diets were fonnulated on a total lysine basis and were fonnulated to
exceed NRC (1998) recommendations, thereby, limiting any affects on growth
perfonnance due to a lysine deficiency.
The effects of graded levels ofL-camitine on pig performance are shown in Table
2.4. Increasing levels of supplemental L-camitine improved ADG (linear, P < 0.09) and
G:F (quadratic, P < 0.02) for the 38-d study. Pigs fed 50 ppm L-camitine exhibited the
greatest response to dietary L-camitine, having the highest ADG (370 g) and best G:F
(0.72) for d 0-38. However, this improvement in ADG and G:F associated with L-
camitine was greatest during Phase 2 (linear, P < 0.03). Again, the best response to L-
camitine was observed in pigs fed 50 ppm, as ADG and G:F tended to plateau at this
concentration, while the maximum level of 100 ppm L-camitine did not elicit further
improvements in performance criteria. Responses to increasing levels of dietary L-
camitine were also observed during Phases 1 and 3. A linear increase (P < 0.06) in G:F
was noted as the level of L-camitine increased in the diet during Phase 1. As well, there
was a numerical increase (P = 0.17) in ADG from d 0-10. During Phase 3, supplemental
L-camitine improved (P < 0.08) G:F; however, it did not affect ADG or ADFI (P > 0.20).
The supplementation of L-camitine had little effect on ADFI (P > 0.20) during any phase
or for the entire experiment. These results suggest that the addition ofL-camitine
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improved growth performance in weanling pigs, with the most pronounced response to
supplemental L-camitine observed in pigs fed 50 ppm.
Table 2.4. Growth performance of weanling pigsB
L-camitine, ppm p>:b
Item: a 25 50 100 SE Linear Quad. Cubic
Phase 1, d 0-10
ADG, g/d 137 136 165 159 13.5 0.18
ADFI, g/d 173 166 185 178 10.2
G:F 0.79 0.80 0.89 0.89 0.04 0.06
Phase 2, d 1] -24
ADG, g/d 342 359 381 377 11.0 0.03 0.16
ADFI, g/d 467 468 489 477 11.2
G:F 0.73 0.76 0.78 0.79 0.0] 0.01 0.16
Phase 3, d 25-38
ADG, g/d 479 491 511 494 ] 5.8
ADFI, g/d 781 782 791 815 25.1
G:F 0.6] 0.63 0.65 0.61 0.02 0.08
Overall, d 0-38
ADG, g/d 337 347 370 363 10.8 0.09
ADFI, g/d 503 502 516 523 14.1
G:F 0.67 0.69 0.72 0.69 0.01 0.] 5 0.02
"Least squares means for six pens/trt of four to six pigslpen
bDashes indicate P > 0.20
Discussion
Given the role of L-camitine in fatty acid metabolism, L-camitine may be
supplemented to the diet of weanling pigs in an effort to increase a naturally low camitine
status. Increases in camitine stores may catalyze the transport of long-chain fatty acids
into the mitochondrial matrix for the production of adenosine triphosphate (energy) in an
effort to improve growth performance. Although data from this study revealed no
differences in feed consumption during Phase 1 (d 0-10), a slight increase in daily gain
resulted in an improvement in feed efficiency due to added L-camitine. Weeden et al.
(1991) also noted an improvement in ADG with the addition of 1,000 ppm L-camitine
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during the first two weeks after weaning; however, supplemental L-carnitine did not alter
feed intake or feed efficiency in their study. An immediate post-weaning response to
added L-camitine (500 ppm) was also reported by Cho et al. (1999b), as pigs fed L-
carnitine grew faster and consumed more feed during the first two weeks. It is worth
noting that both Weeden et al. (1991) and Cho et al. (1999b) had substantially higher
addition levels of L-camitine than those utilized in our experiment.
The responses observed during Phase 2 (d 11-24), due to dietary L-camitine, are
in agreement with results from several studies. This time frame appears to be when
weanling pigs have the capability to begin utilizing the added dietary L-carnitine to
increase fatty acid oxidation, resulting in increased energy production, and subsequently,
improved performance criteria. Li et al. (1999) reported that the addition of 50 ppm L-
carnitine increased ADG and feed consumption from 15 to 28 days post-weaning. An
improvement due to the addition of 50 ppm L-camitine was also noted by Real et al.
(2001). As well, when maximum levels ofL-camitine (500 to 1,000 ppm) were added to
the diet, improvements in feed efficiency during Phase 2 (wk 3 to 5) were observed by
Weeden et al. (1990). Owen et al. (1996) observed a similar effect of carnitine on feed
efficiency in the period of 3 to 5 weeks after weaning. In contrast to the positive
responses to supplemental L-carnitine, Hoffman et al. (1993) reported that 800 ppm L-
carnitine from d 0-21 after weaning did not affect ADG, G:F, and gain per megacalorie of
ME. These authors also noted that the addition of750 ppm L-camitine did not affect any
performance criteria from d 21 to 63 post-weaning.
Minimal responses in growth performance due to the addition of L-camitine were
observed during Phase 3 (d 25-38). There was a slight increase in ADG; with pigs fed 50
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ppm L-camitine having the numerically highest ADG. This minor improvement in ADG
resulted in an increased G:F ratio in pigs fed 25 to 50 ppm L-camitine. A numerical
improvement in ADG and feed efficiency from d 28 to 39 after weaning, in pigs fed 50
ppm L-carnitine, was also reported by Li et al. (1999). We would hypothesize that the
marginal response to added L-carnitine during Phase 3 may be due to the increased
biosynthesis of camitine as the pig matures. Adequate levels of camitine production may
result from typical endogenous and exogenous camitine sources and mask any response
to supplemental L-camitine. Although we did not measure serum camitine status in our
study, Li et al. (1999) noted that there were no differences in total serum camitine and
free serum camitine concentrations between pigs fed 50 ppm L-camitine and those not
fed added dietary L-camitine. As well, on day 39 post-weaning, little variation in total
serum camitine, free serum camitine, and short-chain acyl serum camitine concentrations
was observed between either group.
Implications
Results from the present study suggest that the addition ofL-camitine to the diet
at lower concentration levels (50 ppm) can enhance growth performance of weanling
pigs. Even though a slight improvement in G:F was observed immediately post-weaning
(d 0-10), an adjustment period of approximately 10 days post-weaning may be required
before the greatest response to supplemental L-camitine can be observed in weanling
pigs. Although the exact mechanisms are unknown, we would speculate that the
supplemental L-camitine allows for the improved utilization of the added soybean oil
(energy source) in the diet; thereby, increasing energy production, and subsequently,
improving growth performance in the weanling pig. Further research is needed to
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detennine the mode of action resulting in improved growth perfonnance due to L-
camitine and whether the response to L-camitine is dependent upon dietary fat content.
46
\Chapter III
Experiment 2
Effects of L-Carnitine in the Diet of Weanling Pigs on
Apparent Nutrient Digestibility, Whole Body Composition,
Tissue Accretion, and Blood Metabolites.
Abstract: An experiment was conducted to evaluate the effects of supplementing L-
camitine to the diet of weanling pigs on apparent nutrient digestibility, whole body
composition, tissue accretion, and blood metabolites. Six sets of four littermate barrows
(4.9 kg; 18 d) were randomly allotted to four dietary treatments containing 0,25,50 or
100 ppm added L-camitine. Pigs were fed in three dietary phases (P 1: d 0-10; P2: d 11-
24; and P3: d 25-38 with 1.6, 1.4, and 1.2% Lys, respectively). Phase land 2 diets were
complex com-soybean meal-dried whey based containing lactose and additional protein
sources, while diets for Phase 3 were typical com-soybean meal based. Pigs were housed
individually in metabolism chambers and a 5-d total but separate collection of urine and
feces was performed during each phase (PI: d 4-9; P2: d 17-22; and P3: d 29-34). There
were no treatment by period interactions; therefore, data were pooled across periods.
Increasing L-carnitine resulted in a slight improvement (quadratic, P < 0.10) in energy
digestibility and nitrogen retention with the greatest response observed in pigs fed 25 to
50 ppm L-camitine. As well, pigs were bled by jugular venipuncture at the start of the
study and then at the end of each phase. Minimal effects were noted in blood metabolites
as a result of increasing levels of L-camitine; however, responses in blood urea nitrogen,
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C-reactive protein, glucose, and non-esterified fatty acids, associated with increasing L-
camitine, were observed during Phase 2. At the conclusion ofthe experiment, each pig
was killed and ground for detennination of whole body composition. Additionally, a
fifth littennate from each set of pigs was killed at the beginning of the experiment for the
detennination of initial body composition. Added L-carnitine increased (linear, P < 0.01)
the percentage of protein and decreased (linear, P < .01) the percentage of fat in the
weanling pig. A quadratic increase (P < 0.05) in total (g) and rate (g/d) of protein and
energy accretion was observed with increasing L-camitine. Also, the ratio of protein
accretion to fat accretion (1.59, 2.07, 2.08, and 2.23) improved (linear, P < 0.01) with
supplemental L-carnitine. These results suggest the addition ofL-camitine to the diet
improves whole body composition, tissue accretion, and to a lesser degree, nutrient
digestibility in weanling pigs; however, the greatest response to L-carnitine was noted in
pigs fed 50 ppm.
Introduction
Carnitine is a naturally occurring, vitamin B-Iike compound that is present in
muscle and other tissues. The primary metabolic role of camitine is to facilitate the
transfer of long-chain fatty acids across the mitochondrial membrane into the matrix of
the mitochondria (Fritz and Yue, 1963; Bray and Briggs, 1980). Due to the fact that
camitine is a cosubstrate of carnitine palmitoyltransferase, a vital regulatory enzyme in
the pathway of fatty acid oxidation (Heo et a1., 2000), the status of carnitine could
conceivably affect the utilization of fatty acid stores for the production of adenosine
triphosphate (energy). Up-regulation of the transport of long-chain fatty acids results in
increased ~-oxidation and oxidative phosphorylation in the mitochondrial matrix, in tum,
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leading to increased energy production. As a consequence of the increased energy yield,
a repartitioning of nutrients is possible. Interest in the role of camitine as a feed additive
to improve whole body composition arose from the desire to partition nutrients away
from lipid accretion and towards protein deposition in an effort to produce higher
yielding animals.
Results from Experiment 1 and Real et al. (2001) reported improvements in ADG
and G:F of weanling pigs in response to 50 ppm dietary L-camitine. However, the
question still exists as to the exact mechanisms that elicit the improvements in growth
performance and whether the improvements are the result of a repartitioning of nutrients.
Early experiments conducted by Weeden et al. (1991) reported that pigs fed 1,000 ppm
L-camitine from d a to 14 post-weaning had reduced carcass fat on d 35. Owen et al.
(1996) also reported similar results. These authors reported that 1,000 ppm added L-
camitine from d ato 14 after weaning reduced carcass lipid accretion on d 35. In a
subsequent study conducted by Owen ct al. (200 1), the addition of L-camitine decreased
daily lipid accretion in weanling pigs. As well, Cho et al. (l999b) suggested that the
supplementation of L-camitine improved crude fat and gross energy digestibility,
resulting in improved ADG and G:F during the third week after weaning. In contrast,
Hoffman et al. (1993) reported that added L-camitine did not improve the performance of
young pigs nor metabolizable energy in diets that contained soybean oil. Therefore, the
objective of our study was to detennine the effects of graded levels of L-camitine on
nutrient digestibility, whole body composition, tissue accretion, and blood metabolites in
weanling pigs.
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Materials and Methods
General procedures:
Six sets of four littennate Yorkshire and crossbred (Yorkshire x Hampshire)
barrows (18 ± 2 d), initially averaging 4.9 kg, were individually housed in metabolism
chambers and utilized in a 38-d experiment. Pigs were allotted randomly within litter on
the basis of initial body weight to the four dietary treatments used in Exp. 1 (Table 2.1) in
a randomized complete block design. There were six pigs per treatment. The four
dietary treatments were: 1) control; 2) control + 25 ppm L-carnitine; 3) control + 50 ppm
L-carnitine; and 4) control + 100 ppm L-carnitine. Pigs were fed in three dietary phases:
[Phase 1 (PI): d 0-10; Phase 2 (P2): d 11-24; and Phase 3 (P3): d 25-38].
Pigs were housed in an environmentally controlled room. Room temperature was
maintained initially at 31°C and decreased by 1.1 °C weekly until the room temperature
reached 25.5°C. Each chamber consisted of 12.5 mm thick plexi-glass on the sides and
top of chambers with an outside dimension of .80 x 1.22 m and a total pig space
allowance of.75 x 1.05 m. Floors of the chambers were expanded polyurethane
tenderfoot mesh design. One stainless steel self-feeder and nipple waterer per chamber
were used to allow ad libitum access to feed and water throughou~ the experiment.
Growth performance:
Perfonnance criteria were measured for the 38-d feeding experiment. Pigs were
weighed and feed intake was measured at the beginning and the conclusion of each
dietary phase for the detennination of average daily gain (ADG), average daily feed
intake (ADFI), and gain:feed (G:F).
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Apparent nutrient digestibility:
The chambers were constructed to allow for the total but separate collection of
urine, feces, and refused feed. A 5-d collection period of urine and feces was perfonned
during each phase (pI: d 5-9; P2: d 17-22; and P3: d 29-34). Fecal material was collected
daily during the 5-d collection period by removing a screen (1 mm) that lay directly
beneath the entire floor space of the chamber. Fecal samples were collected and then
placed in a plastic bag and weighed prior to storage in a -20°C freezer. Situated beneath
each fecal collection screen was a stainless steel pan that was graduated toward an 8-mm
hole in the center. Beneath the graduated pan, a five-quart capacity plastic container was
used to collect all urine. During the collection period, 10 ml of HCL acid was added
daily to each urine collection container to prevent any loss of nitrogen due to the
volatilization of ammonia. Urine samples were collected daily at the same time fecal
samples were collected. Total urine volume was recorded daily and a IOO-ml sub-sample
was collected in a plastic cup and stored in a freezer (-20D C) prior to analysis. As well,
pig weights and feed consumption were recorded at the start and end of each collection
period to be used in the determination of apparent nutrient digestibility.
Feed, fecal, and urine samples were assayed for DM, gross energy concentrations,
and nitrogen levels and used in the detennination of apparent nutrient digestibility.
Chemical analysis was performed on each sample in duplicates and averages were then
computed for each sample. Before any analytical procedures were perfonned on urine
samples, the daily IOO-ml sub-samples for each pig were thawed and a composite sample
was gathered. A portion of each daily sub-sample in proportion to that samples
percentage of the total urine output was used to obtain the composite sample. Dry matter
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percentage of fecal samples was determined by initially drying the total 5-d collection of
feces in a forced-air oven for 4 d at SO°C. Partially-dried fecal samples were then ground
in a Wiley Mill (Standard Model No.3; Arthur H. Thomas Co., Philadelphia, PA)
equipped with a I-mm screen. Diet samples were also ground in a Wiley Mill equipped
with a I-mm screen.
Dry matter was then determined for diet and fecal samples by drying an
approximate 3 g sample for 24 hr at 1aaoc (AOAC, 1998). Nitrogen determination of
feed, fecal, and composite urine samples was performed by Kjeldahl methodology (FOSS
Tecator, 2020 Digestor, 2400 Kjeltec Analyzer Unit; Hoganas, Sweden). Gross energy
determinations of feed and fecal samples were made by bomb calorimetry (Parr 1261
Isoperibol Calorimeter; Moline, IL).
For urinary energy analysis, one-half gram of Solka-Floc® (cellulose) was dried
for 24 hr at 100°C to determine the moisture percentage of cellulose. Two milliliters of
the composite urine sample was then added to the dried Solka-Floc® sample and dried for
an additional 24 hr at 100°C to calculate the percentage of dry urine. The dried
urine/Solka-Floc® sample was then pelleted and bombed to determine gross energy. As
well, pure Solka-Floc® pellets were bombed and used in the determination of the gross
energy of the urine. The percentage of dry Solka-Floc® in the combusted pellet along
with the total energy of combustion in the pure Solka-Floc® pellet were used to calculate
the amount of energy that the Solka-Floc® portion provided in the urine/Solka-Floc®
pellet. The amount of energy that the Solka-Floc® portion provided in the urine/Solka-
Floc® pellet was subtracted from the total energy concentration of the urine/Solka-Floc®
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pellet. The remaining value was then divided by the percentage of dry urine to obtain the
amount of energy in the composite urine sample.
Blood metabolites:
Blood samples were collected from each pig on d 0, 3, 10, 24, and 38. On d 38
blood samples were initially taken, then pigs were fasted for 2 hours and a subsequent
blood sample was drawn. Pigs were bled using 22 x I" gauge needles (Sherwood
Medicals, St. Louis, MO) by jugular venipuncture and a serum sample was collected in a
10-ml anticoagulant free vacutainer (Becton Dickinson, Franklin Lakes, NJ). Following
collection, serum samples were chilled in an ice bath for 1 hour and allowed to coagulate.
Next, samples were placed in a centrifuge (J-6B Centrifuge; Beckman Instruments, Inc.
Fullerton, CA) and spun at 2,400 g for 25 minutes at 4°C. After centrifuging,
approximately 3 ml of serum was withdrawn using a pipette and divided between two
l.5-ml micro-centrifuge tubes (Fisher Scientific, Pittsburgh, PA). Micro-centrifuge tubes
were stored in a -20°C freezer until analysis.
Serum samples were allowed to thaw and then analyzed for albumin, blood urea
nitrogen, C-reactive protein, glucose, non-esterified fatty acids, total protein, and
triglyceride concentrations using a COBAS FARA II clinical analyzer (Roche Diagnostic
Systems, Indianapolis, IN). Colorimetric procedures were used to determine the
concentration of blood metabolites. Roche diagnostic kits and reagents were used for all
clinical assays except C-reactive protein. Antibody Reagent Set II was used for C-
reactive protein (Daisorin, Stillwater, MN).
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Whole body composition:
At the conclusion of the 38-d feeding experiment, each pig was euthanized. As
well, a fifth littennate from each set was euthanized at the onset of the experiment for the
detennination of initial body composition. After euthanization, whole pigs were placed
in boxes and stored in a -20oe freezer for grinding and analysis at a latter date.
Whole pigs were ground for composition analysis. Initially, frozen pigs were cut
into smaller sections with a band saw and ground three times in a commercial meat
grinder (Autio Grinder, ModeI801GHP; Astoria, OR) equipped with a 0.64 em screen.
Dry ice was added during the last two grindings to reduce moisture loss. Following
grinding, samples were thoroughly mixed and a sub-sample of approximately 500 g was
collected. Whole body sub-samples were then freeze-dried (Virtis Freezemobile 12SL;
Gardiner, NY) and further ground in a Wiley Mill (Standard Model No.3; Arthur H.
Thomas Co., Philadelphia, PA) equipped with a 2-mm screen.
Whole body samples were analyzed for DM, protein content, lipid concentration,
ash levels, and gross energy values. Proximate analysis of whole body samples was
perfonned in triplicate and averaged for each analytical procedure. Dry matter for whole
body samples was detennined by standard AOAC procedures (1998). Protein content of
whole body samples was determined by Kjeldahl methodology (FOSS Tecator, 2020
Digestor, 2400 Kjeltec Analyzer Unit; Hoganas, Sweden). Lipid content of whole body
samples was detennined by standard extract procedures. Dried samples were placed in a
soxhlet containing petroleum ether for 48 h to allow for lipid extraction. Upon removal
from the soxhlet, samples were air dried for I h and placed in a drying oven for 18 h at
lOO°e. Lipid content of the samples was then calculated using the percent moisture and
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the amount of lipid extraction. Ash levels were determined by heating a sample for 5.5 hr
at 500°C in a muffle furnace (Sybron, Dubuque, IA). Additionally, whole body samples
were assayed for gross energy by bomb calorimetry (Parr 1261 Isoperibol Calorimeter;
Moline, IL).
Littermates from each block of pigs were killed at the start of the experiment for
the determination of initial body composition. Pigs were handled in a similar manner as
those used in the study and whole body composition was determined by the same
analytical procedures. Regression equations were generated, by regressing live body
weights against whole body characteristics, for whole body protein (R2=.97), whole body
fat (R2=.51), whole body ash (R2=.98), whole body water (R2=.95), and whole body
energy (R2=.74). These regression equations were used to estimate initial body
composition of the pigs killed at the end of the feeding study; The amount of protein,
lipid, ash, moisture, and energy accrued during the 38-d study were calculated by
subtracting the final concentration determined for each variable from the estimated initial
concentration of each variable for each pig. In calculating energy accretion, we assumed
one gram ofprotein contained 5.6 kcal of energy and one gram of lipid contained 9.4 kcal
of energy.
Statistical analysis:
Nutrient digestibility data were analyzed as a randomized complete block design
within each period. There were no treatment by period interactions as trends were similar
within periods. Thus, digestibility data were pooled across periods. All data (growth
performance, digestibility, composition, tissue accretion, and blood metabolites) were
then analyzed in a randomized complete block design using analysis of variance as
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described by Steel et al. (1997). The model included the effects ofblock (rep), treatment.
and block x treatment (error). The effects of increasing dietary L-carnitine concentration
were partitioned into linear and curvilinear components using orthogonal polynomial
contrasts. Due to unequally spaced dietary levels of L-carnitine, coefficients were
derived using the integrative matrix language (PROC IML) procedure of SAS (Version
7.11). Pen served as the experimental unit.
Results
The chemical composition of the four dietary treatments is reported in Table 2.2.
The supplemented levels of L-carnitine concentration (Table 2.3) averaged across
periods, were 0, 25, 50, and 89 ppm, respectively. Supplemented levels of carnitine were
in agreement with calculated levels. Because of the inclusion of5% soybean oil, all diets
had a caloric density between 4,125 and 4,206 kcallkg.
Growth performance trends (Table 3.1) were similar to those previously reported
in Exp. 1. Pigs fed dietary L-carnitine had improved ADG (quadratic, P < 0.03) from d
0-38, with the greatest response being observed in pigs fed 50 ppm L-camitine.
Additionally, increasing trends were noted in ADFI (quadratic, P < 0.08) and G:F (linear,
P < 0.08) in response to supplemental L-carnitine. Furthermore, during Phase 2, ADG
(274,319,337, and 368 g) increased (linear, P < 0.02) due to added L-camitine.
Table 3.1. Growth performance of weanling pigsB
L-Carnitine, ppm
Item: 0 25 50 100 SE Linear Quad. Cubic
Overall, d 0-38
ADG,g
ADFI, g
G:F
255
340
0.751
304
379
0.802
347
424
0.826
323
393
0.819
15.6
19.7
0.02
0.03
0.13
0.08
0.03
0.08
0.15
"Least squares means for six pigs/trt
bDashes indicate P> 0.20
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Apparent energy digestibility of weanling pigs is reported in Table 3.2. An
increase (linear, P < 0.04) in GE intake was noted in pigs fed increasing levels of dietary
L-carnitine; however, this increase in GE intake was associated with a linear increase (P
< 0.01) in daily feed consumption. Although fecal GE excretion and urinary GE loss
increased (linear, P < 0.01), increasing trends (linear, P = 0.13) in DE and ME (kcal/d),
respectively, were still observed due to larger increases in GE intake. However, when
DE and ME were converted to a concentration basis (kcallkg), little difference was
observed between pigs fed 0, 25, and 50 ppm L-carnitine, while pigs fed 100 ppm L-
carnitine had lower DE and ME (kcallkg) values (linear. P < 0.01). Additionally, the
inclusion of 25 and 50 ppm L-carnitine had little affect on DE:GE and ME:GE when
compared with the control, while 100 ppm L-carnitine decreased (quadratic, P < 0.09)
DE:GE and ME:GE in weanling pigs.
Table 3.2. Apparent energy digestibility of weanling pigsab
L-Carnitine, ppm P >:c
Item: 0 25 50 100 SE Linear Quad. Cubic
ADFI, g/d 415 430 476 479 14 0.01
GE Intake, kcal/d 1,944 2,001 2,147 2,166 77 0.04
Fecal GE, kcalld 217 214 239 280 8.3 0.01 0.17
DE, kcalld 1,727 1,788 1,907 1,886 76 0.13
DE, kcal/kg 4,159 4,149 4,162 4,059 24 0.01 0.13
Urine GE, kcalld 10.2 12.7 10.9 13.9 0.7 0.01 0.02
ME, kcalld 1,717 1,775 1,896 1,872 76 0.13
ME, kcal/kg 4,136 4,121 4,140 4,030 25 0.01 0.12
DE:GE, % 88.8 89.2 88.8 86.8 0.5 0.01 0.09
ME:DE, % 99.5 99.3 99.5 99.3 0.1 0.01 0,01
ME:GE, % 88.3 88.6 88.3 86.2 0.5 0.01 0.09
"Least squares means for six pigs/trt
bData reported on a dry matter basis
cDashes indicate P > 0.20
Trends for nitrogen balance (Table 3.3) were similar to those reported for energy
digestibility. An increase (linear, P < 0.08) in N intake was observed in pigs fed added L-
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camitine; yet, this increase was associated with an increase in ADFI. Although an
increase in fecal N excretion (linear, P < 0.01) was observed, a greater increase in N
intake was noted in pigs fed 25 and 50 ppm L-camitine, resulting in the percentage ofN
absorbed being improved (quadratic, P < 0.06) in these two groups. A quadratic response
(P < 0.06) was also observed in the percentage ofN retained, as pigs fed 25 and 50 ppm
L-camitine retained more N, while the inclusion of 100 ppm L-camitine decreased the
percentage ofN retained when compared with the controL
Table 3.3. Nitrogen balance of weanling pigS:.lb
L-Camitine, ppm
ltern: 0 25 50 100 SE Linear
N Intake, g/d 14.8 15.7 17.5 17.8 1.5 0.08
N Fecal exc., g/d 2.1 2.0 2.3 2.7 0.22 0.01
NAbs., girl 12.7 13.7 15.2 15.1 1.4 0.13
NAbs., % 86.0 87.2 87.0 84.5 1.0 0.12
Urine N loss, g/d 1.2 1.3 1.2 1.6 0.36
N Ret., girl 11.5 12.4 14.1 13.5 1.1 0.12
N Ret., % 78.6 79.0 80.7 76.2 1.5 0.18
Ret:Abs, % 91.4 90.6 92.8 90.2 1.7
"Least squares means for six pigs/trt
bData reported on a dry matter basis
CDashes indicate P > 0.20
p ;.. .•
Quad. Cubic
0.06
0,06
Whole body percentages ofprotein and lipid are shown in Table 3.4. An
improvement in whole body composition was observed as the percentage of protein
increased (linear, P < 0.01) and the percentage of lipid decreased (linear, P < 0.01) in pigs
fed increasing concentrations of L-camitine. Changes in body composition were also
observed in the percentage of ash (quadratic, P < o.a1) and the percentage of water
(linear, P < 0.01), both of which increased with added L-camitine. Tissue accretion rates
are also shown in Table 3.4. A quadratic increase (P < 0.05) in the rate of protein (g/d)
and energy (kcal/d) accretion was observed with increasing L-camitine. Although the
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rate of lipid accretion was unaffected (P > 0.20) by added L-camitine, the ratio of protein
accretion to lipid accretion improved (linear, P < 0.01) with increasing L-camitine. The
increase in the ratio of protein accretion to lipid accretion indicates a repartitioning of
nutrients away from lipid deposition and towards the accretion of protein. In general, the
response to L-camitine tended to plateau at 50 ppm.
Table 3.4. Whole body composition and tissue accretion of weanling pigs8b
L-Carnitine P >:'
Item 0 25 50 100 SE Linear Quad. Cubic
Protein, % 13.4 14.0 14.0 14.1 0.14 0.01 0.05
Lipid, % 8.35 7.42 7.17 6.89 0.17 0.01 0.01
Ash, % 2.71 2.88 2.79 2.80 0.03 0.01 0.01
Water, % 76.4 77.1 77.4 78.1 0.32 0.01
Protein Ace., g/d 33.6 42.6 48.5 45.4 2.3 0.01 0.01
Lipid Ace., gld 21.2 21.1 23.7 20.4 1.4 0.20
Protein:Lipid, g:g 1.59 2.07 2.08 2.23 0.07 0.01 0.01 0.03
Ash Ace., g/d 7.22 9.12 9.83 9.51 0.53 0.01 0.01
Water gain, gld 197 238 271 256 9.5 0.01 0.01
Energy gain, kcal/d 379 425 483 426 29.0 0.05
"Least squares means for six pigs/trt
bData reported on an as-is basis
'Dashes indicate P > 0.20
The effects of increasing levels of supplemental L-camitine on blood metabolites
of weanling pigs are presented in Table 3.5. Although, serum samples were analyzed for
albumin, blood urea nitrogen (BUN), C-reactive protein (CRP), glucose, non-esterified
fatty acids (NEFA), protein, and triglycerides, the majority of the changes were observed
in CRP, BUN, glucose, and NEFA. Most of the response associated with increasing
levels of L-camitine was observed at the end of Phases 1 (d 10) and 2 (d 24). On U 10,
decreases in CRP (quadratic, P < 0.01), BUN (quadratic, P < 0.06), and NEFA (linear, P
< 0.05) were noted, while an increase in glucose (quadratic, P < 0.03) was observed due
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to added L-camitine. As well, supplemental L-camitine increased CRP (linear, P < 0.02),
glucose (quadratic, P < 0.05), and NEFA (quadratic, P < 0.09) in weanling pigs on d 24.
Table 3.5. Blood metabolites of weanling pigs&
L-Camitine P >:0
Item a 25 50 100 SE Linear Quad. Cubic
CRP, mg/Lc
DO 1.28 1.29 1.62 1.33 0.97
D3 1.67 1.84 1.53 2.22 0.37
D 10 2.55 1.62 1.32 2.72 0.29 0.01
D 24 1.19 1.42 1.74 2.41 0.29 0.02
D38 2.77 3.02 2.80 3.66 1.03
BUN, mg/dLc
DO 7.57 8.25 4.77 5.59 0.98 0.16 0.13
D3 23.12 15.40 12.34 19.17 2.79 0.05
D 10 17.93 6.97 5.32 8,16 4.39 0.14 0.06
D 24 9.33 10.22 8.79 7.89 0.94
D 38 12.20 13.63 10.04 12.11 0.85 0.03
Glucose, mg/dL
DO 142.3 135.3 113.2 139.0 9.34 0.11
D3 91.3 99.0 105.6 93.4 5.34 0.13
D 10 105.2 125.3 125.3 118.5 10.83 0.03
D 24 126.3 136.2 146.2 118.0 7.29 0.05
D 38 131.0 121.7 128.6 119.0 4.5 0.19
NEFA, mmoVL •
DO 0.47 0.40 0.40 0.41 0.07
D3 2.43 1.47 1.04 1.56 0.34 0.08
D 10 0.26 0.13 0.11 0.11 0.37 0.04 O.ll
D 24 0.09 0.10 0.13 0.07 0.02 0.09
D 38 0.07 0.07 0.08 0.08 0.01
Albumin, g/dL
DO 2.78 2.53 2.53 2.42 0.14 0.11
D3 2.98 2.82 2.52 2.57 0.14 0.03 0.19
D 10 2.63 2.35 2.40 2.42 0.12
D 24 2.28 2.30 2.46 2.29 0.05 0.07 0,14
D38 2.48 2.40 2.59 2.46 0.09
Protein, g/dL
DO 5.07 4.77 4.88 4.87 0.13
D3 5.33 5.13 4.90 5.17 0.13 0.05
D 10 4.77 4.32 4.37 4.65 0.12 0,01
D 24 4.32 4.28 4.47 4.47 0.10
D 38 4.80 4.73 4.88 5.04 0.15
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Table 3.5. Continued. Blood metabolites of weanling pigs·
L-Camitine P >:6
Item 0 25 50 100 SE Linear Quad. Cubic
TRIG, mg/dL'
DO 86.33 76.17 96.70 57.82 19.77
D3 92.83 80.33 63.72 75.39 11.35
D 10 48.00 49.83 52.68 39.58 8.99
D 24 45.00 47.17 58.38 48.08 7.20
D 38 34.50 49.33 38.45 45.95 7.56
"Least squares means for six pigs/trt
bDashes indicate P > 0.20
cCRP = C-reactive protein
dBUN = Blood urea nitrogen
3NEFA = Non-esterified fatty acids
fTRIG = Triglycerides
Discussion
Results from the apparent nutrient digestibility data combined with findings from
the whole body composition data lead one to believe that a repartitioning of nutrients
occurred in the weanling pig due to the addition ofL-camitinc. We would hypothesize
that the availability ofL-camitine was increased in pigs fed diets containing added L-
carnitine, resulting in the increased transport of long-chain fatty acids into the
mitochondrial matrix. The addition of soybean oil, of which long-chain fatty acids are
the major constituent, is an excellent source of energy in the diet. Upon entering the
matrix of the mitochondria, fatty acids are oxidized for the production of energy
(adenosine triphosphate). A decrease in the percentage oflipid in the weanling pig
supports the idea that an increase in the utilization of fatty acids as an energy source
occurred. Additionally, a decrease in NEFA levels on d 10 supports the idea of increased
fatty acid utilization, while an increase in glucose concentrations on d 10 and 24 suggests
a sparing effect on carbohydrates as an energy source.
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Upon review of the apparent nutrient digestibility data, the greatest response
associated with supplemental L-carnitine was noted in pigs fed 25 and 50 ppm, while the
addition of 100 ppm L-carnitine tended to reduce DE:GE and ME:GE when compared
with the control. These results answer questions for data reported in Exp. 1 and data
presented by Real et al. (2001). Both of these authors reported improvements in ADG
and G:F due to the addition of25 and 50 ppm L-camitine in the diets ofweanling pigs.
These findings suggest weanling pigs fed 25 and 50 ppm L-camitine improved the
utilization of dietary energy, resulting in improved growth performance. Uncertainties
still exist as to why 100 ppm L-camitine did not elicit further improvements in energy
utilization and growth performance.
Results published by Cho et al. (l999a) noted improvements in proximate nutrient
digestibility when 1,000 ppm L-carnitine was supplemented to the diet. Of interest is that
eho and coworkers observed the greatest improvement in nutrient digestibility when
diets contained 1.60% total lysine, while diets for our experiment were fonnulated to
contain 1.60% total lysine only during Phase 1 (d 0-10). In a subsequent study by Cho et
al. (1999b), improvements in nutrient digestibility due to the addition of 500 ppm L-
carnitine were again reported. Not all studies have reported positive nutrient digestibility
results. Hoffman et al. (1993) did not improve the utilization of metabolizable energy in
diets that contained soybean oil with the supplementation of 800 ppm L-carnitine.
A similar response was observed in nitrogen balance. The supplementation of 25
and 50 ppm L-carnitine to the diet of weanling pigs improved the percentage of nitrogen
absorption and the percentage of nitrogen retention. However, the addition of 100 ppm
L-carnitine did not elicit further improvements in the percentage of nitrogen absorption
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and the percentage of nitrogen retention when compared with the control. Results from
the serum analysis are in agreement with these findings. Pigs fed 25 and 50 ppm L-
carnitine had lower BUN levels on d 3 and 10. Conclusions from our study are in
contrast to those reported by Heo et a1. (2000). These authors conducted an experiment
to evaluate nitrogen balance in weanling pigs. Low energy, fat-supplemented basal diets
containing low or high protein were fonnulated so that protein accretion would be limited
by metabolizable energy. Each basal diet was supplemented with 0 or 500 ppm L-
carnitine. The addition of L-carnitine to the diet reduced urinary nitrogen excretion by
14% and improved the percentage of absorbed nitrogen retained in the body, however it
did not alter daily fecal nitrogen excretion.
Transformations in whole body composition of pigs fed increasing levels of L-
carnitine suggest a repartitioning of nutrients occurred and resulted in improvements in
whole body composition and tissue accretion rates. Many studies have reported
improvements in body composition and tissue accretion rates as a result of supplemental
L-camitine, although, only a few have also evaluated nutrient digestibility at the same
time. Heo et a1. (2000) reported that the addition of 500 ppm L-carnitine to the diet
decreased the percentage of fat in the carcass and increased the crude protein accretion
rate. Heo and coworkers suggested that the improvements in nutrient digestibility they
observed explained the improvements in carcass characteristics. Findings from our
experiment are consistent with those of Heo et a1. in that supplemental L-camitine had a
greater affect on protein accretion rates than lipid accretion rates. However, in contrast to
our results, studies by Weeden ct a1. (1991) and Owen et al. (1996) reported that pigs fed
1,000 ppm L-camitine had reduced daily fat accretion and, less carcass lipid and daily
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lipid accretion, respectively, while supplemental L-camitine did not alter protein
accretion rates.
Implications
This study indicates that the supplementation ofL-camitine improved nitrogen
balance and utilization of gross energy provided in the diet of weanling pigs. However,
the greatest improvement in nitrogen balance and energy utilization was observed in pigs
fed 25 and 50 ppm L-camitine. As well, pigs fed increasing levels of L-camitine had
improved whole body composition. Supplemental L-camitine resulted in an increased
percentage of protein and a decreased percentage of lipids in weanling pigs. Tissue
accretion was also improved due to added L-camitine, indicated by the increased protein
accretion to lipid accretion ratio. We would hypothesize that the supplemental L-
camitine increased the utilization of the soybean oil provided in the diet. The increased
utilization of the soybean oil resulted in improved energy utilization, which in tum led to
a repartitioning of nutrients away from lipid deposition toward an increase in protein
accretion as evident by the improvements in whole body composition.
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Chapter IV
Experimen t 3
Effects of L-Carnitine and Soybean Oil on
Growth Performance in Weanling Pigs.
Abstract: Two-hundred sixteen weanling pigs were used in a 2 x 2 factorial arrangement
of treatments in two separate experiments to evaluate the effects of L-carnitine (0 vs 50
ppm) and soybean oil (SBO; 0 vs 5) on growth performance. In Exp. 1, 96 weanling pigs
(6.0 kg; 18 d) were randomly allotted based on BW, sex, and litter to four dietary
treatments (6 pens/trt of 4 pigs/pen). In Exp. 2, 120 pigs (5.6 kg; 18 d) were randomly
allotted to the same treatments as in Exp. 1 (6 pens/tft of 5 pigs/pen). The four dietary
treatments were: 1) 0% SBO and 0 ppm L-carnitine; 2) 0% SBO and 50 ppm L-carnitine;
3) 5% SBO and 0 ppm L-carnitine; and 4) 5% SBO and 50 ppm L-camitine. Pigs were
fed in three dietary phases (PI: d 0-10; P2: d 11-24; and P3 d 25-38 with 1.6, 1.4, and
1.2% Lys, respectively). Phase 1 and 2 diets were complex com-soybean meal-dried
whey based containing lactose and additional protein sources, while diets for P3 were
com-soybean meal based. Pigs were weighed and feed consumption recorded weekly for
the determination of ADG, ADFI, and G:F. Additionally, in Exp. 2, two pigs per pen
were bled by jugular venipuncture at the initiation of the experiment and subsequently, at
the conclusion of each dietary phase. There were no treatment by experiment
interactions; therefore, data were pooled across experiments (12 pens/tft). For the 38-d
study, ADG, ADFl, and G:F were: 394,398,370, and 391 g; 556,567,536, and 540 g;
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and 0.696, 0.703, 0.690, and 0.725, respectively. Pigs fed SBO tended (P < 0.10) to grow
slower and consume less feed compared to those not fed SBO, but G:F was not affected
(P > 0.10). The addition ofL-camitine did not affect (P > 0.10) ADG or ADFI~ however,
it did improve (P < 0.01) G:F. Also, the increase in G:F associated with L-camitine was
more pronounced in pigs fed SBD than those not fed SBO (camitine x SBO, P < 0.08).
The greatest response to L-camitine occurred in P2 with an increase in ADG (P < 0.05)
and G:F (P < 0.01). In contrast, the response (G:F) to SBO was greatest during P3.
Furthermore, a marked response to L-carnitine and soybean oil was noted in serum stores
of albumin, blood urea nitrogen, non-esterified fatty acids, protein, and triglycerides.
These results suggest that the addition of 50 ppm L-camitine improved growth
performance in weanling pigs; however, supplemental L-camitine was more effective
when SBO was provided in the diet. As well, the addition of L-camitine and SBD altered
blood metabolites in weanling pigs.
Introduction
Camitine is a naturally occurring vitamin B-like compound that is present in
muscle and other tissues. The primary role of carnitine in intermediary metabolism is as
a cofactor for enzymes that shuttle long-chain fatty acids across the otherwise
impermeable inner mitochondrial membrane into the matrix of the mitochondria. Once
in the mitochondrial matrix, long-chain fatty acids are utilized in the production of energy
(adenosine triphosphate) via ~-oxidation and oxidative phosphorylation (Fritz and Yue,
1963; Bray and Briggs, 1980).
In an effort to diminish post-weaning lag, complex, nutrient dense diets have been
developed to be fed to early-weaned pigs (Tokach et aI., 1994). The increase in caloric
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density within these complex diets is typically obtained from high inclusion levels of
milk products (20 to 40%) and supplemental fat (5 to 10%). However, in research
conducted by Mahan (1991) and Tokach et a1. (1995), fat addition to the diet did not elicit
an improvement in ADG ofpigs less than 28 d of age. Yet, when fat was supplemented
to the diet an improvement in ADG and feed efficiency was observed from d 14 to 35
post-weaning (Mahan, 1991; Tokach et aI., 1995). Ironically, the period immediately
post-weaning is when L-carnitine synthesis is lowest in weanling pigs (Kerner et aL,
1984). Another set back is that plant products, which are a major constituent of weanling
pig diets, are low in or devoid of camitine. Therefore, studies have been conducted to
evaluate the effects of supplementing L-camitine to the diet of weanling pigs on growth
performance. Results from Exp. 1 and Real et a1. (2001) indicated that supplementing 50
ppm L-camitine to diets containing added fat, improved growth performance in weanling
pigs. Therefore, we speculated that immediately post-weaning, when camitine stores are
minimal, supplemental L-camitine may be required before an improvement in growth
performance due to added fat is observed. Thus, the objective of our study was to
evaluate the effects of supplementing L-camitine and soybean oil to the diet on growth
performance and blood metabolites ofweanling pigs.
Materials and Methods
Two-hundred sixteen Yorkshire, Hampshire, and crossbred (Yorkshire x
Hampshire) pigs were weaned at 20 ± 2 d and utilized in two separate 38-d experiments.
In each experiment, pigs were used in a 2 x 2 factorial arrangement of treatments and
allotted randomly by initial BW, while equalizing ancestry and gender across treatments,
to four dietary treatments in a randomized complete block design. The four dietary
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treatments were obtained from combining either 0 or 50 ppm L-camitine with either 0 or
5% soybean oil (SBO). The four dietary treatments were: 1) 0% SBO and 0 ppm L-
camitine; 2) 0% SBO and 50 ppm L-camitine; 3) 5% SBO and 0 ppm L-camitine; and 4)
5% SBO and 50 ppm L-camitine. The composition of the basal diet for the three dietary
phases is shown in Table 4.1.
Table 4.1. Composition of basal diets (as-is basis).
Ingredient, % Phase 1 Phase 2 Phase 3
0.03
0.35
0.30
0.08
0.50
5.10
2.37
0.68
56.84
33.75
2.50
2.50
2.1 ]
0.61
0.13
0.03
0.25
0.30
0.28
50.19
25.00
10.00
30.19
20.75
20.00
10.00
5.00
2.50
2.50
1.53
0.42
0.20
0.03
0.25
0.30
0.28
Com
SBM (48%)
Whey, dried
Lactose
Plasma, spray-dried
Blood meal, spray-dried
Fish meal, menhaden
DicaIcium phosphate
Limestone
DL-methionine
Ethoxyquin
Salt
Trace minlVit premixb
Zinc Oxide
Copper sulfate
AntibioticC 1.00 1.00
Comstarchd 5.05 5.10
3Diets formulated to contain 1.6, 1.4, and 1.2% total lysine for PI, P2, and P3,
respectively
bProvided the following per kg feed: Zn, 120 mg; Fe, 120 mg; Mn, 24 mg; Cu, 12 mg; I,
.36 mg; Se, .36 mg; vitamin A, 6,615 IU; vitamin D3, 661 IV; vitamin E, 40 IV; vitamin
K (menadione activity), 4.4 mg; riboflavin, 6.6mg; d-pantothenic acid, 30 mg; niacin, 40
mg; vitamin B 12, 33 ug; d-biotin, 265 ug; choline, 144 mg; and folic acid, 2 mg.
cp1 and P2 contained Neo-tcrramycin® (100 glton oxytetracycline & 140 glton neomycin
base) and P3 contained Lincomix® (200 glton lincomycin)
dL-carnitine (Camiking 10, Lonza Inc., Fair Lawn, NJ) substituted at 0.05% and SBO
substituted at 5.0% for cornstarch to obtain the four dietary treatments
In Exp. 1,96 weanling pigs (6.0 kg initial BW) were randomly allotted to the four
dietary treatments with 6 pens per treatment of4 pigs per pen. In Exp. 2, 120 weanling
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pigs, initially averaging 5.6 kg, were randomly allotted to the four dietary treatments with
6 pens per treatments of 5 pigs per pen. Pigs in both experiments were fed in three
dietary phases: [Phase 1 (PI), d 0-10; Phase 2 (P2), d 11-24; and Phase 3 (P3), d 25-38].
Complexity of the diet changed with phases to satisfy the nutrient requirements (NRC,
1998) of the weanling pig. As well, total lysine concentration of the diets was fonnulated
to exceed NRC (1998) recommendations, thereby preventing any lysine deficiency
effects on growth perfonnance. Phase 1 (1.6% Lys) and Phase 2 (1.4% Lys) diets were
complex corn-soybean meal-dried whey based containing lactose, spray-dried animal
plasma, spray-dried blood meal, and fish meal, while Phase 3 (1.2% Lys) diets were
typical com-soybean meal based. AU diets were fed in pelleted form.
Pigs were housed in temperature-controlled nursery rooms and grouped in
elevated pens with wire flooring. Each pen provided 1.72 square meters of space and
contained a five-hole, stainless steel feeder and one nipple waterer that allowed for the ad
libitum access to feed and water throughout the experiment. Room temperature was
maintained initially at 31°C, and decreased by 1.1 °C weekly until the room temperature
reached 25.5°C. Pigs were weighed and feed consumption was measured weekly for the
detennination of average daily gain (ADG), average daily feed intake (ADFI) and
gain:feed (G:F).
At the start of Exp. 2, blood samples were drawn from the two pigs closest to the
mean pen weight. Subsequent blood samples were taken at the end of each dietary phase,
d 10, 24, and 38, respectively. Blood samples were drawn using a 22 xl" gauge needle
(Sherwood Medicals; St. Louis, MO) by jugular venipuncture into a 10-ml anticoagulant
free vacutainer (Becton Dickinson; Franklin Lakes, NJ). After collection, samples were
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placed in an ice bath for 2 h and allowed to coagulate. Following coagulation,
vacutainers were centrifuged at 2,400 g for 25 min at 4°C (1-6B Centrifuge; Beckman
Instruments, Inc., Fullerton, CAl. Next, approximately 3 ml of a serum sample was
pipetted from the vacutainers into two 1.5-ml micro-centrifuge tubes. Micro-centrifuge
tubes were then stored in a -20c C freezer until analysis.
Chemical an.alysis:
Diets were analyzed for DM according to AOAC (1998) procedures. Gross
energy determinations were made by bomb calorimetry (Parr 1261 Isoperibol
Calorimeter, Moline, IL), and nitrogen determinations were performed by Kjeldahl
methodology (FOSS Tecator, 2400 Kjeltec Analyzer unit, 2020 Digestor, Hoganas,
Sweden). As well, diets were analyzed for L-camitine concentrations using methods
described by Parvin and Pande (1977). Chemical composition of the control diets is
shown in Table 4.2. The L-camitine concentration for the four dietary treatments for
each phase is detailed in Table 4.3.
Table 4.2. Chemical composition of basal diets (as-is basis).
Item Phase 1 Phase 2 Phase 3
Calculated analysis
ME, kcallkg 3,155 3,164 3,193
Crude protein, % 22.58 21.70 21.19
Total lysine, % 1.60 lAO 1.20
Digestible lysine, % 1.36 1.18 1.00
Digestible threonine, % 0.80 0.70 0.61
Digestible Met + Cys, % 0.80 0.69 0.56
Digestible tryptophan, % 0.25 0.23 0.21
Calcium, % 0.90 0.90 0.90
Phosphorus, % 0.80 0.80 0.80
Available phosphorus, % 0.62 0.56 0.51
Analyzed values
GE, kcallkg 3,938 4,025 3,901
Crude protein, % 22.49 20.82 20.41
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Table 4.3. L-Carnitine concentration of diets".
Item:
Calculated
Concentration
Analyzed
Concentration
Supplemented
Levelb
Serum samples were allowed to thaw and then analyzed for albumin, blood urea
aAnalysis reported on an as-is basis
bSupplemented level obtained by subtracting analyzed concentration from analyzed
concentration of unsupplemented diets (diets 1 & 3)
o
50
o
50
o
51
o
55
o
55
o
38
o
49
o
47
1
50
1
48
19
70
19
74
37
92
37
75
L-camitine, ppm
o
50
o
50
Phase 1
Diet 1
Diet 2
Diet 3
Diet 4
Phase 2
Diet 1
Diet 2
Diet 3
Diet 4
Phase 3
Diet 1 0
Diet 2 50
Diet 3 0
Diet 4 50
nitrogen (BUN), C-reactive protein (CRP), glucose, non-esterified fatty acids (NEFA), !~.,"
".
total protein, and trig1ycerides (TRIG) (COBAS FARA II clinical analyzer; Roche
Diagnostic Systems, Indianapolis, IN). Determination of blood metabolite levels was
made by colorimetric procedures. Roche diagnostic kits and reagents were used for all
clinical chemistries except C-reactive protein. For C-reactive protein an antibody
Reagent Set II was used (Daisorin; Stillwater, MN).
Statistical analysis:
The data were analyzed as a randomized complete block design within each
experiment using analysis of variance procedures (Steel et aI., 1997). There were no
treatment by experiment interactions as trends were similar within experiments. Thus,
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data were pooled across experiments with 12 pens per treatment and analyzed as a 2 x 2
factorial in a randomized complete block design. The model included the effects of block
(rep), treatment, and block x treatment (error). Orthogonal contrasts were used to test the
effects ofL-carnitine level (0 vs 50 ppm), SBO level (0 vs 5%), and the L-carnitine level
x SBO level interaction. Pen served as the experimental unit.
Results
The chemical analyses of the four dietary treatments are presented in Tables 4,2
and 4.3. Supplemented levels ofL-carnitine were consistent with calculated levels,
signifying proper diet mixing. Five percent added soybean oil increased the caloric
density of the diet by approximately 200-225 kcal/kg.
The effects ofL-camitine and soybean oil on pig performance are shown in Table
4.4. For the 38-d study, pigs fed SBO tended (P < 0.1 0) to grow slower and consume less
feed compared with those not fed SBO, but G:F was not affected (P > 0.10). The
addition ofL-carnitine did improve (P < 0.01) G:F; however, it did not affect (P > 0,10)
ADG or ADFI. Also, the increase in G:F associated with L-carnitine was more
pronounced in pigs fed SBO than those not fed SBO (L-carnitine x SBO, P < 0.08), The
greatest response to L-camitine occurred in P2 with an increase in ADG (P < 0.05) and
G:F (P < 0.01). As well, the addition ofSBO to the diet decreased ADG (P < 0.04) and
ADFI (P < 0.02) during P2. During P3, the inclusion of SBO had little affect on ADG (P
> 0.20); however, a decrease in ADFI (P < 0.02) was observed, resulting in an increase in
G:F (P < 0.01). These results suggest that the addition of 50 ppm L-camitine improved
growth performance in weanling pigs; however, supplemental L-camitine was more
effective when SBO was included in the diet.
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Table 4.4. Growth performance of weanling pigs·
p >:bSBO,% 0 0 5 5
Camitine, ppm 0 50 0 50 SE SBO Camitine Inte
Phase 1, d 0-10
ADG, g/d 186 189 177 179 8.9
ADFI, g/d 213 211 208 208 7.7
G:F 0.87 0.90 0.85 0.86 0.03 0.19
Phase 2, d 11-24
ADG, g/d 420 428 386 418 9.8 0.03 0.05
ADFI, g/d 565 564 534 537 11.5 0.02
G:F 0.74 0.76 0.72 0.78 0.01 0.01 0.14
Phase 3, d 25-38
ADG, g/d 517 518 493 516 12.7
ADFI, g/d 819 824 773 780 18.0 0.02 ,'
~ :G:F 0.63 0.63 0.64 0.66 0.01 0.01 0.14 .,
..
Overall, d 0-38 I:
"
"ADG, g/d 394 398 370 392 8.7 0.09 0.16 C',
"
540 11.4 0.02 "ADFI, g/d 566 567 536 'JI,
G:F 0.70 0.70 0.69 0.73 0.01 0.18 om 0.08 II
'Least squares means for six pens/trt of four to six pigs/pen
"11bDashes indicate P > 0.20 II
ernt = SBO level x L-camitine level interaction 'I
II
.
The effects of dietary L-camitine and soybean oil on blood metabolites of
weanling pigs are presented in Tahle 4.5. The greatest response associated with L- ,.
camitine and soybean oil occurred at the end of Phases 1 (d 10) and 2 (d 24). On d 10,
pigs fed SBO had higher TRIG (P < 0.08) and NEFA (P < 0.04) levels than those not fed
SBO. As well, the addition ofL-camitine tended (P < 0.07) to decrease NEFA levels on
d 10; however, the decrease in NEFA levels was more obvious in pigs fed SBO than
those not fed SBO (L-camitine x SBO, P = 0.11). The supplementation ofL-camitine
also increased (P < 0.06) albumin status on d 10. However, on d 24 albumin levels
decreased in pigs fed SBO due to the addition ofL-camitine, while the addition ofL-
carnitine increased albumin levels in pigs not fed SBO (L-camitine x SBO, P < 0.09).
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Table 4.5. Blood metabolites of weanling pigsi
SBO,% 0 0 5 5 P >:0
Carnitine, ppm 0 50 0 50 SE SBO Carnitine IntC
Albumin, g/dL
DO 2.82 2.80 2.86 2.77 0.09
D 10 2.32 2.48 2.44 2.49 0.05 0.06
D24 2.37 2.52 2.52 2.42 0.07 0.09
D 38 2.70 2.73 2.65 2.59 0.08
BUN, mg/dLd
DO 6.30 7.24 6.94 7.58 0.72
D 10 6.13 7.43 7.24 6.14 1.07
D 24 7.55 8.64 7.82 6.31 0.47 0.04 0.01
D 38 12.62 12.66 11.98 11.09 0.63 0.10
Protein, g/dL
DO 5.08 5.41 5.43 5.21 0.12 0.04 ,..
'.D 10 4.48 4.66 4.68 4.66 0.08 ::~f:~D 24 4.28 4.73 4.39 4.38 0.15 0.17 0.14 .'.,
.....
D 38 4.73 1.90 4.65 4.53 0.13 (J.09 I'", ~w
NEFA, mmol/L • ji~
DO 0.363 0.318 0.361 0.308 0.05 I J
D 10 0.097 0.093 0.171 0.103 0.02 0.04 0.07 U.l1 r~
I'D 24 0.089 0.121 0.107 0.113 0.02 ,e.
D 38 0.059 0.057 0.104 0.093 0.01 0.01
TRIG, mg/dLf
DO 98.17 76.75 92.92 112.08 13.1<8 0.16
010 33.17 32.33 36.50 38.75 2.64 0.08
024 38.25 38.83 39.08 39.58 3.54
D 38 43.33 36.08 41.75 49.08 5.03 0.17
:eCRP, mg/L&
DO 2.19 1.33 1.78 3.75 n.7U 0.20 0.08
..~010 2.76 3.67 2.04 3.73 0.59 0.04
D 24 4.31 4.16 4.42 6.23 1.00
D 38 5.01 5.54 4.30 5.20 0.76
Glucose, mg/dL
DO 128.92 131.92 152.00 132.67 9.61
DI0 96.92 103.83 106.42 103.83 5.02
D 24 110.92 107.08 107.83 104.92 4.52
D 38 121.83 118.67 123.33 125.67 5.19
"Least squares means for six pigs/trt
bDashes indicate P> 0.20
CInt = SBO level x L-camitine level interaction
dBUN = Blood urea nitrogen
"NEFA = Non-esterified fatty acids
fTRIG = Triglycerides
gCRP = C-reactive protein
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A similar tendency was also noted in BUN levels on d 24, as pigs fed SBO had lower (P
< 0.04) BUN levels than those not fed SBO. However, when L-carnitine was added to
the diet, a decrease in BUN levels was noted in pigs fed SBO, while an increase in BUN
levels was observed in pigs not fed SBO (L-camitine x SBO, P < 0.01). Responses to
added soybean oil were also noted in BUN, protein, and NEFA levels at the end of Phase
3 (d 38). The supplementation of SBO decreased BUN (P < 0.10) and protein (P < 0.09)
levels, while SBO increased NEFA (P < 0.01) levels ofweanling pigs on d 38.
Discussion
Results from this study suggest that the addition of 50 ppm L-carnitine does not
improve the perfonnance of weanling pigs fed nutrient dense diets containing soybean oil
during Phase 1 (d 0-10). These findings are in agreement with data reported by Owen et
al. (1996) and Weeden et a1. (1990). These authors reported that L-camitine and SBO
had no affect on pig performance immediately post-weaning (d 0-14). However, results
from our study indicate that after approximately 10 d, weanling pigs have the capabilities
to improve performance criteria due to supplemental L-camitine and soybean oil.
Although SBO decreased ADG and ADFI during Phase 2, the inclusion of L-camitine
elicited an improvement in ADG and G:F, with the greatest response being observed in
pigs fed SBO. Owen et a1. (1996) reported that from d 14-35 after weaning, increasing
dietary L-camitine improved G:F, while SBO improved ADG and G:F during this period.
Weeden et a1. (1990) also reported improvements in feed efficiency due to supplemental
L-camitine during 3 to 5 wk post-weaning. It is worth noting that Owen et aI. (1996) and
Weeden et a1. (1990) supplemented up to 1,000 ppm L-camitine and 10% soybean oil.
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Given the metabolic role of camitine in fatty acid oxidation, we would
hypothesize that an increased camitine status enhanced the utilization of dietary SBO,
resulting in improved growth perfonnance during P2. Additionally, we would
hypothesize that increased fatty acid oxidation would decrease triglyceride and non-
esterified fatty acid levels during this period. However, neither triglycerides nor non-
esterified fatty acids were affected by camitine and soybean oil supplementation on d 24.
Li et a1. (1999) also reported no differences in triglyceride levels on d 14 and 28 ofpigs
weaned at 35 days of age and fed 50 ppm L-camitine.
For the overall study Cd 0-38), improvements in growth perfonnance were
observed due to the supplementation of L-camitine only when the diet contained soybean
oil. Given the increased caloric density of diets containing added SBO, as would be
expected, the weanling pig consumed less feed to meet its energy requirement. A
decrease in daily gain was also observed in pigs fed SBO when compared with pigs fed
diets without added SBO. However, when L-camitine was added to the diet, an increase
in daily gain was noted in pigs fed SBO, resulting in an improved feed efficiency. Yet,
performance criteria of weanling pigs, fed diets without SBO, were not affected by the
addition of L-camitinc. This would suggest sufficient camitine biosynthesis for energy
production in pigs fed diets without added fat sources. In contrast to results from our
study, Hoffman et al. (1993) reported that the addition ofL-carnitine did not affect any
performance criteria, including ADG, G:F, and gain per megacalorie of ME, in pigs fed
diets with and without high levels of soybean oil.
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Implications
Soybean oil and other fat sources are supplemented to the diet of weanling pigs to
increase the energy density of the diet, in an effort to improve growth performance,
thereby diminishing the effects of post-weaning lag. However, the biosynthesis of
camitine is minimal immediately after weaning in pigs, possibly hindering the utilization
of the increased caloric density of the diet. Results from the present study suggest that
supplemental L-camitine to the diet of weanling pigs does not improve the response to
added soybean oil immediately post-weaning (d 0-10). However, after an adaptation
period, added L-camitine enhances growth performance when soybean oil is provided in
the diet of weanling pigs.
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Chapter V
Experiment 4
Effects of L-Carnitine and Source of Dietary Fat on
Growth Performance of Weanling Pigs.
Abstract: Two-hundred thirty-six weanling pigs were used in two separate experiments
to evaluate the effects ofL-camitine (0 vs 50 ppm) and source of dietary fat [soybean oil
(SBO) vs coconut oil (CO)] on growth perfonnance. Pigs were randomly allotted to one
of five dietary treatments, in a 2 x 2 factorial arrangement of treatments, with a negative
control, in a randomized complete block design. The five dietary treatments were
obtained from combining the control with either 0 or 50 ppm L-camitine and either 5%
SBO or 5% CO. The five dietary treatments were: 1) control; 2) control + 0 ppm L-
camitine and 5% SBO; 3) control + 50 ppm L-camitine and 5% SBO; 4) control + 0 ppm
L-camitine and 5% CO; and 5) control + 50 ppm L-camitine and 5% CO. In Exp. 1, 116
weanling pigs (5.2 kg; 21 ± 1 d) were randomly allotted based on BW, sex, and litter to
the five dietary treatments (Trt 1 = 4 pens of 4 to 5 pigs/pen; Trt 2-5 = 5 pens/trt of 4 to 5
pigs/pen). Pigs were fed in three dietary phases (PI: d 0-13; P2: d 14-27; and P3 d 28-
41). In Exp. 2, 120 weanling pigs (5.3 kg) were randomly allotted to the same treatments
as in Exp. 1 (Trt 1 = 4 pens of 5 pigs/pen; Trt 2-5 = 5 pens/trt of 5 pigs/pen). Pigs were
fed in three dietary phases (PI: d 0-10; P2: d 11-24; and P3 d 25-38). In both
experiments, diets were fonnulated to contain 1.6, 1.4, and 1.2% Lys for PI, P2, and P3,
respecti vely. Pigs were weighed and feed intake recorded at the start and end of each
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dietary phase for the determination of ADG, ADFI, and G:F. There were no treatment by
experiment interactions; therefore, data were pooled across experiments. Overall
performance data for ADG, ADFI, and G:F were: 334,330,335,337, and 338 g; 479,
460,471,471, and 452 g; and 0.699,0.719,0.712,0.718, and 0.750, respectively. The
addition of a fat source to the diet of weanling pigs improved overall G:F (P < 0.04)
when compared with the control. However, when L-camitine was supplemented to the
diet, an improvement in G:F was noted only in pigs fed CO (L-camitine x Fat source, P <
0.06). Added L-camitine and fat did not affect overall ADG and ADFI (P > 0.20). The
greatest response associated with supplemental fat sources was observed in Phase 1. Pigs
fed a diet containing an additional fat source consumed more feed (P < 0.01) and grew
faster (P < 0.08) than control pigs. As well, the addition ofL-camitine, during Phase 1,
only elicited an improvement in ADG and ADFl in pigs fed SBO (L-carnitine x Fat
source, P < 0.06). Minimal responses were observed in growth performance, during
Phase 2 and 3, due to the addition ofL-camitine or a dietary fat source. Results from this
study suggest that the addition of a dietary fat source can enhance growth performance in
weanling pigs. However, the improvements in performance criteria were greater in pigs
fed coconut oil than pigs fed soybean oil. Additionally, the response in growth
performance that was attributed to the supplementation ofL-camitine varied between
pigs fed soybean oil and pigs fed coconut oil. Also, the response associated with L-
camitine varied among phases.
Introduction
Camitine is a naturally occurring compound that is also known as vitamin BT, to
indicate its place in the B-group of vitamins (Fraenkel, 1948). The presence of camitine
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in muscle and other tissues is necessary to facilitate the transfer of long-chain fatty acids
into the enzymatically active intra-mitochondrial matrix, resulting in the production of
adenosine triphosphate (energy) via ~-oxidation and oxidative phosphorylation (Fritz and
Yue, 1963; Bray and Briggs, 1980). However, other metabolic roles of carnitine have
been proposed. Markwell et a1. (1973) reported that in pig liver both short- and medium-
chain camitine acyltransferase activity is present in microsomes, peroxisomes, and
mitochondria. The hepatic role of these short- and medium-chain carnitine
acyltransferases is to shuttle chain-shortened products, due to ~-oxidation, out of
peroxisomes (Bieber et a1., 1982).
Typically, soybean oil is added as a fat source, to increase the caloric density of
the diet. The fatty acid profile of soybean oil reveals that is comprised of approximately
95% long-chain fatty acids (;?:: 16 C). However, the weanling pig is able to more
efficiently utilize dietary fat sources that are constituted primarily of medium-chain fatty
acids. Friedman and Nylund (1980) demonstrated through in vitro studies that medium-
chain fatty acids are easily solubilized by bile salts. Consequently, medium-chain fatty
acids have a greater potential to enter the micellar phase of the lipid-bile interface than do
long-chain fatty acids (Hofman, 1963). Given that coconut oil contains a high percentage
(>80%) of medium-chain fatty acids, it may be more effective as a source of dietary fat
for weanling pigs than other fat sources containing high concentrations of long-chain
fatty acids.
Results from Experiment 3 suggest that the supplementation of 50 ppm L-
camitine was more effective in enhancing growth performance when soybean oil was
provided in the diet. Therefore, the objective of our study was to evaluate the effects of
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supplementing L-camitine with either soybean oil (long-chain fatty acids) or coconut oil
(medium-chain fatty acids) to the diet on growth performance of weanling pigs.
Materials and Methods
Two-hundred thirty-six Yorkshire, Hampshire, and crossbred (Yorkshire x
Hampshire) pigs were weaned at 21 ± 1 d and utilized in two separate experiments. The
experimental design for each experiment was a 2 x 2 factorial arrangement of treatments,
with a negative control. Pigs were allotted randomly by initial BW, stratifying pigs by
litter and gender across treatments, to five dietary treatments in a randomized complete
block design. The five dietary treatments were obtained from combining the control diet
with either 0 or 50 ppm L-camitine and either 5% soybean oil (SBO) or 5% coconut oil
(CO). The five dietary treatments were: 1) control; 2) control + 0 ppm L-camitine and
5% SBO; 3) control + 50 ppm L-camitine and 5% SBO; 4) control + 0 ppm L-camitine
and 5% CO; and 5) control + 50 ppm L-camitine and 5% CO. The composition of the
control diet for the three dietary phases is shown in Table 5.1.
In Exp. 1, 116 weanling pigs (5.2 kg) were randomly allotted to the five dietary
treatments. Four pens, with 4 to 5 pigs per pen, were allotted to Treatment 1, while five
pens, with 4 to 5 pigs per pen, were assigned to Treatments 2 through 5. Pigs were fed in
three dietary phases [Phase 1 (PI): d 0-13; Phase 2 (P2): d 14-27; and Phase 3 (P3) d 28-
41). In Exp. 2, 120 weanling pigs (5.3 kg) were randomly allotted to the same treatments
as in Exp. 1. Pigs were allotted with 5 pigs per pen. Four pens were allotted to
Treatment 1, while five pens were allotted to Treatments 2 through 5. Pigs were fed in
three dietary phases (PI: d 0-10; P2: d 11-24; and P3 d 25-38). In both experiments, diets
were fonnulated to contain 1.6, 1.4, and 1.2% Lys for Phase 1, Phase 2, and Phase 3,
81
respectively. As well, complexity of the diet changed with phases to satisfy the nutrient
requirements (NRC, 1998) of the weanling pig. Phase 1 and Phase 2 diets were complex
com-soybean meal-dried whey based containing lactose, spray-dried animal plasma,
spray-dried blood meal, and fish meal, while Phase 3 diets were typical com-soybean
meal based. AU diets were fed in pelleted fonn.
Table 5.1. Composition of control diets (as-is basis).
Ingredient, % Phase 1 Phase 2 Phase 3
3Diets formulated to contain 1.6, 1.4, and 1.2% total lysine for PI, P2, and P3,
respectively
bprovided the following per kg feed: Zn, 120 mg; Fe, 120 mg; Mn, 24 mg; Cu, 12 mg; I,
.36 mg; Se, .36 mg; vitamin A, 6,615 ill; vitamin D 3, 661 IU; vitamin E, 40 IU; vitamin
K (menadione activity), 4.4 mg; riboflavin, 6.6mg; d-pantothenic acid, 30 mg; niacin, 40
mg; vitamin B 12, 33 ug; d-biotin, 265 ug; choline, 144 mg; and folic acid, 2 mg.
cpl and P2 contained Neo-terramycin® (100 g/ton oxytetracycline & 140 g/ton neomycin
base) and P3 contained Lincomix® (200 g/ton lincomycin)
dL-camitine (Camiking 10, Lonza Inc., Fair Lawn, NJ) substituted at 0.05%, and SBO
and CO substituted at 5.0% for cornstarch to obtain the five dietary treatments
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0.08
0.50
5.10
2.37
0.68
0.03
0.35
0.30
56.84
33.75
2.11
0.61
0.13
0.03
0.25
0.30
0.28
2,50
2.50
50.19
25.00
10.00
30.19
20.75
20.00
10.00
5.00
2.50
2.50
1.53
0.42
0.20
0.03
0.25
0.30
0.28
Com
SBM (48%)
Whey, dried
Lactose
Plasma, spray-dried
Blood meal, spray-dried
Fish meal, menhaden
Dicalcium phosphate
Limestone
DL-methionine
Ethoxyquin
Salt
Trace min/Vit premixh
Zinc Oxide
Copper sulfate
AntibioticC 1.00 1.00
Comstarchd 5.05 5.10
Pigs were housed in temperature-controlled nursery rooms and grouped in
elevated pens with wire flooring. Each pen provided 1.72 m2 of space and contained a
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five-hole, stainless steel feeder and one nipple waterer that allowed for the ad libitum
access to feed and water throughout the experiment. Room temperature was maintained
initially at 31°C, and decreased by 1.1 °C weekly until the room temperature reached
25.5°C. Pigs were weighed at the initiation of the experiment and then pigs weights and
feed consumption were measured at the end of each dietary phase for the determination
of average daily gain (ADG), average daily feed intake (ADFI), and gain:feed (G:F).
Chemical analysis:
Diets were analyzed for DM according to AOAC (1998) procedures. Gross
energy determinations were made by bomb calorimetry (Parr 1261 lsoperibol
Calorimeter, Moline, IL), and nitrogen determinations were performed by Kjeldahl
methodology (FOSS Tecator, 2400 Kjeltec Analyzer unit, 2020 Digestor, Hoganas,
Sweden). As well, diets were analyzed for L-camitine concentrations using methods
described by Parvin and Pande (1977). Chemical composition of the control diets is
shown in Tahle 5.2. The L-camitine concentration for the five dietary treatments for each
phase is detailed in Table 5.3.
Table 5.2. Chemical composition of control diets (as-is basis).
Item Phase 1 Phase 2 Phase 3
Calculated analysis
ME, kcal/kg 3,155 3,164 3,193
Crude protein, % 22.58 21.70 21.19
Total lysine, % 1.60 1.40 1.20
Digestible lysine, % 1.36 1.18 1.00
Digestible threonine, % 0.80 0.70 0.61
Digestible Met + Cys, % 0.80 0.69 0.56
Digestible tryptophan, % 0.25 0.23 0.21
Calcium, % 0.90 0.90 0.90
Phosphorus, % 0.80 0.80 0.80
Available phosphorus, % 0.62 0.56 0.51
Analyzed values
GE, kcal/kg 3,979 3,972 4,003
Crude protein, % 21.09 20.57 20.70
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Table 5.3. L-Carnitine concentration of diets·.
Item:
Calculated
Concentration
Analyzed
Concentration
Supplemented
Levelb
o
o
50
o
50
o
o
50
o
50
Phase 1
Diet 1
Diet 2
Diet 3
Diet 4
Diet 5
Phase 2
Diet 1
Diet 2
Diet 3
Diet 4
Diet 5
Phase 3
Diet 1 0
Diet 2 0
Diet 3 50
Diet 4 0
Diet 5 50
L-carnitine ppm
37
37
83
37
83
19
19
56
19
63
1
1
29
I
28
o
o
46
o
46
o
o
37
o
44
o
o
28
o
27
-"
ii;i':
",
'"
-',
:;:
-"i'l:.,
:,1
;1':
.,
~.,
aAnalysis reported on an as-is basis
bSupplemented level obtained by subtracting analyzed concentration from analyzed
concentration of unsupplemented diets (diet 1)
Statistical analysis:
The data were analyzed as a randomized complete block design within each
experiment using analysis of variance procedures (Steel et al.. 1997). There were no
treatment by experiment interactions as trends were similar within experiments. Thus.
data were pooled across experiments and analyzed as a 2 x 2 factorial. with a negative
control. in a randomized complete block design. Treatment 1 contained 8 reps/trt and
Treatments 2 through 5 contained 10 reps/trt. The model included the effects of block
(rep). treatment. and block x treatment (error). Orthogonal contrasts were used to test the
effects of control vs addition of a dietary fat source. L-carnitine level (0 vs 50 ppm).
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source of dietary fat (SBO vs CO), and the L-camitine level x added dietary fat source
interaction. Pen served as the experimental unit.
Results
The chemical analyses of the five dietary treatments are presented in Tables 5.2
and 5.3. For Phase I, supplemented levels ofL-camitine were consistent with calculated
levels, signifying proper diet mixing. However, supplemented levels ofL-camitine for
Phase 2 and 3 diets were considerably lower than calculated levels. Reasons for the
discrepancy between the calculated and supplemented L-camitine levels are unknown.
The addition of five-percent soybean oil and coconut oil to the diet increased the caloric
density to approximately 4,157-4,240 kcallkg.
The effects of L-camitine and source of dietary fat on growth performance are
presented in Table 5.4. The addition ofL-camitine and either soybean oil or coconut oil
had little affect on overall performance. Neither ADG nor ADFI (P > 0.20) were affected
by L-camitine or source of dietary fat; however, pigs fed a diet containing added fat had
greater G:F (P < 0.04) when compared with pigs fed the control diet. Additionally, when
L-carnitine was supplemented to the diet an improvement in G:F was noted in pigs fed
CO, while pigs fed SBO tended to have decreased G:F ratios (L-camitine x fat source, P
< 0.06).
The greatest response attributed to the supplementation of a fat source to the diet
was observed in Phase 1. The inclusion of a dietary fat source increased ADG (P < 0.08)
and ADFI (P < 0.01) when compared with performance criteria of pigs fed the control
diet. However, the addition of L-camitine to the diet increased ADG and ADF! in pigs
fed diets containing SBO, while pigs fed diets containing CO had decreased ADG and
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ADFI due to the addition ofL-camitine (L-carnitine x fat source, P < 0.03).
Additionally, pigs fed SBO consumed more feed than pigs fed CO (SBO vs CO effect, P
< 0.04).
The addition of a dietary fat source also elicited a response in growth perfonnance
during Phase 3. Pigs fed a diet containing added fat tended to eat less (P = 0.14) feed,
resulting in improved feed efficiency (P < 0.01) when compared with pigs fed the control
diet. As well, when L-carnitine was added to the diet, pigs fed CO had increased G:F,
while pigs fed SBO had decreased G:F (L-camitine x SBO & CO interaction, P < 0.01).
Feed efficiency was also affected by source of dietary fat, as pigs fed diets containing CO
had greater G:F (P < 0.04) than pigs fed diets containing SBO.
Neither the addition of L-camitine nor the supplementation of a fat source
enhanced perfonnance criteria during Phase 2. No differences in ADG, ADFI, and G:F
(P > 0.18) were noted due to alterations in dietary treatments.
Results from this study suggest that the addition of soybean oil or coconut oil, to
increase caloric density of the diet, can enhance growth perfonnance of weanling pigs.
The greatest response in growth perfonnance, attributed to the inclusion of soybean oil or
coconut oil in the diet, was observed immediately post-weaning (Phase 1). However,
minimal responses associated with the supplementation of L-camitine were observed,
with the responses being varied among phases and source of dietary fat.
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Table 5.4. Growth performance of weanling pigs.
Camitine, ppm 0 0 50 0 50
Fat Source, % 0 5 SBO 5 SBO 5 CO 5CO P <:c
Treatment 13 2b 3b 4b Sb SE L-camitine Fat Sourced Interactione
Phase 1g
f 105 117 146 128 115 13.92 0.04ADG,g
ADFI, gf 135 159 179 164 142 11.58 0.06 0.01
G:F 0.78 0.73 0.82 0.78 0.80 0.05 0.18
Phase 2h
ADG,g 366 347 346 356 361 15.20
ADFI, g 467 441 443 453 444 17.91
G:F 0.79 0.79 0.78 0.79 0.82 0.02 0.20
Phase 3j
ADG,g 489 495 480 487 501 22.19
ADFI, g 774 738 738 739 718 29.18
00 G:Ff 0.63 0.67 0.65 0.66 0.70 0.02 0.05 0.01
-.-J
OveraIlk
ADG,g 334 330 335 337 338 12.77
ADFI, g 479 460 471 471 452 17.15
G:Ff 0.70 0.72 0.71 0.72 0.75 0.01 0.09 0.08
aLeast squares means for eight pens/trt of four to five pigs/pen
hLeast squares means for ten pens/trt of four to five pigs/pen
cDashes indicate P > 0.20
dSBO vs CO effect
eL-camitine x fat source interaction
fSBO and CO vs negative control (P < 0.10)
gPhase 1 = d 0-13 in Exp. I; d 0-10 in Exp. 2
hPhase 2 = d 14-27 in Exp. 1; d 11-24 in Exp. 2
JPhase 3 = d 28-41 in Exp. 1: d 25-38 in Exp. 2
kOveraIl = d 0-41 in Exp. 1; d 0-38 in Exp. 2
- - - - -
~ :&-£t :i; l! i~·;;..il!tii~· ; N;~i~ r;r~·(~ ;!~·Gt;~7; ;
Discussion
The addition of either soybean oil or coconut oil increased ADG and ADFI during
Phase 1. In contrast to the responses reported during Phase 1, results from Experiment 3
suggest that performance criteria are not affected by the addition of a fat source during
Phase 1. Cho et al. (1999b) also reported that ADG and ADFI were not affected by the
addition of either soybean oil or coconut oil to the diet. The results from Exp. 3 and Cho
et a1. (1999b) are in agreement with findings by Tokach et a1. (1995). These authors
reported that weanling pigs require an adjustment period to utilize fat, with no
improvements in growth performance, due to added fat, being observed from d 0 to 14
post-weaning. However, we would assume that the increases in ADG and ADFI of pigs
fed diets containing coconut oil, observed during Phase 1 of this study, could be
attributed to the improved utilization of the medium-chain fatty acids provided in the
coconut oil.
The addition of L-camitine to the diet improved ADG and ADFI in pigs fed SED
during Phase 1. Given the role of L-camitine in fatty acid metabolism, we would
hypothesize that an increase in the oxidation oflong-chain fatty acids found in the
soybean oil occurred, resulting in the improved performance criteria. Increases in feed
intake and daily gain during Phase 1 (0 to 2 wk after weaning), due to the addition of
1,000 ppm L-camitine in diets containing 5% SBO, were also reported by Weeden et a1.
(1991). However, studies by Owen et a1. (1996; 2001) and Weeden et a1. (1990) did not
report any improvements in performance criteria that were attributed to the
supplementation of L-camitine to diets containing added fat sources immediately post-
weanmg.
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Results from Experiment 1 and Experiment 3 suggest that the greatest response
associated with L-camitine was observed during Phase 2 (d 10-24). The fact that
minimal responses were observed during Phase 2 and 3 in this study could be attributed
to the insufficient levels of supplemented L-camitine in the diets. Supplemented levels of
L-camitine were 37 and 44 ppm for Diets 3 and 5, respectively, in Phase 2. In Exp. I,
slight numeric increases in performance criteria were noted in pigs fed 25 ppm L-
camitine during Phase 2. Additionally, in Exp. 4, supplemented levels ofL-camitine
were substantially lower than calculated levels, as Diets 3 and 5 contained 28 and 27
ppm, respectively. These findings would suggest that marginal levels of L-camitine were
available for the utilization of the long-chain fatty acids provided in the form of soybean
oil.
Overall performance indicates that pigs fed diets containing added fat sources
have improved feed efficiency. Although not significant, numeric increases in ADG and
decreases in ADFI were observed resulting in the improved feed efficiency. Lawrence
and Maxwell (1983) also reported that added dietary fat improved feed efficiency, while
not affecting ADG of weaned pigs.
Minimal differences in performance criteria were observed between pigs fed
coconut oil and soybean oil. Pigs fed coconut oil consumed less feed during Phase 1 and
had greater feed efficiency during Phase 3. As well, overall feed efficiency was
improved in pigs fed coconut oil when compared with pigs fed soybean oil. These results
are in agreement with findings by Cera et al. (1989). These authors reported that pigs fed
coconut oil (medium-chain fatty acids) had improved feed efficiency when compared
with pigs fed diets containing added fat sources that were comprised primarily of long-
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chain fatty acids, However, Cho et al. (1999b) reported that the supplementation of
coconut oil to the diet improved ADG, while having no affect on ADFI or feed efficiency
of weanling pigs,
Results from this study suggest that the addition of soybean oil or coconut oil can
enhance growth performance of weanling pigs, The greatest response in performance
criteria, associated with a supplemental fat source, was observed immediately post-
weaning (Phase 1), However, minimal responses associated with the addition of L-
camitine to the diet were observed, with the responses being varied among phases and
source of dietary fat.
Implications
Weanling pig diets are supplemented with fat sources, to increase the caloric
density of the diet, in an effort to improve growth performance, thereby diminishing the
effects ofpost-weaning lag, However, the efficiency with which weanling pigs utilize
supplemental fat varies between source of dietary fat. Research has shown that weanling
pigs are able to more efficiently utilize sources of dietary fat that are comprised primarily
of medium-chain fatty acids, Results from this study suggest that diets containing added
fat sources enhanced performance criteria ofweanling pigs, As well, slight
improvements in growth perfonnance of weanling pigs fed coconut oil (medium-chain
fatty acids) when compared with pigs fed diets containing soybean oil (long-chain fatty
acids) were observed, However, because of questionable supplemented levels of L-
camitine, the effects of L-camitine on different fat sources are uncertain,
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Chapter VI
Summary and Conclusions
A common practice in today's swine industry is weaning pigs at 21 days of age or
younger. Ironically, the gastrointestinal tract is immaturely developed and enzyme
activity is limited at this early age of the pig, resulting in inefficient utilization of added
dietary plant protein sources and fat sources, The inefficient utilization of these dietary
ingredients is one of the major causes of a dilemma known as post-weaning lag. Another
factor contributing to the effects of post-weaning lag is that during the first few days after
weaning, appreciable quantities of feed can not be consumed to meet the young pig's
energy demand for growth.
In an effort to diminish the negative effects attributed to post-weaning lag,
nutritionists are developing complex, nutrient-dense diets, containing ingredients that are
highly digestible and appropriate for the pig's stage of physiological development. One
area that nutritionists are evaluating in the feeding regime of weanling pigs is the
improved utilization of supplemental fat sources. On average, fat sources provide 2.25
times more energy than protein or carbohydrate sources. Therefore, during periods of
minimal feed consumption, if an improvement in the utilization of dietary fat sources can
be obtained, an enhancement in the performance of weanling pigs is conceivable.
One possible method to improving dietary fat utilization is by supplementing L-
camitine, a cosubstrate in lipid metabolism, to the diet of weanling pigs. The primary
metaboljc role of L-camitine is to facilitate the transfer of long-chain fatty acids across
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the otherwise impermeable mitochondrial membrane into the matrix of the mitochondria
for the production of adenosine triphosphate (energy) via beta-oxidation and oxidative
phosphorylation.
Thus, the obj ectives of this thesis were to evaluate the effects of supplementing L-
camitine to the diet of weanling pigs and its subsequent effects on growth perfonnance,
nutrient digestibility, and whole body composition.
In Exp. 1, improvements in growth performance were observed in pigs fed
increasing levels of L-camitine. Although no changes were noted in daily feed intake for
the 38-d study, increases in daily gain were observed due to the addition of L-camitine,
resulting in improved feed efficiencies in weanling pigs. Pigs fed 50 ppm L-camitine had
the highest ADG and best G:F for d 0-38. The improvement in ADG and G:F, associated
with L-camitine, was greatest during Phase 2. Again, the best response to supplemental
L-camitine was noted in pigs fed 50 ppm. Results from Exp. 1 indicate that the addition
of L-camitine improved growth perfonnance in weanling pigs, with the most pronounced
response to supplemental L-camitine observed in pigs fed 50 ppm.
Growth performance trends observed in Exp. 2 were similar to those reported in
Exp. 1. Weanling pigs fed dietary L-camitine had improved ADG from d 0-38, with the
greatest response being observed in pigs fed 50 ppm L-camitinc. Additionally, in Exp. 2,
pigs fed increasing levels of L-camitine had increased fecal GE and urine GE excretion;
however, increasing trends in DE and ME (kcalld) were still observed, due to greater
increases in GE intake. We would assume that the slight improvements in nutrient
digestibility observed in pigs fed supplemental levels of L-camitine resulted in the
improvements in growth perfonnance of weanling pigs.
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Trends for nitrogen balance were similar to those reported for energy digestibility.
The addition of increasing levels ofL-camitine to the diet increased fecal nitrogen
excretion of weanling pigs. However, larger increases in nitrogen intake were noted in
pigs fed 25 and 50 ppm L-camitine resulting in the percentages of nitrogen absorbed and
nitrogen retained being greater in these two groups when compared with pigs fed diets
containing a and 100 ppm added L-camitine.
Improvements in whole body composition were also observed in Exp. 2. In
general, the response to L-camitine tended to plateau at 50 ppm. Increasing
concentrations ofL-camitine resulted in increases in the percentage of protein and
decreases in the percentage of lipid in weanling pigs. Additionally, increasing levels of
L-camitine enhanced the daily rate of protein accretion. Although, no affects on the daily
rate of lipid accretion were observed, the ratio of protein accretion to lipid accretion
improved with increasing levels ofL-camitine. The increase in the ratio ofprotein
accretion to lipid accretion indicates a repartitioning of nutrients away from lipid
deposition and towards the accretion of protein in weanling pigs.
Results from Exp. I and Exp. 2 indicate that supplementing 50 ppm L-camitine to
diets containing added fat improves growth performance in weanling pigs. The next
question we tried to answer was whether the addition of fat sources to the diet of
weanling pigs might be required before an improvement in growth performance
attributed to supplemental L-camitine is observed.
Results from Exp. 3 suggest that the addition of 50 ppm L-camitine improved
growth performance in weanling pigs; however, supplemental L-camitine was more
effective in improving performance criteria when soybean oil was included in the diet.
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The addition ofL-carnitine did improve G:F for the 38-d study. However, the increase in
G:F associated with L-carnitine was more pronounced in pigs fed soybean oil than those
not fed soybean oil. Similar to Exp. 1, the greatest response to L-camitine occurred in
Phase 2 with an increase in ADG and G:F. Given the role ofL-carnitine in lipid
metabolism, we would assume that in pigs fed diets without soybean oil, adequate levels
of L-camitine were synthesized for long-chain fatty acid oxidation and supplemental L-
camitine was not required. However, when soybean oil was added to the diet and long-
chain fatty acid concentrations were increased, supplemental levels of L-carnitine were
needed to utilize the additional long-chain fatty acids.
The addition of L-carnitine and either soybean oil or coconut oil to the diet of
weanling pigs had little affect on overall performance in Exp. 4. However, we would
attribute this to insufficient levels of L-camitine supplementation in the diets. The
reasons for the discrepancy between supplemented levels and formulated levels ofL-
carnitine in Exp. 4 are unknown. In Exp. 4, the greatest response associated with the
supplementation of a fat source to the diet was observed in Phase 1. The inclusion of a
dietary fat source increased ADG and ADFI when compared with performance criteria of
pigs fed the control diet. Additionally, as would be expected, the addition of L-carnitine
to the diet increased ADG and ADFI in pigs fed diets containing soybean oil (long-chain
fatty acids) while pigs fed diets containing coconut oil (medium-chain fatty acids) had
decreased ADG and ADFI due to the addition ofL-carnitine. The response in
performance criteria observed during Phase 1 is in contrast to results from Exp. 1 and
Exp. 3, in which both experiments reported the greatest improvements, associated with
the addition ofL-camitine during Phase 2.
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The topic of this thesis focused on the supplementation of L-carnitine to the diet
of weanling pi.gs and its subsequent effects on growth perfonnance, nutrient digestibility,
and whole body composition. In summarizing the data from all four experiments, we
would believe that beneficial effects are conceivable due to the addition of L-carnitine to
the diet of weanling pigs. Data indicates positive responses attributed to the
supplementation ofL-carnitine when soybean oil or other fat sources are provided in the
diet as a means to increase caloric density; thereby, meeting the energy requirements of
weanling pigs and improving growth performance. Additionally, data indicates
improvements in body composition as a repartitioning of nutrients from lipid deposition
towards protein accretion occurred. The improvements in body composition offer an
incentive to producers, by allowing the producer to merit greater rewards in today's
industry in which the majority of the animals are marketed on a carcass based system.
However, more research is needed to better understand the mode of action of L-camitine
in lipid metabolism and its subsequent effects on perfonnance criteria.
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APPENDIX
Pen Means and Analysis of Variance Tables
105
Appendix Table 1
Pen means for average daily gain, average daily feed intake, and gain:feed for
Phases 1 and 2 - Experiment t.
Phase 1 Phase 2
ADG ADFI ADG ADFI
Pen Trt Rep (g) (g) G:F (g) (g) G:F
2 4 1 116 163 .715 409 498 .822
3 2 1 80 153 .524 372 492 .756
4 1 2 139 176 .789 320 439 .728
5 4 2 142 159 .891 343 449 .764
6 1 3 125 174 .718 266 373 .714
7 2 3 115 136 .843 261 350 .747
:119 1 1 117 184 .635 360 483 .746 '"
10 3 I 191 210 .909 429 520 .825 '"
II 2 2 169 188 .899 373 477 .783 '"
12 3 2 173 179 .964 344 445 .772
13 4 3 222 225 .986 293 408 .719
14 3 3 133 154 .862 346 434 .799 ;:J
22 1 4 135 160 .844 366 506 .724 "
558 .789 '"23 2 4 188 206 .912 441
24 4 5 159 179 .886 418 510 .819 "
25 3 5 194 197 .984 371 494 .752 i1'
26 4 6 151 174 .867 367 482 .761
'I,
27 1 6 159 187 .850 357 504 .708 I;II
29 4 4 163 168 .968 434 513 .847 'it
30 3 4 183 194 .941 455 585 .777 '.'"
31 1 5 144 159 .906 380 495 .767 :ii
32 2 5
,II
33 3 6 117 174 .674 340 457 .744 :11
34 2 6 114 148 .775 324 442 .732 '"
Trt 1: Control diet
Trt 2: Control diet + 25 ppm L-camitine
Trt 3: Control diet + 50 ppm L-camitine
Trt 4: Control diet + 100 ppm L-camitine
Dashes indicate data for this variable not included in analysis due to poor pen
perfonnance.
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Appendix Table 2
Analysis of variance for average daily gain, average daily feed intake, and gain:feed
for Phases 1 and 2 - Experiment 1.
Mean Squares
Phase 1 Phase 2
Source d.f. ADG ADFI G:F ADG ADFI G:F
Total 22
Error 14 1099.9 621.3 .009 729.0 757.7 .001
Repetition 5 949.8 63.3 .028 8581.6 10245.5 .002
Treatment 3 1291.5 331.0 .016 1972.6 611.0 .004
Linear 1 2231.8 229.8 .035 4053.2 179.0 .009
Quadratic 1 493.1 54.8 .005 1588.9 711.1 .002
Cubic 1 1155.8 713.4 .007 179.4 586.4 .000 JII
-',
C.V.,% 22.26 14.2 11.05 7.4 5.8 3.81 '1,
-',
",
~I •
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Appendix Table 3
Pen means for average daily gain, average daily feed intake, and gain :feed for Phase
3 and the entire 38-d period - Experiment 1.
Phase 3 Overall
ADG ADFI ADG ADFI
Pen Trt Rep (g) (g) G:F (g) (g) G:F
2 4 1 557 868 .642 386 546 .708
3 2 1 479 793 .604 335 513 .652
4 1 2 457 795 .575 323 501 .645
5 4 2 529 821 .645 359 510 .703
6 1 3 456 758 .602 291 448 .649
7 2 3 441 630 .700 289 397 .728 Iii9 1 1 479 785 .610 340 516 .659 '"
10 3 1 595 900 .661 428 578 .739 ",
2 2 538 380 528 .719
",
11 822 .654
12 3 2 470 715 .658 345 474 .728
13 4 3 483 768 .629 345 492 .700
14 3 3 480 749 .641 325 449 .725 :1
'.22 1 4 493 773 .638 352 513 .686
'"23 2 4 524 871 .601 405 581 .697
24 4 5 496 858 .578 378 551 .686 "0
"0
25 3 5 528 849 .621 382 547 .699
26 4 6 412 775 .532 326 509 .641
"
27 1 6 504 780 .646 359 522 .688
29 4 4 489 802 .610 383 528 .725 ,I ~
30 3 4 547 900 .608 417 598 .697
"
31 1 5 484 795 .609 356 517 .688
'\'
32 2 5 'I
:I
33 3 6 447 632 .707 321 447 .717 II
34 2 6 468 757 .618 311 463 .671
Trt 1: Control diet
Trt 2: Control diet + 25 ppm L-camitine
Trt 3: Control diet + 50 ppm L-camitine
Trt 4: Control diet + 100 ppm L-camitine
Dashes indicate data for this variable not included in analysis due to poor pen
performance.
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Appendix Table 4
Analysis of variance for average daily gain, average daily feed intake, and gain:feed
for Phase 3 and tbe entire 38-d period - Experiment 1.
Mean Squares
Phase 3 Overall
Source d.f. ADG ADFI G:F ADG ADFI G:F
Total 22
Error 14 1487.9 3768.7 .002 703.7 1186.4 .001
Repetition 5 2969.9 10011.0 .001 3285.0 6405.8 .001
Treatment 3 1050.7 1465.0 .002 1312.4 585.5 .002
Linear 1 744.2 4166.0 .001 2356.5 1598.0 .002
Quadratic 1 2004.5 271.9 .006 1140.0 .08 .005 It
Cubic 1 298.2 11.2 .001 376.7 207.5 .001 "
C.V.,% 7.81 7.76 6.45 7.50 6.75 3.90
"
II
'.
"
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Appendix Table 5
Pen means for initial and final body weight, average daily gain, average daily feed
intake, and gain:feed for the entire 38-d period - Experiment 2.
Overall
Initial Wt. Final Wt. ADG ADFI
Pen Trt Rep (kg) (kg) (g) (g) G:F
1 2 1 6.67 17.28 279 352 .793
2 3 1 7.26
3 4 1 5.44 16.69 296 383 .772
4 1 1 5.31 15.51 269 350 .766
5 4 2 5,,12 16.83 308 411 .749
6 2 2 4.49 18.10 358 438 .818
7 1 2 5.22 17.41 321 436 .737
8 3 2 3.76
9 1 3 4.22 12.52 218 275 ,796
10 4 3 4.31 17.82 356 415 .857
11 3 3 3.76 17.46 360 449 .803
12 2 3 4.63 17.01 326 413 .788 I
13 2 4 5.26 17.10 312 369 .843
14 4 4 5.44
15 3 4 5.76 17.87 319 396 .804
16 1 4 5.35 14.10 230 308 .749
17 2 5 5.49 16.19 282 366 .770
18 1 5 4.26 13.24 236 327 .724
19 4 5 3.90 16.78 339 374 .906
20 3 5 3.13 13.83 282 305 .925
21 4 6 4.72
22 2 6 3.17 13.42 270 338 .799
23 1 6 4.67 14.33 254 347 .732
24 3 6 4.94 20.27 403 499 .808
Trt 1: Control diet
Trt 2: Control diet + 25 ppm L-camitine
Trt 3: Control diet + 50 ppm L-camitine
Trt 4: Control diet + 100 ppm L-carnitine
Dashes indicate data for this variable not included in analysis due to poor pig
performance.
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Appendix Table 6
Analysis of variance for average daily gain, average daily feed intake, and gain :feed
for tbe entire 38-d period - Experiment 2.
Mean Squares
Overall
Source
Total
Error
Repetition
Treatment
Linear
Quadratic
Cubic
C.V., %
d.f.
19
11
5
3
1
1
1
ADG
1454.9
1428.8
7493.3
9480.8
9433.1
331.4
12.68
III
ADFI
2323.3
3707.2
5767.2
6064.9
8455.5
838.9
12.77
G:F
0.00243
0.00139
0.00598
0.00896
0.00578
0.00003
6.19
'1
, .
'.
'.
Appendix Table 7
Pen means for average daily feed intake, gross energy intake, fecal energy excretion,
and digestible energy (kcal/d, kcal/kg) - Experiment 2 (Period 1).
Energy Balance
ADFI GE FE DE DE
Pen Trt Rep (g) (kcal/d) (kcal/d) (kcaUd) (kcal/kg)
1 2 1 61.99 281.66 20.73 260.93 4209.3
2 3 1
3 4 1 111.68 503.35 52.86 450.49 4033.6
4 1 1 137.34 620.70 52.90 567.81 4134.4
5 4 2 196.91 887.43 70.38 817.05 4143.5
6 2 2 235.82 1071.51 116.62 954.89 4049.3
7 1 2 197.45 892.40 57.97 834.43 4226.0
8 3 2
9 1 3
10 4 3 176.66 796.20 63.99 732.21 4144.7
11 3 3 244.75 11 01.02 118.83 982.19 4013.0
12 2 3 204.07 927.23 64.38 862.85 4228.3
13 2 4 206.48 938.21 95.44 842.77 4081.6
14 4 4
15 3 4 185.58 834.85 43.40 791.44 4264.7
16 1 4
17 2 5
18 1 5 19.19 86.72 6.82 79.90 4164.2
19 4 5 145.40 655.29 58.77 596.51 4102.7 .,..
20 3 5 54.13 243.49 44.97 198.52 3667.7
21 4 6
-,
22 2 6 91.91 417.63 32.20 385.43 4193.4
23 1 6 83.04 375.33 18.52 356.81 4296.6
24 3 6 243.08 1093.49 105.37 988.12 4065.0
Trt 1: Control diet
Trt 2: Control diet + 25 ppm L-camitine
Trt 3: Control diet + 50 ppm L-carnitine
Trt 4: Control diet + 100 ppm L-carnitine
Dashes indicate data for this variable not included in analysis due to poor pig
perfonnance.
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Appendix Table 8
Analysis of variance for average daily feed intake, gross energy intake, fecal energy
excretion, and digestible energy (kcalJd, kcalJkg) - Experiment 2 (Period 1).
Mean Squares
DE DE
Source d.f. ADF! GE FE (kcal/d) (kcal/kg)
Total 16
Error 8 3017.2 61699.4 1044.3 48966.9 16393.9
Repetition 5 9103.8 185902.9 1010.1 160950.2 20826.3
Treatment 3 2344.3 45682.3 1133.2 33576.6 37951.0
Linear I 2734.9 53135.7 747.4 41276.6 13507.5
Quadratic 1 2823.6 57354.7 2582.5 35596.0 94323.2
Cubic I 1626.0 29559.6 130.7 25759.8 9412.3
C.V.,% 35.98 36.01 53.64 35.15 3.11
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Appendix Table 9
Pen means for fecal excretion and urine excretion, urinary energy and
metabolizable energy (kcal/d, kcal/kg) - Experiment 2 (Period 1).
Energy Balance
Feces Urine UE ME ME
Pen Trt Rep (g) (g) (kcaVd) (kcaVd) (kca1Ikg)
1 2 1 4.07 0.81 2.71 258.22 4165.6
2 3 1
3 4 1 11.20 1.15 3.32 447.17 4003.9
4 1 1 12.79 1.05 2.13 565.68 4118.9
5 4 2 16.37 1.52 3.89 813.16 4129.7
6 2 2 28.22 1.43 1.88 953.01 4041.3
7 1 2 13.86 1.63 4.26 830.17 4204.4
8 3 2
9 1 3
10 4 3 14.15 1.13 2.36 729.85 4131.3
11 3 3 28.93 1.74 2.76 979.43 4001.7
12 2 3 14.77 2.74 6.69 856.16 4195.5
13 2 4 23.00 1.25 3.18 839.59 4066.2
14 4 4
15 3 4 10.50 2.22 5.51 785.93 4234.9
16 1 4
:117 2 5
18 1 5 0.97 0.85 1.76 78.14 4072.6
19 4 5 12.81 2.27 5.45 591.07 4065.2 ...,
20 3 5 10040 0.61 1.52 197.00 3639.6 , .
21 4 6 •, .
22 2 6 6.50 0.89 2.13 383.30 4170.2
23 1 6 4.05 1.17 3.21 353.60 4257.9
24 3 6 23.72 2.65 5.34 982.78 4043.1
Trt 1: Control diet
Trt 2: Control diet + 25 ppm L-camitine
Trt 3: Control diet + 50 ppm L-camitine
Trt 4: Control diet + 100 ppm L-camitine
Dashes indicate data for this variable not included in analysis due to poor pig
perfonnance.
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Appendix Table 10
Analysis of variance for fecal excretion and urine excretion, urinary energy and
metabolizable energy (kcaUd, kcal/kg) - Experiment 2 (Period 1).
Source
Total
Error
Repetition
Treatment
Linear
Quadratic
Cubic
C.V., %
d.f.
16
8
5
3
1
1
1
Feces
62.101
66.919
63.169
26.377
156.150
11.756
56.68
Urine
0.6052
0.2162
0.1434
0.2165
0.1021
0.1150
52.67
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Mean Squares
DE
(kcal/d)
3.8969
0.8976
0.6739
1.8754
0.0320
0.0703
57.76
ME
(kcalld)
48549.9
160429.2
33379.9
40723.4
35662.8
25674.1
35.19
ME
(kcallkg)
13766.0
25247.8
32348.2
8955.2
82778.0
8377.6
2.87
Appendix Table 11
Pen means for energy ratios - Experiment 2 (Period 1).
Energy Balance
DE:GE ME:DE ME:GE
Pen Trt Rep (%) (%) (%)
1 2 1 92.64 98.96 91.68
2 3 1
3 4 1 89.50 99.26 88.84
4 1 1 91.48 99.63 91.13
5 4 2 92.07 99.52 91.63
6 2 2 89.12 99.80 88.94
7 1 2 93.50 99.49 93.03
8 3 2
9 1 3
10 4 3 91.96 99.68 91.67
11 3 3 89.21 99.72 88.96
12 2 3 93.06 99.22 92.34
13 2 4 89.83 99.62 89.49
14 4 4
15 3 4 94.80 99.30 94.14
16 1 4
17 2 5 118 1 5 92.14 97.80 90.11
19 4 5 91.03 99.09 90.20
20 3 5 81.53 99.23 80.91
21 4 6
22 2 6 92.29 99.45 91.78
23 1 6 95.07 99.10 94.21
24 3 6 90.36 99.46 89.R8 IITrt 1: Control diet
Trt 2: Control diet + 25 ppm L-camitine
Trt 3: Control diet + 50 ppm L-camitine
Trt 4: Control diet + 100 ppm L-camiline
Dashes indicate data for this variable not included in analysis due to poor pig
performance.
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Appendix Table 12
An alysis of variance for energy ratios - Experiment 2 (Period 1).
Mean Squares
Source d.f.
Total 16
Error 8
Repetition 5
Treatment 3
Linear 1
Quadratic 1
Cubic 1
C.V., %
DE:GE
8.0633
10.2777
16.6529
3.5725
46.1710
0.9222
3.12
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ME:DE
0.17391
0.29636
0.14167
0.24286
0.17198
0.01352
0.42
ME:GE
6.7778
12.4517
14.1929
1.9950
40.4497
0.7098
2.88
Appendix Table 13
Pen means for average daily feed intake, gross energy intake, fecal energy excretion,
and digestible energy (kcal/d, kcal/kg) - Experiment 2 (Period 2).
Energy Balance
ADFI GE FE DE DE
Pen Trt Rep (g) (kcal/d) (kcalJd) (kcal/d) (kcal/kg)
1 2 1 347.4 1607 159.0 1448 4167
2 3 1
3 4 1 393.5 1824 214.8 1609 4089
4 1 1 315.5 1473 147.1 1326 4202
5 4 2 329.1 1525 236.5 1289 3916
6 2 2 396.3 1833 194.9 1638 4133
7 1 2 394.1 1840 124.7 1715 4352
8 3 2
9 1 3 209.0 976 117.6 858 4106
10 4 3 374.7 1737 216.6 1520 4057
11 3 3 397.9 1861 249.2 1611 4049
12 2 3 273.7 1266 139.4 1126 4115
13 2 4 346.7 1603 165.6 1438 4147
14 4 4
15 3 4 348.5 1629 141.1 1488 4270
:116 1 4 327.4 1528 184.3 1344 4106
17 2 5 366.8 1696 201.5 1495 4075 I
18 1 5 368.6 1721 202.3 1519 4120
19 4 5 451.5 2092 293.2 1799 3985
20 3 5 362.3 1694 241.1 1453 4010
21 4 6 .,,
22 2 6 345.9 1600 184.9 1415 40<)0
23 1 6 354.0 1652 224.5 1428 4034
24 3 6 494.9 2314 259.4 2054 4151
Trt 1: Control diet
Trt 2: Control diet + 25 ppm L-carnitine
Trt 3: Control diet + 50 ppm L-carnitine
Trt 4: Control diet + 100 ppm L-carnitine
Dashes indicate data for this variable not included in analysis due to poor pig
performance.
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Appendix Table 14
Analysis of variance for average daily feed intake, gross energy intake, fecal energy
excretion, and digestible energy (kcal/d, kcaVkg) - Experiment 2 (Period 2).
Mean Squares
DE DE
Source d.C ADFI GE FE (kcal/d) (kcal/kg)
Total 19
Error 11 2770.29 60157.2 1099.02 53685.5 7878.96
Repetition 5 3903.41 84501.9 2652.62 64663.7 7910.08
Treatment 3 6240.12 137041.6 5970.20 91189.0 17064.63
Linear 1 11092.94 229697.2 16175.87 123970.3 45732.42
Quadratic 1 3521.85 76511.1 20.23 76653.3 7366.45
Cubic 1 2741.42 76271.5 1009.65 59491.4 5338.57
C.V., % 14.62 14.66 17.01 15.67 2.16
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Appendix Table 15
Pen means for fecal excretion and urine excretion, urinary energy and
metabolizable energy (kcal/d, kcal/kg) - Experiment 2 (Period 2).
Energy Balance
Feces Urine VE ME ME
Pen Trt Rep (g) (kg) (kcal/d) (kcal/d) (kcal/kg)
1 2 1 36.01 0.0027 7.76 1440 4145
2 3 1
3 4 1 45.26 0.0024 7.66 1601 4069
4 1 1 32.92 0.0016 5.61 1320 4185
5 4 2 48.21 0.0021 6.31 1283 3897
6 2 2 45.30 0.0024 5.92 1632 4118
7 1 2 26.15 0.0020 5.86 1709 4337
8 3 2
9 1 3 24.80 0.0014 4.20 854 4086
10 4 3 49.06 0.0029 7.58 1512 4036
11 3 3 55.09 0.0014 4.85 1606 4037
12 2 3 28.96 0.0018 5.28 1121 4096
13 2 4 36.53 0.0014 3.50 1434 4137
14 4 4
15 3 4 30.97 0.0018 4.44 1484 4258
16 1 4 41.43 0.0023 5.39 1339 4086
17 2 5 42.61 0.0029 7.23 1487 4055
18 1 5 45.89 0.0019 5.31 1513 4105
19 4 5 66.40 0.0031 7.29 1792 3969
20 3 5 55.32 0.0011 2.68 1450 4002
21 4 6
22 2 6 40.83 0.0019 5.09 1410 4075
23 1 6 48.75 0.0019 4.66 1423 4021
24 3 6 58.24 0.0021 4.91 2049 4141
Trt 1: Control diet
Trt 2: Control diet + 25 ppm L-carnitine
Trt 3: Control diet + 50 ppm L-carnitine
Trt 4: Control diet + 100 ppm L-carnitine
Dashes indicate data for this variable not included in analysis due to poor pig
performance.
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Appendix Table 16
Analysis of variance for fecal and urine excretion, urinary energy, and
metabolizable energy (kcal/d, kcal/kg) - Experiment 2 (Period 2).
Mean Squares
UE ME ME
Source d.f. Feces Urine (kcal/d) (kcal/d) (kcal/kg)
Total 19
Error 11 66.615 2.77e-7 1.2627 53327.7 7850.3
Repetition 5 143.162 6.42e-8 0.8926 64540.5 7776.1
Treatment 3 282.665 7.38e-7 3.8866 91332.9 17843.2
Linear 1 736.420 1.05e-6 5.7094 122532.6 46494.2
Quadratic 1 6.501 5.92e-7 3.8011 77718.6 8787.6
Cubic 1 63.604 1.11e-6 5.1927 60693.9 6576.6
C.Y.,% 19.01 25.62 20.15 15.68 2.16
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Appendix Table 17
Pen means for energy ratios - Experiment 2 (Period 2).
Energy Balance
DE:GE ME:DE ME:GE
Pen Trt Rep (%) (%) (%)
1 2 1 90.1 99.5 89.6
2 3 1
3 4 1 88.2 99.5 87.8
4 1 I 90.0 99.6 89.6
5 4 2 84.5 99.5 84.1
6 2 2 89.4 99.6 89.0
7 1 2 93.2 99.7 92.9
8 3 2
9 1 3 87.9 99.5 87.5
10 4 3 87.5 99.5 87.1
11 3 3 86.6 99.7 86.3
12 2 3 89.0 99.5 88.6
13 2 4 89.7 99.8 89.5
14 4 4
15 3 4 91.3 99.7 91.1
16 1 4 87.9 99.6 87.6
17 2 5 88.1 99.5 87.7
18 1 5 88.2 99.7 87.9
19 4 5 86.0 99.6 85.6
20 3 5 85.8 99.8 85.6
21 4 6
22 2 6 88.4 99.6 88.1
23 1 6 86.4 99.7 86.1
24 3 6 88.8 99.8 88.6
Trt 1: Control diet
Trt 2: Control diet + 25 ppm L-camitine
Trt 3: Control diet + 50 ppm L-camitine
Trt 4: Control diet + 100 ppm L-camitine
Dashes indicate data for this variable not included in analysis due to poor pig
perfonnance.
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Appendix Table 18
Analysis of variance for energy ratios - Experiment 2 (period 2).
Mean Squares
Source d.f.
Total 19
Error 11
Repetition 5
Treatment 3
Linear 1
Quadratic 1
Cubic 1
C.V., %
DE:GE
3.59141
3.65474
5.99290
16.29025
3.11969
0.02040
2.14
123
ME:DE
0.00664
0.00922
0.02454
0.00781
0.03048
0.05490
0.08
ME:GE
3.63896
3.60330
6.08855
16.45825
3.55290
0.00080
2.17
L.
Appendix Table 19
Pen means for average daily feed intake, gross energy intake, fecal energy excretion,
and digestible energy (kcal/d, kcal/kg) - Experiment 2 (Period 3).
Energy Balance
ADFI GE FE DE DE
Pen Trt Rep (g) (kcal/d) (kcal/d) (kcal/d) (kcalJkg)
1 2 1 516.6 2415 200.4 2215 4287
2 3 1
3 4 1 596.5 2813 240.3 2572 4312
4 1 1 480.8 2260 194.1 2066 4297
5 4 2 640.7 3021 385.0 2636 4114
6 2 2 594.6 2780 258.6 2521 4240
7 1 2 663.7 3119 343.1 2776 4183
8 3 2
9 1 3 401.3 1886 257.7 1629 4058
10 4 3 474.8 2239 290.2 1948 4104
11 3 3 544.1 2557 267.9 2289 4207
12 2 3 528.2 2469 238.4 2231 4224
13 2 4 443.3 2073 295.0 1778 4010
14 4 4
15 3 4 496.1 2332 231.8 2100 4232
16 1 4 489.1 2299 278.6 2020 4131
17 2 5 464.3 2171 237.6 1933 4163
18 1 5 467.6 2]98 202.8 1995 4267
19 4 5 589.5 2779 282.4 2497 4236
20 3 5 491.9 2312 235.3 2076 4221
21 4 6
22 2 6 535.3 2502 290.8 2212 4132
23 1 6 505.9 2378 327.1 2051 4054
24 3 6 545.9 2565 337.4 2228 4081
Trt 1: Control diet
Trt 2: Control diet + 25 ppm L-camitine
Trt 3: Control diet + 50 ppm L-camitine
Trt 4: Control diet + 100 ppm L-camitine
Dashes indicate data for this variable not included in analysis due to poor pig
performance.
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Appendix Table 20
Analysis of variance for average daily feed intake, gross energy intake, fecal energy
excretion, and digestible energy (kcal/d, kcal/kg) - Experiment 2 (Period 3).
Mean Squares
DE DE
Source d.f. ADFI GE FE (kcaIJd) (kcal/kg)
Total 19
Error II 2043.20 45047.9 772.01 44447.7 4629.8
Repetition 5 9578.18 211169.1 7079.55 175489.8 19099.9
Treatment 3 4109.76 98266.1 3002.77 74576.1 658.3
Linear 1 10864.27 260634.4 6877.80 182380.2 323.7
Quadratic I 214.27 2787.5 2792.58 11142.1 8881.8
Cubic 1 532.43 16336.1 76.44 14088.9 3251.7
C.V.,% 8.63 8.63 10.30 9.63 1.63
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Appendix Table 21
Pen means for fecal and urine excretion, urinary energy and metabolizable energy
(kcalld, kcallkg) - Experiment 2 (Period 3).
Energy Balance
Feces Urine UE ME ME
Pen Trt Rep (g) (kg) (kcal/d) (kcal/d) (kcal/kg)
1 2 1 46.45 0.0060 18.52 2196 4251
2 3 1
3 4 1 55.10 0.0083 24.42 2548 4271
4 1 1 45.11 0.0054 15.82 2050 4264
5 4 2 86.72 0.0114 28.72 2607 4069
6 2 2 60.14 0.0080 21.94 2499 4203
7 I 2 75.17 0.0101 26.01 2750 4144
8 3 2
9 I 3 55.72 0.0051 11.28 1617 4030
10 4 3 63.20 0.0084 21.44 1927 4059
11 3 3 57.49 0.0060 14.76 2275 4180
12 2 3 51.54 0.0102 24.26 2207 4178
13 2 4 62.98 0.0078 21.51 1756 3961
14 4 4
15 3 4 51.64 0.0048 11.74 2088 4209
16 1 4 61.55 0.0045 11.66 2009 4107
17 2 5 51.72 0.0070 17.93 1915 4125
18 I 5 44.68 0.0051 13.88 1981 4237
19 4 5 61.45 0.0055 14.09 2483 4212
20 3 5 53.12 0.0063 16.90 2060 4187
21 4 6
22 2 6 63.36 0.0050 12.95 2199 4108
23 1 G 71.82 0.0058 12.86 2038 4028
24 3 6 74.02 0.0074 18.10 2210 4048
Trt 1: Control diet
Trt 2: Control diet + 25 ppm L-camitine
Trt 3: Control diet + 50 ppm L-camitine
Trt 4: Control diet + 100 ppm L-camitine
Dashes indicate data for this variable not included in analysis due to poor pig
performance.
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Appendix Table 22
Analysis of variance for fecal and urine excretion, urinary energy and metabolizable
energy (kcal/d, kcal/kg) - Experiment 2 (Period 3).
Source d.f. Feces Urine
Mean Squares
VE
(kcal/d)
ME
(kcaVd)
ME
(kcallkg)
Total
Error
Repetition
Treatment
Linear
Quadratic
Cubic
C.V.,%
19
11
5
3
1
1
1
29.9113 0.000003 15.8151 44469.1 5253.3
330.6480 0.000006 38.8956 170933.9 18579.1
145.6074 0.000003 29.7156 72979.0 3807.0
343.1027 6.715e-6 49.3362 176808.8 626.4
115.1079 1.088e-8 0.9703 11005.7 8725.1
7.4505 3.295e-6 31.8676 15610.8 5086.5
9.17 23.12 22.17 9.71 1.75
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Appendix Table 23
Pen means for energy ratios - Experiment 2 (Period 3).
Energy Balance
DE:GE ME:DE ME:GE
Pen Trt Rep (%) (%) (%)
1 2 1 91.7 99.2 90.9
2 3 1
3 4 1 91.5 99.1 90.6
4 1 1 91.4 99.2 90.7
5 4 2 87.3 98.9 86.3
6 2 2 90.7 99.1 89.9
7 1 2 89.0 99.1 88.2
8 3 2
9 1 3 86.3 99.3 85.7
10 4 3 87.0 98.9 86.1
11 3 3 89.5 99.4 88.9
12 2 3 90.3 98.9 89.4
13 2 4 85.8 98.9 84.7
14 4 4
15 3 4 90.1 99.4 89.6
16 1 4 87.9 99.4 87.4
17 2 5 89.1 99.1 88.2
18 1 5 90.8 99.3 90.1
19 4 5 89.8 99.4 89.3
20 3 5 89.8 99.2 89.1
21 4 6
22 2 0 88.4 99.4 87.9
23 1 G 86.2 99.4 85.7
24 3 6 86.8 99.2 86.1
Trt 1: Control diet
Trt 2: Control diet + 25 ppm L-camitine
Trt 3: Control diet + 50 ppm L-carnitine
Trt 4: Control diet + 100 ppm L-camitine
Dashes indicate data for this variable not included in analysis due to poor pig
performance.
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Appendix Table 24
Analysis of variance for energy ratios - Experiment 2 (Period 3).
Mean Squares
Source d.f.
Total 19
Error 11
Repetition 5
Treatment 3
Linear 1
Quadratic 1
Cubic 1
c.Y., %
DE:GE
2.10171
8.74890
2.37871
1.12268
6.68087
0.21811
1.6295
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ME:DE
0.03538
0.02298
0.05608
0.03370
0.00001
0.12873
0.1897
ME:GE
2.43588
8.33872
2.37565
1.44409
6.43074
0.62869
1.7687
Appendix Table 25
Analysis of variance for average daily feed intake, gross energy intake, fecal energy
excretion, and digestible energy (kcal/d, kcal/kg) - Experiment 2 (Periods 2 & 3
pooled).
Mean Squares
DE DE
Source d.f. ADFI GE FE (kcal/d) (kca1Ikg)
Total 47
Error 20 1981.4 42971.18 1591.93 36786.04 5560.71
Repetition 5 12539.3 224933.95 7831. 72 186928.2 24899.28
Treatment 3 12658.9 142095.39 11112.58 85683.5 29292.17
Linear 1 30459.0 352640.24 30616.75 175277.2 64926.86
Quadratic 1 3981.7 42372.83 1699.12 60892.76 18398.54
Cubic 1 3535.8 31273.11 1021.85 20880.64 4551.09
Rep x TIt 15 2466.1 72525.67 825.29 68826.57 7046.65
Period 1 324262.6 7188912.0 67432.52 5863212 60634.08
TIt x Period 3 663.0 20715.17 1360.01 13153.06 8737.25
C.V.,% 9.89 10.04 16.80 10.50 1.80
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Appendix Table 26
Analysis of variance for urinary energy and metabolizable energy (kcal/d, kcal/kg) -
Experiment 2 (Periods 2 & 3 pooled).
Source d.f.
Total 47
Error 20
Repetition 5
Treatment 3
Linear 1
Quadratic 1
Cubic 1
Rep x Trt 15
Period 1
Trt x Period 3
C.V.,%
DE
(kcal/d)
11.61916
31.83295
33.73480
61.46394
0.68271
39.05782
5.58420
1920.77603
9.40098
28.5674
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Mean Squares
ME
(kcal/d)
36080.592
183299.200
84434.944
169121.877
61341.325
22841.687
68645.278
5655387.000
13105.056
10.4655
ME
(kca1/kg)
5846.7250
23219.1833
32231.7222
70150.4341
19662.7236
6882.0015
7327.8389
32448.0000
8123.8333
1.8619
Appendix Table 27
Analysis of variance for energy ratios - Experiment 2 (Periods 2 & 3 pooled).
Mean Squares
Source d.f.
Total 47
Error 20
Repetition 5
Treatment 3
Linear 1
Quadratic 1
Cubic 1
Rep x Trt 15
Period 1
Trt x Period 3
C.V., %
DE:GE
2.5141250
11.41770833
14.00743056
30.86147444
10.89587595
0.26491] 98
3.20759722
5.13520833
2.24909722
1.793707
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ME:DE
0.01920833
0.03120833
0.08743056
0.09300599
0.01000537
0.15928048
0.01343056
2.47520833
0.01520833
0.139445
ME:GE
2.6894167
10.49483333
14.94500000
33.37751656
11.44000327
0,01745330
3.38116667
0.65333333
1.96944444
1.866578
Appendix Table 28
Pen means for average daily feed intake, nitrogen intake, nitrogen excretion, and
nitrogen absorbed (g/d, %) - Experiment 2 (Period 1).
Energy Balance
ADFI N Intake NExc. NAbs. NAbs.
Pen Trt Rep (g) (g/d) (g/d) (g/d) (%)
1 2 1 61.99 2.37 0.196 2.17 91.74
2 3 1
3 4 1 111.68 4.30 0.650 3.65 84.88
4 1 1 137.34 4.93 0.674 4.25 86.33
5 4 2 196.91 7.59 0.989 6.60 86.96
6 2 2 235.82 9.00 1.595 7.41 82.28
7 1 2 197.45 7.08 0.793 6.29 88.80
8 3 2
9 1 3
10 4 3 176.66 6.81 0.862 5.94 87.33
11 3 3 244.75 9.28 1.544 7.74 83.37
12 2 3 204.07 7.79 0.895 6.89 88.51
13 2 4 206.48 7.88 1.147 6.73 85.45
14 4 4
15 3 4 185.58 7.04 0.526 6.51 92.53
16 1 4
17 2 5
18 1 5
19 4 5 145.40 5.60 0.732 4.87 86.93
20 3 5 54.13 2.05 0.558 1.4~ 72.80
21 4 6
22 2 6 91.91 3.51 0.303 3.21 91.37
23 1 6 83.04 2.98 0.226 2.75 92.41
24 3 6 243.08 9.22 1.370 7.85 85.14
Trt 1: Control diet
Trt 2: Control diet + 25 ppm L-camitine
Trt 3: Control diet + 50 ppm L-camitine
Trt 4: Control diet + 100 ppm L-carnitine
Dashes indicate data for this variable not included in analysis due to poor pig
performance.
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Appendix Table 29
Analysis of variance for average daily feed intake, nitrogen intake, fecal nitrogen
excretion, and nitrogen absorbed (g/d, %) - Experiment 2 (Period 1).
Mean Squares
NAbs. NAbs.
Source d.f. ADFI N Intake N Exc. (g/d) (%)
Total 15
Error 7 3299.171 4.71755 0.206194 3.200873 22.4702
Repetition 5 7149.507 10.24887 0.204860 7.821428 25.7174
Treatment 3 1069.822 2.06750 0.124266 1.276718 20.5855
Linear 1 1017.240 2.61205 0.066354 1.848954 0.1387
Quadratic 1 1484.278 2.74735 0.314450 1.214448 51.7959
Cubic 1 1665.147 1.66155 0.039620 1.187149 12.7071
C.V.,% 35.67 35.67 55.63 33.94 5.47
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Appendix Table 30
Pen means for urinary nitrogen excretion, nitrogen retention (g/d, 0/0), and nitrogen
retention:nitrogen absorption - Experiment 2 (Period 1).
Energy Balance
Urine N Exc N Ret. N Ret. N Ret:N Abs
Pen Trt Rep (g/d) (g/d) (%) (%)
1 2 1 0.184 1.99 83.95 91.51
2 3 1
3 4 1 0.260 3.39 78.85 92.89
4 1 1 0.232 4.02 81.61 94.54
5 4 2 0.438 6.16 81.19 93.36
6 2 2 0.330 7.08 78.62 95.54
7 1 2 0.328 5.96 84.17 94.78
8 3 2
9 1 3
10 4 3 0.276 5.67 83.28 95.36
11 3 3 0.384 7.36 79.24 95.04
12 2 3 0.414 G.48 83.20 93.99
13 2 4 0.248 6.49 82.31 96.32
14 4 4
15 3 4 0.383 6.13 87.09 94.12
16 1 4
17 2 5
18 1 5
19 4 5 0.410 4.46 79.60 91.57
20 3 5 0.183 1.31 63.88 87.74
21 4 6
22 2 6 0.277 2.93 83.47 91.35
23 1 6 0.243 2.51 84.26 91.17
24 3 6 0.338 7.51 81.48 95.70
Trt 1: Control diet
Trt 2: Control diet + 25 ppm L-camitine
Trt 3: Control diet + 50 ppm L-camitine
Trt 4: Control diet + 100 ppm L-camitine
Dashes indicate data for this variable not included in analysis due to poor pig
performance.
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Appendix Table 31
Analysis of variance for urinary nitrogen excretion, nitrogen retention (g/d, %), and
nitrogen retention :nitrogen absorption - Experiment 2 (Period 1).
Mean Squares
Source d.f. Urine N Exc
N Ret. N Ret.
(g/d) (O~) N RetN Abs
-
Total
Error
Repetition
Treatment
Linear
Quadratic
Cubic
C.V.,%
19
7
5
3
1
1
1
0.0071557 3.0274998 17.813187 4.2828844
0.0075144 7.3905126 41.086207 9.3008511
0.0036114 1.1731837 17.842942 0.3371752
0.0098518 1.5814456 0.004768 0.3318555
0.0000111 1.2038421 47.654266 0.1939701
0.0005421 1.1341880 6.896344 0.3089093
27.4648 35.0403 5.2098 2.2149
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Appendix Table 32
Pen means for average daily feed intake, nitrogen intake, nitrogen excretion, and
nitrogen absorbed (g/d, %) - Experiment 2 (Period 2).
Energy Balance
ADFI N Intake NExc. NAbs. NAbs.
Pen Trt Rep (g) (g/d) (g/d) (gld) (%)
1 2 1 347.44 12.70 1.302 11.40 89.75
2 3 1
3 4 1 393.48 14.73 1.816 12.92 87.67
4 1 I 315.55 11.31 1.543 9.77 86.36
5 4 2 329.13 12.32 2.413 9.91 80.42
6 2 2 396.31 14.49 2.092 12.40 85.56
7 1 2 394.06 14.13 1.211 12.92 91.43
8 3 2
9 1 3 209.00 7.49 1.024 6.47 86.33
10 4 3 374.72 14.03 2.090 11.94 85.10
11 3 3 397.94 14.98 2.678 12.30 82.12
12 2 3 273.70 10.1 1.268 8.74 87.33
13 2 4 346.65 12.67 1.744 10.93 86.24
14 4 4
15 3 4 348.48 13.12 1.363 11.75 89.61
16 1 4 327.39 11.74 1.855 9.88 84.20
17 2 5 366.76 13.41 1.799 11.61 86.58
18 1 5 368.64 13.22 1.947 11.27 85.27
19 4 5 451.46 16.90 3.036 13.87 82.04
20 3 5 362.31 13.64 2.296 11.34 83.16
21 4 6
22 2 6 345.89 12.65 1.801 10.85 85.76
23 1 6 353.96 12.69 2.181 10.51 82.81
24 3 6 494.88 18.63 2.527 16.10 86.43
Trt 1: Control diet
Trt 2: Control diet + 25 ppm L-camitine
Trt 3: Control diet + 50 ppm L-camitine
Trt 4: Control diet + 100 ppm L-camitine
Dashes indicate data for this variable not included in analysis due to poor pig
perfonnance.
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Appendix Table 33
Analysis of variance for average daily feed intake, nitrogen intake, fecal nitrogen
excretion, and nitrogen absorbed (g/d, %) - Experiment 2 (Period 2).
Mean Squares
NAbs. NAbs.
Source d.f. ADFI N Intake NExc. (g/d) (%)
Total 19
Error 11 2769.61 3.75588 0.188740 3.17451 8.34016
Repetition 5 3901.30 5.19663 0.262846 6.39758 5.91384
Treatment 3 6240.67 12.62648 0.625533 8.08727 8.33295
Linear 1 11089.10 22.58692 1.625442 12.12182 19.20842
Quadratic 1 3524.64 7.37502 0.004268 6.98922 6.22649
Cubic 1 2744.85 4.99054 0.166693 3.30950 0.79715
C.V., % 14.62 14.63 22.87 15.71 3.37
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Appendix Table 34
Pen means fOT urinary nitrogen excretion, nitrogen retention (g/d, %), and nitrogen
retention:nitrogen absorption - Experiment 2 (Period 2).
Energy Balance
UrineN Exc NRet. N Ret. N Ret:N Abs
Pen Trt Rep (g/d) (g/d) (%) (%)
1 2 1 0.869 10.53 82.91 92.38
2 3 1
3 4 I 1.012 11.90 80.80 92.16
4 1 1 0.562 9.21 81.39 94.25
5 4 2 0.553 9.36 75.93 94.42
6 2 2 0.449 11.95 82.46 96.37
7 1 2 0.803 12.11 85.74 93.78
8 3 2
9 1 3 0.619 5.85 78.06 90.43
10 4 3 0.814 11.13 79.30 93.18
11 3 3 0.604 11.70 78.08 95.09
12 2 3 1.163 7.58 75.71 86.70
13 2 4 0.556 10.37 81.85 94.92
14 4 4
15 3 4 1.029 10.72 81.76 91.25
16 1 4 0.513 9.37 79.83 94.81
17 2 5 0.867 10.74 80.12 92.53
18 1 5 0.630 10.64 80.50 94.41
19 4 5 0.672 13.19 78.06 95.15
20 3 5 0.249 11.09 81.34 97.81
21 4 6
22 2 6 0.468 10.38 82.06 95.69
23 1 6 0.454 10.05 79.23 95.68
24 3 6 0.626 15.47 83.07 96.11
Trt 1: Control diet
Trt 2: Control diet + 25 ppm L-camitine
Trt 3: Control diet + 50 ppm L-camitine
Trt 4: Control diet + 100 ppm L-camitine
Dashes indicate data for this variable not included in analysis due to poor pig
performance.
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Appendix Table 35
Analysis of variance for urinary nitrogen excretion, nitrogen retention (g/d, %), and
nitrogen retention:nitrogen absorption - Experiment 2 (Period 2).
Mean Squares
Source d.f. Urine N Exc
N Ret. N Ret.
(g/d) (%) N Ret:N Abs
Total
Error
Repetition
Treatment
Linear
Quadratic
Cubic
C.V.,%
19
11
5
3
1
1
1
0.06227587 2.9512749 5.1412910 5.4085301
0.04263087 4.3557886 8.3336231 9.5797521
0.02424547 7.8091254 6.2702579 3.2644008
0.02665422 10.9979684 11.0434841 0.8591274
0.00047930 6.8868228 9.8595261 1.0017741
0.04021843 4.0842080 2.6070408 8.3881556
36.9377 16.1051 2.8199 2.4779
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Appendix Table 36
Pen means for average daily feed intake, nitrogen intake, nitrogen excretion, and
nitrogen absorbed (g/d, %) - Experiment 2 (Period 3).
Energy Balance
ADFI N Intake NExc. NAbs. NAbs.
Pen Trt Rep (g) (g/d) (g/d) (g/d) (%)
1 2 1 516.63 18.87 1.626 17.24 91.38
2 3 1
3 4 1 596.53 21.93 2.146 19.78 90.21
4 1 1 480.79 17.00 1.689 15.31 90.06
5 4 2 640.70 23.55 3.975 19.58 83.13
6 2 2 594.56 21.71 2.477 19.24 88.59
7 1 2 663.68 23.47 3.211 20.26 86.32
8 3 2
9 1 3 401.34 14.19 2.649 11.54 81.33
10 4 3 474.77 17.45 2.623 14.83 84.97
11 3 3 544.15 19.72 2.505 17.21 87.29
12 2 3 528.19 19.29 2.070 17.22 89.27
13 2 4 443.35 16.19 2.604 13.59 83.91
14 4 4
15 3 4 496.12 17.98 1.899 16.08 89.44
16 1 4 489.11 17.29 2.662 14.63 84.61
17 2 5 464.32 16.96 2.170 14.79 87.20
18 I 5 467.55 16.53 1.722 14.81 89.58
19 4 5 589.47 21.67 2.669 19.00 87.68
20 3 5 491.91 17.83 2.197 15.63 87.67
21 4 6
22 2 (j 535.27 19.55 2.883 16.66 ~5.25
23 1 6 505.93 17.89 2.979 14.91 83.34
24 3 6 545.88 19.78 3.205 16.58 83.80
Trt 1: Control diet
Trt 2: Control diet + 25 ppm L-camitine
Trt 3: Control diet + 50 ppm L-camitine
Trt 4: Control diet + 100 ppm L-camitine
Dashes indicate data for this variable not included in analysis due to poor pig
performance.
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Appendix Table 37
Analysis of variance for average daily feed intake, nitrogen intake, fecal nitrogen
excretion, and nitrogen absorbed (g/d, %,) - Experiment 2 (Period 3).
Mean Squares
NAbs. NAbs.
Source d.f. ADFl N Intake NExc. (g/d) C%)
Total 19
Error 11 2042.86 2.61872 0.111001 2.74060 4.93388
Repetition 5 9574.68 12.41514 0.919561 9.42713 17.75539
Treatment 3 4109.85 8.32781 0.381012 6.39429 6.72829
Linear 1 ]0862.63 22.24671 0.819288 14.53537 1.47225
Quadratic ] 215.02 0.77975 0.407980 2.30856 18.63566
Cubic 1 533.07 0.06195 0.010355 0.02132 0.0067]
C.V.,% 8.63 8.54 13.33 10.07 2.56
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Appendix Table 38
Pen means for urinary nitrogen excretion, nitrogen retention (g/d, %), and nitrogen
retention:nitrogen absorption - Experiment 2 (Period 3).
Energy Balance
Urine N Exc N Ret. N Ret. N RetN Abs
Pen Trt Rep (g/d) (g/d) (%) (%)
1 2 1 2.024 15.22 80.65 88.26
2 3 1
3 4 1 3.092 16.69 76.11 84.37
4 1 1 2.169 13.14 77.30 85.83
5 4 2 3.646 15.93 67.65 81.38
6 2 2 1.472 17.76 81.81 92.35
7 1 2 3.474 16.78 71.51 82.85
8 3 2
9 1 3 1.402 10.14 71.45 87.85
10 4 3 2.081 12.75 73.05 85.97
11 3 3 1.170 16.04 81.36 93.20
12 2 3 2.888 14.33 74.30 83.23
13 2 4 2.220 11.37 70.20 83.66
14 4 4
15 3 4 1.999 14.08 78.32 87.57
16 1 4 1.007 13.63 78.79 93.12
17 2 5 1.493 13.29 78.39 89.90
18 1 5 1.555 13.25 80.18 89.50
19 4 5 1.693 17.31 79.87 91.09
20 3 5 1.363 14.27 80.03 91.28
21 4 6
22 2 6 1.538 15.13 77.39 90.77
23 I 6 0.819 14.09 78.77 94.51
24 3 6 1.023 15.55 78.63 93.83
Trt 1: Control diet
Trt 2: Control diet + 25 ppm L-camitine
Trt 3: Control diet + 50 ppm L-camitine
Trt 4: Control diet + 100 ppm L-camitine
Dashes indicate data for this variable not included in analysis due to poor pig
performance.
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Appendix Table 39
Analysis of variance for urinary nitrogen excretion, nitrogen retention (g/d, %), and
nitrogen retention:nitrogen absorption - Experiment 2 (Period 3).
Mean Squares
Source d.f. Urine N Exc
N Ret. N Ret.
(g/d) (0/0) N Ret:N Abs
Total
Error
Repetition
Treatment
Linear
Quadratic
Cubic
C.V.,%
19
11
5
3
1
I
1
0.4737388 2.6384712 15.2436638 14.2726274
0.8115952 6.2998800 16.9991731 16.9963580
0.4453463 4.7309944 19.2550357 10.0823716
1.0269068 7.8546035 14.4098922 10.5466547
0.2630902 4.1132153 47.1762759 12.2372729
0.2982970 0.4759013 11.1181538 16.0821840
36.1040 11.1734 5.0845 4.2676
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Appendix Table 40
Analysis of variance for average daily feed intake, nitrogen intake, fecal nitrogen
excretion, and nitrogen absorbed (g/d, 0/0) - Experiment 2 (Periods 2 & 3 pooled).
Mean Squares
NAbs. NAbs.
Source d.f. ADFI N Intake NExc. (g/d) (%)
Total 39
Error 11 1451.03 1.97984 0.125901 1.73588 4.86464
Repetition 5 9992.95 13.02800 0.803465 9.98655 18.27750
Treatment 3 9942.29 19.94557 0.880406 13.91662 12.43114
Rep x Trt 11 3361.44 4.39476 0.173840 4.17923 8.40940
Period 1 252215.4 303.6708 3.333320 243.3554 11.47248
Trt x Period 3 408.24 1.00872 0.126138 0.56494 2.63001
Rep x Period 5 3483.03 4.58378 0.378942 3.13815 5.39173
C.V., % 8.62 8.74 16.14 9.48 2.56
145
Appendix Table 41
Analysis of variance for urinary nit.rogen excretion, nitrogen retention (g/d, %), and
nitrogen retention:nitrogen absorption - Experiment 2 (Periods 2 & 3 pooled).
Mean Squares
Source d.f. Urine N Exc
N Ret. N Ret.
(gld) (%) NRetN Abs
Total
Error
Repetition
Treatment
Rep x Trt
Period
Trt x Period
Rep x Period
C.V., %
39
11
5
3
11
1
3
5
0.17425809 1.5050746 10.3229579 5.3383311
0.47893303 9.1737610 15.8339978 20.1162786
0.31390648 12.1636433 23.0772463 9.8247394
0.36175662 4.0846715 10.0619669 14.3428264
15.26884413 136.782096 133.417206 291.499885
0.15568530 0.3764766 2.4480472 3.5220330
0.37529299 1.4819076 9.4987983 6.4598315
32.3348 9.7349 4.0878 2.5337
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Appendix Table 42
Pen means for initial and final body weight, and average daily gain - Experiment 2.
Initial BW Final BW Overall ADG
Pen Trt Rep (g) (g) (g/d)
1 2 1 6674 17297 279.6
2 3 1
3 4 1 5448 16707 296.3
4 1 1 5312 15527 268.8
5 4 2 5130 16843 308.2
6 2 2 4495 18115 358.4
7 1 2 5221 17434 321.4
8 3 2
9 1 3 4222 12530 218.6
10 4 3 4313 17842 356.0
11 3 3 3768 17479 360.8
12 2 3 4631 17025 326.2
13 2 4 5266 17116 311.8
14 4 4
15 3 4 5766 17888 319.0
16 1 4 5357 14119 230.6
17 2 5 5493 16208 282.0
18 1 5 4268 13257 236.6
19 4 5 3904 16798 339.3
20 3 5 3133 13847 282.0
21 4 6
22 2 6 3178 13438 270.0
23 1 6 4676 14346 254.5
24 3 6 4949 20294 403.8
Initial Pigs
1 1 ()219.8
2 2 4630.8
3 3 3995.2
4 4 5084.8
5 5 4403.8
6 6 4040.6
Trt 1: Control diet
Trt 2: Control diet + 25 ppm L-camitine
Trt 3: Control diet + 50 ppm L-camitine
Trt 4: Control diet + 100 ppm L-camitine
Dashes indicate data for this variable not included in analysis due to poor pig
performance.
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Appendix Table 43
Analysis of variance for initial and final body weight, and average daily gain-
Experiment 2.
Source d.f.
Total 19
Error 11
Repetition 5
Treatment 3
Linear 1
Quadratic 1
Cubic 1
C.V., %
Initial BW
586242.24
1487548.456
77879.787
81078.153
2031.917
141315.036
16.085
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Mean Squares
Final BW
3245427.23
2999245.56
9978482.94
11686237.94
13313927.10
100112.76
11.116
ADG
1457.19941
1429.33564
7504.09357
9487.767060
9453.303860
331.999049
12.674
Appendix Table 44
Pen means for percentage of protein, lipid, ash, and water - Experiment 2.
Protein Lipid Ash Water
Pen Trt Rep (%) (%) (%) (%)
1 2 1 13.73 7.03 2.70 77.72
2 3 1
3 4 1 13.85 6.77 2.75 78.79
4 1 1 13.73 8.59 2.59 76.48
5 4 2 13.92 7.18 2.59 78.19
6 2 1 14.24 7.71 2.83 77.13
7 1 2 13.51 8.47 2.62 76.14
8 3 2
9 1 3 12.65 8.66 2.79 76.71
10 4 3 14.05 6.99 2.91 77.75
11 3 3 13.88 7.39 2.80 77.09
12 2 3 14.34 8.13 3.08 75.64
13 2 4 13.58 7.38 2.77 77.47
14 4 4
15 3 4 14.24 7.84 2.72 76.31
16 1 4 13.38 8.85 2.54 75.98
17 2 5 14.27 7.50 3.01 76.14
18 1 5 13.28 8.11 2.83 76.33
19 4 5 14.23 6.66 2.96 77.83
20 3 5 13.44 5.85 2.94 79.08
21 4 6
22 2 6 13.91 6.79 2.89 78.22
23 1 6 13.99 7.39 2.86 76.89
24 3 6 14.41 7.44 2.93 76.47
Initial Pigs
1 1 13.76 11.45 2.91 68.73
2 2 14.42 6.78 2.47 73.46
3 3 14.11 6.75 2.80 74.22
4 4 13.22 13.12 2.60 68.68
5 5 14.44 8.42 2.69 71.86
6 6 13.83 13.82 2.57 67.13
Trt 1: Control diet
Trt 2: Control diet + 25 ppm L-carnitine
Trt 3: Control diet + 50 ppm L-carnitine
Trt 4: Control diet + 100 ppm L-carnitine
Dashes indicate data for this variable not included in analysis due to poor pig
performance.
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Appendix Table 45
WaterProteind.f.Source
Analysis of variance for percentage of protein, lipid, ash, and water - Experiment 2.
Mean Squares
Lipid Ash
Total
Error
Repetition
Treatment
Linear
Quadratic
Cubic
C.V.,%
19
11
5
3
1
1
1
0.1631758
0.0776066
0.5002998
0.6535578
0.3604240
0.1665366
2.9205
0.2402041
0.4734476
2.0393655
4.1246908
0.9037437
0.1367051
6.5031
0.0053729
0.0515196
0.0306771
0.0051294
0.0221852
0.0424234
2.6127
0.8142193
0.3976160
2.2602100
6.2916513
0.0548495
0.0650133
1.1701
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Appendix Table 46
Pen means for rates of protein, lipid, ash, water, and energy accretion - Experiment
2.
Protein Lipid Ash Water Energy
Pen Trt Rep Ace., gld Ace., gld Ace., gld Gain, g/d Gain, keal/d
1 2 1 38.12 14.73 7.24 227.29 314.68
2 3 1
3 4 1 40.96 17.14 8.57 239.94 355.28
4 1 1 36.66 22.95 7.19 208.39 399.37
5 4 2 42.88 20.26 8.26 245.70 420.20
6 2 2 51.20 27.17 10.65 278.43 534.52
7 1 2 42.86 26.99 8.69 246.82 498.51
8 3 2
9 1 3 25.93 19.78 6.45 168.89 326.41
10 4 3 49.91 23.75 10.90 279.24 495.99
11 3 3 49.53 26.44 10.19 279.42 537.17
12 2 3 47.13 26.45 10.89 247.10 504.15
13 2 4 41.87 21.22 9.13 245.63 416.32
14 4 4
15 3 4 45.99 23.13 8.96 247.34 438.57
16 1 4 30.11 20.56 6.02 177.43 329.04
17 2 5 40.78 19.21 9.30 217.50 399.70
18 1 5 30.40 19.37 7.10 181.35 363.92
19 4 5 48.12 21.52 10Al 266.18 481.84
20 3 5 36.59 15.26 7.lJ9 226.01 368.33
21 4 6
22 2 6 36.69 17.86 7.49 213.50 382.90
23 1 6 35.52 17.77 7.88 197.64 359.63
24 3 6 58.76 28.77 12.54 310.75 612.97
Trt 1: Control diet
Trt 2: Control diet + 25 ppm L-camitine
Trt 3: Control diet + 50 ppm L-carnitine
Trt 4: Control diet + 100 ppm L-carnitine
Dashes indicate data for this variable not included in analysis due to poor pig
performance.
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Appendix Table 47
Analysis of variance for rates of protein, lipid, ash, water, and energy accretion -
Experiment 2.
Mean Squares
Source d.f. Protein Lipid Ash Water Energy
Total 19
Error 11 42.87573 16.25834 2.26458 742.5279 5698.210
Repetition 5 33.50832 24.53071 1.64028 779.5655 7606.781
Treatment 3 209.2437 7.22267 7.] 4625 5164.634 9840.869
Linear I 275.3044 0.58610 9.47025 7238.268 6630.070
Quadratic 1 248.4180 14.46934 7.73646 5793.975 18062.44
Cubic 1 1.2167 12.18360 0.14284 136.2903 2969.365
C.V., % 15.7780 18.7399 17.1152 11.5843 17.679
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Appendix Table 48
Pen means for albumin levels - Experiment 2.
Albumin levels, g/dL
Pen Trt Rep DO 03 D 10 D24 D 38
1 2 1 2.7 3.2 2.3 2.1 2.2
2 3 1 2.9 2.8 2.8
3 4 1 2.9 3.0 2.3 2.2 2.3
4 1 1 2.8 2.9 2.5 2.1 2.4
5 4 2 3.2 3.1 2.7 2.7 3.0
6 2 2 3.0 3.2 2.7 2.7 2.8
7 1 2 3.1 3.1 2.6 2.6 2.8
8 3 2 3.0 2.9 2.8
9 I 3 2.4 2.7 2.6 2.3 2.2
10 4 3 2.0 2.3 2.1 2.1 2.4
11 3 3 2.4 2.2 2.3 2.6 2.5
12 2 3 2.6 2.9 2.3 2.3 2.6
13 2 4 2.1 2.4 2.2 2.3 2.4
14 4 4 2.0 2.5 2.6
15 3 4 2.3 2.6 2.2 2.4 2.6
16 1 4 2.5 3.1 2.8 2.2 2.4
17 2 5 2.9 3.0 2.6 2.1 2.2
18 I 5 2.8 3.2 2.7 2.4 2.9
19 4 5 1.7 1.8 1.9 2.3 2.3
20 3 5 1.9 2.0 1.9 2.3 2.3
21 4 6 2.7 2.7 2.9
22 2 6 1.9 2.2 2.0 2.3 2.2
23 1 6 3.1 2.9 2.6 2.1 2.2
24 3 6 2.7 2.6 2.4 2.3 2.7
Trt 1: Control diet
Trt 2: Control diet + 25 ppm L-camitine
Trt 3: Control diet + 50 ppm L-camitine
Trt 4: Control diet + 100 ppm L-camitine
Dashes indicate data for this variable not included in analysis due to poor pig
perfonnance.
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Appendix Table 49
Analysis of variance for albumin levels - Experiment 2.
Mean Squares
Source d.f. DO D3 D 10 d.f. D24 D 38
Total 23 19
Error 15 0.1233 0.1088 0.0864 8 0.0143 0.0502
Repetition 5 0.4387 0.2374 0.0880 5 0.1077 0.1288
Treatment 3 0.1433 0.2871 0.0944 3 0.0259 0.0278
Linear 1 0.3360 0.5921 0.0762 1 0.0006 0.0009
Quadratic 1 0.0503 0.2091 0.1431 1 0.0549 0.0111
Cubic 1 0.0410 0.0601 0.6402 1 0.0352 0.0790
C.V., % 13.6827 12.1203 12.0006 5.1526 9.0670
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Appendix Table 50
Pen means for blood urea nitrogen levels - Experiment 2.
Blood urea nitrogen levels, mg/dL
Pen Trt Rep DO 03 D 10 D 24 D 38
1 2 1 3.8 18.1 9.4 8.6 12.7
2 3 1
3 4 1 3.7 30.4 10.7 7.3 14.3
4 1 1 4.8 13.4 8.6 7.8 12.6
5 4 2 12.6 12.1 7.2 7.6 9.2
6 2 2 15.3 12.3 5.3 6.9 12.9
7 1 2 10.0 18.1 7.5 10.5 12.2
8 3 2
9 1 3 5.2 21.5 41.1 14.0 12.1
10 4 3 5.1 23.2 8.1 11.4 12.9
11 3 3 4.6 11.9 5.6 7.7 8.7
12 2 3 7.0 21.2 6.7 12.7 14.0
13 2 4 3.5 17.8 6.9 10.8 16.7
14 4 4
15 3 4 5.3 17.8 8.0 9.1 7.6
16 1 4 8.4 42.0 19.9 8.9 10.7
17 2 5 13.0 13.3 4.1 10.5 13.2
18 1 5 11.2 26.6 20.4 8.9 15.0
19 4 5 3.5 8.7 7.1 5.9 12.4
20 3 5 3.1 19.2 8.7 12.2 11.8
21 4 6
22 2 6 6.9 9.7 <).4 11.8 12.3
23 1 6 5.8 17.1 1().1 5.9 10.6
24 3 6 3.6 4.1 4.8 ~.2 12.7
Trt 1: Control diet
Trt 2: Control diet + 25 ppm L-camitine
Trt 3: Control diet + 50 ppm L-camitine
Trt 4: Control diet + 100 ppm L-camitine
Dashes indicate data for this variable not included in analysis due to poor pig
performance.
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Appendix Table 51
Analysis of variance for blood urea nitrogen levels - Experiment 2.
Mean Squares
Source d.f. DO D3 D 10 D 24 D38
Total 19
Error 8 7.07374 54.2664 57.9929 5.30298 4.28296
Repetition 5 27.00693 93.1375 41.5799 6.17177 2.07615
Treatment 3 12.45211 104.5964 175.4154 4.45268 9.73830
Linear 1 15.88734 16.6101 141.3952 8.13577 1.65455
Quadratic 1 2.55383 253.6970 246.1452 1.09304 3.30426
Cubic 1 18.06215 0.0440 20.9310 3.47929 26.03862
C.V.,% 38.9978 41.0967 72.6652 24.6687 16.9218
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Appendix Table 52
Pen means for C-reactive protein levels - Experiment 2.
C-reactive protein levels, mgIL
Pen Trt Rep DO D3 D 10 D24 D 38
1 2 1 1.10 1.78 1.10 4.37
2 3 1
3 4 1 1.10 1.10 2.87 2.72 2.02
4 1 1 1.76 1.10 1.88 1.62 1.75
5 4 2 1.10 2.10 2.63 1.59 6.71
6 2 2 1.78 4.07 2.52 1.10 3.13
7 1 2 1.50 2.17 3.35 1.10 8.25
8 3 2
9 1 3 1.10 1.10 2.14 1.10 2.11
10 4 3 2.04 2.22 3.37 3.55 4.07
11 3 3 1.10 1.56 1.58 1.10 3.97
12 2 3 1.56 2.32 1.41 1.62 6.23
13 2 4 1.10 1.46 1.82 2.51 2.17
14 4 4
15 3 4 2.66 1.58 1.10
16 1 4 1.10 3.47 4.36 1.10 1.50
17 2 5 1.10 1.10 1.10 1.10 1.10
18 1 5 1.10 1.10 1.10 1.10 1.88
19 4 5 3.31 1.70 1.62 4.39
20 3 5 1.10 1.10 2.78 1.10
21 4 6
22 2 6 1.10 1.10 1.10 1.10 1.10
23 1 6 1.10 1.10 2.46 1.10 1.10
24 3 6 1.10 1.84 1.10 1.10 1.93
Trt 1: Control diet
Trt 2: Control diet + 25 ppm L-carnitine
Trt 3: Control diet + 50 ppm L-camitine
Trt 4: Control diet + 100 ppm L-camitine
Dashes indicate data for this variable not included in analysis due to poor pig
performance.
157
Appendix Table 53
Analysis of variance for C-reactive protein - Experiment 2.
Mean Squares
Source DF DO DF D3 DF DlO DF D24 D 38
Total 17 18 19 18
Error 9 0.2798 10 0.9115 11 0.455 10 0.493 3.247
Repetition 5 0.1118 5 0.9417 5 0.948 5 0.301 7.978
Treatment 3 0.0778 3 0.3162 3 1.950 3 1.182 0.657
Linear 1 0.0140 1 0.5488 1 0.300 1 3.544 1.633
Quadratic 1 0.1324 1 0.2609 1 5.537 1 0.013 0.240
Cubic 1 0.1319 1 0.3161 1 0.001 1 0.002 0.276
C.V., % 38.86 51.98 33.35 44.29 58.15
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Appendix Table 54
Pen means for glucose levels - Experiment 2.
Glucose levels, mg/dL
Pen Trt Rep DO D3 D 10 D24 D 38
1 2 1 126 103 126 128 125
2 3 1
3 4 1 187 92 101 98 118
4 1 1 123 87 107 134 131
5 4 2 129 98 131 121 126
6 2 2 112 122 139 168 128
7 1 2 146 94 124 124 128
8 3 2
9 1 3 178 94 74 127 122
10 4 3 136 73 III 127 133
II 3 3 105 116 125 141 137
12 2 3 161 93 11 1 151 119
13 2 4 135 82 138 127 126
14 4 4
15 3 4 132 89 124 184 137
16 1 4 135 94 11 1 119 133
17 2 5 130 81 117 119 119
18 1 5 142 80 I 11 123 154
19 4 5 101 106 123 126 104
20 3 5 109 79 105 123 116
21 4 6
22 2 6 148 113 121 124 113
23 6 130 99 104 131 118
24 3 6 110 129 137 133 120
Trt 1: Control diet
Trt 2: Control diet + 25 ppm L-camitine
Trt 3: Control diet + 50 ppm L-camitine
Trt 4: Control diet + 100 ppm L-camitine
Dashes indicate data for this variable not included in analysis due to poor pig
perfonnance.
159
Appendix Table 55
Analysis of variance for glucose levels - Experiment 2.
Mean Squares
Source d.f. DO 03 D 10 D 24 D 38
Total 19
Error 8 544.277 185.273 134.050 318.413 121.731
Repetition 5 331.673 357.766 322.674 238.874 89.208
Treatment 3 673.094 170.998 500.290 539.734 148.597
Linear 1 46.177 3.155 193.851 219.098 211.752
Quadratic 1 1600.781 484.464 819.106 1542.472 0.301
Cubic 1 587.663 21.857 128.332 105.700 227.945
C.V., % 17.44 14.15 9.90 13.58 8.80
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Appendix Table 56
Pen means for non-esterified fatty acid levels - Experiment 2.
Non-esterified fatty acid levels, mmollL
Pen Tn Rep DO D3 D 10 D24 D 38
1 2 1 0.33 2.58 0.31 0.07 0.07
2 3 1
3 4 1 0.51 2.58 0.14 0.08 0.06
4 1 1 0.56 2.86 0.17 0.07 0.05
5 4 2 0.43 2.16 0.09 0.12 0.11
6 2 2 0.43 0.32 0.10 0.09 0.06
7 1 2 0.39 1.89 0.15 0.16 0.06
8 3 2
9 1 3 0.32 2.02 0.11 0.08
10 4 3 0.27 1.78 0.09 0.08 0.06
11 3 3 0.31 0.16 0.07 0.09 0.08
12 2 3 0.25 2.39 0.09 0.13 0.07
13 2 4 0.34 1.40 0.07 0.05 0.05
14 4 4
15 3 4 0.40 1.91 0.08 0.11 0.06
16 1 4 0.79 1.76 0.38 0.06 0.06
17 2 5 0.51 1.81 0.13 0.17 0.07
18 1 5 0.31 3.11 0.28 0.08 0.08
19 4 5 0.26 0.16 0.08 0.07 0.08
20 3 5 0.32 lAO 0.19 0.24 0.09
21 4 6
22 2 6 0.51 0.31 0.10 0.09 0.07
23 1 6 0.46 2.93 0.34 0.07 0.06
24 3 6 0.54 0.21 0.09 0.07 0.08
Trt 1: Control diet
Trt 2: Control diet + 25 ppm L-camitine
Trt 3: Control diet + 50 ppm L-camitine
Trt 4: Control diet + 100 ppm L-camitine
Dashes indicate data for this variable not included in analysis due to poor pig
performance.
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Appendix Table 57
Analysis of variance for non-esterified fatty acid levels - Experiment 2.
Mean Squares
Source d.f. DO 03 D 10 D24 D 38
Total 19
Error 11 0.01554 0.82723 0.00740 0.00172 0.00018
Repetition 5 0.02584 0.64520 0.00363 0.00334 0.00025
Treatment 3 0.00716 1.72142 0.02305 0.00226 0.00020
Linear 1 0.00493 1.24604 0.03706 0.00090 0.00030
Quadratic 1 0.00854 2.98421 0.02321 0.00583 0.00007
Cubic 1 0.00272 0.00260 0.00228 0.00178 0.00019
C.V., % 30.26 53.91 55.40 41.30 19.37
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Appendix Table 58
Pen means for protein levels - Experiment 2.
Protein levels, g/dL
Pen Trt Rep DO D3 D 10 D 24 D 38
1 2 1 4.7 5.6 4.7 4.0 4.5
2 3 1 5.0 5.0 4.5
3 4 1 4.8 5.4 4.3 4.3 4.7
4 1 I 4.9 4.9 4.5 4.0 4.8
5 4 2 5.9 6.0 5.1 4.8 5.7
6 2 2 5.6 5.8 5.0 4.7 5.0
7 1 2 5.9 6.1 5.0 4.9 5.4
8 3 2 5.8 5.8 5.3
9 1 3 4.4 4.7 4.8 4.2 4.3
10 4 3 4.3 4.6 4.5 4.4 5.1
11 3 3 4.6 4.5 4.1 4.6 4.9
12 2 3 4.8 5.2 4.0 4.5 5.2
13 2 4 4.8 5.1 4.5 4.6 5.0
14 4 4 4.2 5.3 5.0
15 3 4 4.9 5.3 4.2 4.4 5.2
16 1 4 4.7 5.8 4.9 4.1 4.7
17 2 5 4.6 4.6 4.0 4.0 4.5
18 I 5 5.1 5.5 4.8 4.5 5.2
19 4 5 4.8 4.6 4.2 4.5 4.8
20 3 5 4.3 4.4 3.9 4.1 4.2
21 4 6 5.2 5.1 4.8
22 2 6 4.1 4.5 3.7 1.9 4.2
23 1 6 5.4 5.0 4.6 4.2 4.4
24 3 6 4.7 4.4 4.2 4.6 4.9
Trt 1: Control diet
Trt 2: Control diet + 25 ppm L-camitine
Trt 3: Control diet + 50 ppm L-camitine
Trt 4: Control diet + 100 ppm L-camitine
Dashes indicate data for this variable not included in analysis due to poor pig
perfonnance.
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Appendix Table 59
Analysis of variance for protein levels - Experiment 2.
Mean Squares
Source d.f. DO D3 D 10 d.f. D 24 D 38
Total 23 19
Error 15 0.10775 0.09844 0.08667 8 0.05526 0.13504
Repetition 5 0.84642 0.89267 0.40600 5 0.17526 0.27108
Treatment 3 0.09375 0.19111 0.28500 3 0.04683 0.07652
Linear 1 0.05030 0.07619 0.00043 1 0.08388 0.18325
Quadratic 1 0.10823 0.45926 0.76001 1 0.00293 0.01835
Cubic 1 0.12273 0.03788 0.09456 1 0.04750 0.02608
C.V.,% 6.705 6.112 6.506 5.385 7.600
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Appendix Table 60
Pen means for triglyceride levels - Experiment 2.
Triglyceride levels, mg/dL
Pen Trt Rep DO D3 D 10 D 24 D 38
1 2 1 124 166 45 52 47
2 3 1
3 4 1 38 55 57
4 1 1 35 110 40 30 32
5 4 2 133 82 39 65 77
6 2 2 73 36 57 47 47
7 1 2 142 90 46 42 29
8 3 2
9 1 3 109 63 90 75 46
10 4 3 46 74 44 35 39
11 3 3 100 56 61 70 46
12 2 3 75 70 46 81 43
13 ') 4 44 91 51 38 29
14 4 4
15 3 4 43 55 34 88 35
16 1 4 120 141 42 40 26
17 2 5 68 79 62 35 89
18 1 5 57 72 25 38 37
19 4 5 36 32 40 42 23
20 3 5 131 80 36 26 23
21 4 6
22 2 6 73 40 38 30 41
23 6 55 81 45 45 37
24 3 6 73 26 83 46 40
Trt 1: Contra1diet
Trt 2: Control diet + 25 ppm L-camitine
Trt 3: Control diet + 50 ppm L-camitine
Trt 4: Control diet + 100 ppm L-camitine
Dashes indicate data for this variable not included in analysis due to poor pig
performance.
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Appendix Table 61
Analysis of variance for triglyceride levels - Experiment 2.
Mean Squares
Source d.f. DO D3 d.f D 10 D 24 D 38
Total 18 19
Error 10 1566.890 841.191 11 295.562 310.833 343.102
Repetition 5 1306.537 1947.134 5 233.479 446.282 99.343
Treatment 3 846.201 654.973 3 110.771 142.998 251.405
Linear 1 1103.371 523.546 1 181.266 36.911 120.797
Quadratic 1 879.399 984.659 1 202.010 269.235 30.380
Cubic 1 1299.086 143.573 1 20.926 157.159 496.785
C.V.,% 49.03 38.16 35.74 35.98 43.95
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Appendix Table 62
Pen means for average daily gain, average daily feed intake, and gain:feed for
Phases 1 and 2 - Experiment 3 (Room A).
Phase 1 Phase 2
ADG ADFI ADG ADFI
Pen Trt Rep (g) (g) G:F (g) (g) G:F
2A 4 1 249 302 .824 537 679 .790
3A 2 1 215 225 .956 528 668 .791
4A 4 2 224 224 1.000 441 554 .796
5A 3 2 168 183 .918 415 592 .700
6A 2 3 197 210 .935 387 536 .721
7A 1 3 177 188 .944 399 588 .679
9A 3 1 258 290 .890 457 695 .658
lOA 1 1 242 256 .947 555 717 .775
llA 2 2 178 199 .897 490 610 .804
12A 1 2 232 228 1.014 487 671 .726
13A 4 3 145 174 .836 395 496 .796
14A 3 3 203 207 .985 414 548 .755
22A 1 4 226 257 .881 410 543 .754
23A 2 4 250 269 .927 471 641 .736
24A 2 5 204 232 .882 485 602 .806
25A 4 5 199 213 .932 405 528 .768
26A 4 6 228 229 .996 475 580 .819
27A 1 6 173 179 .962 392 501 .783
29A 4 4 195 225 .869 449 557 .806
30A 3 4 152 181 .842 365 479 .763
31A 1 5 266 274 .970 486 642 .757
32A 3 5 145 182 .800 396 508 .779
33A 2 6 212 217 .979 410 550 .745
34A 3 6 222 259 .856 349 551 .633
Trt 1: 0% SBO and 0 ppm L-carnitine
Trt 2: 0% SBO and 50 ppm L-carnitine
Trt 3: 5% SBO and 0 ppm L-carnitine
Trt 4: 5% SBO and 50 ppm L-carnitine
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Appendix Table 63
Analysis of variance for average daily gain, average daily feed intake, and gain:feed
for Phases 1 and 2 - Experiment 3 (Room A).
Mean Squares
Phase 1 Phase 2
Source d,f. ADG ADFI G:F ADG ADFI G:F
Total 23
Error 15 1214.58 1174.65 0.0033 1148.86 2011.79 0.0020
Repetition 5 1522.08 2498.25 0.0037 7777.55 12761.2 0.0008
Treatment 3 793.86 207.27 0.0055 4913.53 3587.51 0.0070
SBO 1 1387.91 178.05 0.0124 6772.42 10467.1 0.0001
L-carnitine 1 47.01 57.75 0.0001 5039.04 47.12 0.0158
Interaction 1 946.65 386.00 0.0040 2929.13 248.26 0.0053
C.V.,% 16.87 15.23 6.21 7.68 7.67 5.91
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Appendix Table 64
Pen means for average daily gain, average daily feed intake, and gain:feed for Phase
3 and overall - Experiment 3 (Room A).
Phase 3 Overall
ADG ADFI ADG ADFI
Pen Trt Rep (g) (g) G:F (g) (g) G:F
2A 4 1 621 911 .682 492 666 .739
3A 2 1 594 896 .663 470 635 .740
4A 4 2 589 878 .670 439 587 .748
5A 3 2 556 841 .661 402 576 .698
6A 2 3 477 751 .635 370 529 .698
7A 1 3 540 795 .679 392 558 .702
9A 3 1 556 902 .617 441 664 .664
lOA 1 1 615 947 .650 495 680 .728
11A 2 2 599 907 .661 449 611 .734
12A 1 2 571 910 .627 451 642 .702
13A 4 3 447 678 .659 348 478 .728
14A 3 3 455 747 .609 373 532 .702
22A 1 4 528 762 .693 405 548 .738
23A 2 4 637 975 .654 474 666 .712
24A 2 5 550 866 .635 435 602 .723
25A 4 5 520 762 .682 393 531 .740
26A 4 6 558 818 .682 440 575 .766
27A 1 6 477 691 .690 365 486 .752
29A 4 4 664 949 .700 461 614 .751
30A 3 4 505 790 .639 360 515 .700
31A 1 5 628 987 .637 481 672 .716
32A 3 5 465 704 .661 356 494 .720
33A 2 6 538 838 .643 405 568 .713
34A 3 6 470 711 .661 360 533 .716
Trt 1: 0% SBQ and a ppm L-camitine
Trt 2: 0% SBQ and 50 ppm L-carnitine
Trt 3: 5% SBQ and appm L-camitine
Trt 4: 5% SBQ and 50 ppm L-camitine
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Appendix Table 65
Analysis of variance for average daily gain, average daily feed intake, and gain:feed
for Pbase 3 and Overall - Experiment 3 (Room A).
Mean Squares
Phase 3 Overall
Source d.f. ADG ADFI G:F ADG ADFI G:F
Total 23
Error 15 1961.44 5596.47 0.0004 974.55 2316.41 0.0003
Repetition 5 8570.81 18761.8 0.0004 5117.75 9487.45 0.0002
Treatment 3 5958.44 8596.88 0.0017 3657.78 3148.96 0.0027
SBO I 5026.30 16522.3 0.0001 4378.32 7832.26 0.0001
L-camitine 1 7636.95 8198.10 0.0008 3605.91 1082.19 0.0036
Interaction 1 5212.06 1070.27 0.0041 2989.09 532.42 0.0046
C.V.,% 8.08 8.97 3.17 7.45 8.27 2.56
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Appendix Table 66
Pen means for average daily gain, average daily feed intake, and gain:feed for
Phases 1 and 2 - Experiment 3 (Room B).
Phase 1 Phase 2
ADG ADFI ADG ADFI
Pen Trt Rep (g) (g) G:F (g) (g) G:F
2B 1 7 170 213 .796 402 547 .736
3B 2 7 119 186 .639 381 551 .692
4B 2 8 217 222 .980 440 595 .740
5B 4 8 109 182 .600 378 507 .746
6B 1 9 143 196 .731 425 563 .756
7B 2 9 175 187 .937 459 563 .816
9B 4 7 118 184 .640 431 547 .788
lOB 3 7 131 190 .689 415 523 .794
lIB 1 8 168 215 .784 440 590 .747
12B 3 8 153 199 .767 388 521 .745
13B 4 9 153 202 .753 442 577 .766
14B 3 9 149 188 .792 385 526 .733
22B 2 10 192 215 .890 336 563 .725
23B 4 10 186 208 .893 413 549 .752
24B 1 11 16 ] 204 .787 370 509 .728
25B 4 11 169 173 .974 348 459 .759
26B 3 12 150 194 .771 303 453 .670
27B 4 12 173 175 .990 30] 415 .725
29B 1 10 162 201 .805 315 455 .691
30B 3 10 201 225 .891 389 535 .726
31B 2 11 143 161 .893 380 478 .795
32B 3 11 177 200 .886 360 477 .755
33B 2 12 165 204 .804 369 511 .722
34B 1 12 111 144 .767 350 457 .768
Trt 1: 0% SBO and 0 ppm L-camitine
Trt 2: 0% SBO and 50 ppm L-camitine
Trt 3: 5% SBO and 0 ppm L-camitine
Trt 4: 5% SBO and 50 ppm L-camitine
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Appendix Table 67
Analysis of variance for average daily gain, average daily feed intake, and gain:feed
for Phases 1 and 2 - Experiment 3 (Room B).
Mean Squares
Phase 1 Phase 2
Source d.f. ADG ADFI G:F ADG ADFI G:F
Total 23
Error 15 729.29 328.73 0.0101 1108.26 1297.71 0.0012
Repetition 5 1120.02 588.24 0.0197 5494.62 6765.81 0.0014
Treatment 3 377.13 147.63 0.0067 437.31 572.39 0.0005
SBO 1 136.37 29.95 0.0017 562.60 1558.32 0.0001
L-camitine 1 82.47 195.80 0.0116 742.59 140.70 0.0013
Interaction 1 912.54 217.14 0.0073 6.72 18.15 0.0001
C.V.,% 17.09 9.32 12.39 8.66 6.99 4.67
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-Appendix Table 68
Pen means for average daily gain, average daily feed intake, and gain:feed for Phase
3 and overall - Experiment 3 (Room B).
Phase 3 Overall
ADG ADFI ADG ADFI
Pen Trt Rep (g) (g) G:F (g) (g) G:F
2B 1 7 490 781 .627 373 545 .684
3B 2 7 418 700 .597 326 510 .638
4B 2 8 520 872 .597 411 599 .686
5B 4 8 503 776 .649 353 520 .679
6B 1 9 431 782 .551 353 547 .646
7B 2 9 491 782 .627 396 544 .728
9B 4 7 395 661 .598 336 494 .680
lOB 3 7 500 800 .625 371 537 .691
lIB 1 8 558 890 .628 412 602 .685
12B 3 8 498 789 .632 366 535 .685
13B 4 9 523 765 .683 396 548 .722
14B 3 9 499 734 .680 365 513 .711
22B 2 10 468 783 .598 346 516 .672
23B 4 10 518 841 .616 392 567 .692
24B 1 11 494 807 .612 360 538 .669
25B 4 11 477 720 .663 349 480 .727
26B 3 12 437 712 .614 312 480 .650
27B 4 12 378 598 .632 296 420 .706
29B 1 10 435 769 .566 319 503 .633
30B 3 10 476 791 .602 371 548 .678
31B :2 11 475 780 .608 353 506 .697
32B 3 11 494 750 .660 361 505 .716
33B 2 12 451 744 .606 345 516 .669
348 1 12 442 711 .622 321 469 .686
Trt 1: 0% SBO and 0 ppm L-carnitine
Trt 2: 0% SBO and 50 ppm L-camitine
Trt 3: 5% SBO and 0 ppm L-camitine
Trt 4: 5% SBO and 50 ppm L-camitine
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LAppendix Table 69
Analysis of variance for average daily gain, average daily feed intake, and gain:feed
for Pbase 3 and Overall- Experiment 3 (Room B).
Mean Squares
Phase 3 Overall
Source d.f. ADG ADFI G:F ADG ADFI G:F
Total 23
Error IS 1393.09 2058.08 0.0007 674.31 914.10 0.0005
Repetition 5 4089.74 9348.06 0.0010 2187.49 3960.04 0.0008
Treatment 3 365.72 4442.94 0.0024 91.87 1093.00 0.0012
SBO 1 28.86 8988.46 0.0072 94.68 2569.70 0.0025
L-carnitine 1 783.70 3572.65 0.0001 5.37 458.15 0.0011
Interaction 1 284.42 767.72 0.0001 175.55 251.1 7 0.0001
C.V.,% 7.88 5.93 4.31 7.26 5.79 3.38
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Appendix Table 70
Analysis of variance for average daily gain, average daily feed intake, and gain :feed
for Phases 1 and 2 - Experiment 3 (Rooms A and B pooled).
Mean Squares
Phase I Phase 2
Source d.f. ADG ADFI G:F ADG ADFI G:F
Total 47
Error 33 949.90 709.27 0.0067 1147.16 1575.52 0.0016
Repetition 11 3779.23 2413.50 0.0233 9611.97 14128.0 0.0012
Treatment 3 441.46 69.84 0.0057 4017.65 3376.67 0.0055
SBO 1 1197.20 177.02 0.0106 5619.48 10051.4 0.0001
L-camitine I 127.01 20.44 0.0063 4825.23 12.48 0.0131
Interaction 1 0.16 12.06 0.0003 1608.23 66.08 0.0035
C.V., % 16.90 12.70 9.43 8.20 7.22 5.40
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Appendix Table 71
Analysis of variance for average daily gain, average daily feed intake, and gain:feed
for Phase 3 and Overall- Experiment 3 (Rooms A and B pooled).
Mean Squares
Phase 3 Overall
Source d.f. ADG ADFI G:F ADG ADFl G:F
Total 47
Error 33 1934.83 3894.24 0.0007 918.15 1557.70 0.0005
Repetition 11 11817.9 18074.7 0.0021 7421.14 9936.82 0.0019
Treatment 3 1813.70 8475.94 0.0025 1894.35 3259.79 0.0025
SBO 1 2146.69 24941.8 0.0046 2880.37 9687.24 0.0010
L-camitine 1 176.70 473.45 0.0008 1944.76 66.04 0.0044
Interaction 1 1530.70 12.54 0.0020 857.93 26.11 0.0021
C.V., % 8.61 7.81 4.05 7.80 7.15 3.28
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Appendix Table 72
Pen means for albumin levels - Experiment 3.
Albumin levels, g/dL
Pen TIt Rep DO D 10 D 24 D 38
2 1 1 3.00 2.45 2.35 2.60
3 2 1 3.30 2.70 2.15 2.50
4 2 2 3.05 2.65 2.55 2.95
5 4 2 3.05 2.75 2.60 2.70
6 1 3 3.10 2.45 2.60 2.80
7 2 3 2.85 2.35 2.70 2.95
9 4 I 2.70 2.65 2.15 2.25
10 3 1 2.90 2.70 2.45 2.85
11 1 2 2.60 2.20 2.35 2.70
12 3 2 2.70 2.25 2.40 2.35
13 4 3 2.90 2.45 2.60 2.50
14 3 3 2.95 2.55 2.65 2.80
22 2 4 2.80 2.45 2.50 2.50
23 4 4 2.60 2.25 2.40 2.90
24 1 5 2.80 2.25 2.05 2.85
25 4 5 2.65 2.55 2.45 2.70
26 3 6 2.75 2.30 2.65 2.60
27 4 6 2.70 2.30 2.30 2.50
29 1 4 2.70 2.30 2.70 2.65
30 3 4 3.15 2.35 2.50 2.55
31 2 5 2.50 2.45 2.45 2.75
32 3 5 2.70 2.50 2.45 2.75
33 2 6 2.30 2.30 2.75 2.70
34 I 6 2.70 2.25 2.15 2.60
Trt 1: 0% SBO and 0 ppm L-carnitine
TIt 2: 0% SBO and 50 ppm L-carnitine
Trt 3: 5% SBO and 0 ppm L-carnitine
Trt 4: 5% SBO and 50 ppm L-carnitine
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Appendix Table 73
Analysis of variance for albumin levels - Experiment 3.
Source d.f. DO
Mean Squares
D 10 D 24 D 38
Total
Error
Repetition
Treatment
SBO
L-carnitine
Interaction
C.V.,%
23
15
5
3
1
1
I
0.0474653
0.0873542
0.0087153
0.0001042
0.0176042
0.0084375
7.7521
0.0168333
0.0546667
0.0391667
0.0266667
0.0704167
0.0204167
5.3319
I78
0.0283333
0.0656667
0.0337500
0.0037500
0.0037500
0.0937500
6.8587
0.0359167
0.0294167
0.0208333
0.0504167
0.0016667
0.0104167
7.]069
Appendix Table 74
Pen means for blood urea nitrogen levels - Experiment 3.
Blood urea nitrogen levels, mg/dL
Pen Trt Rep DO D 10 D24 038
2 1 1 6.35 5.60 6.50 12.50
3 2 1 5.50 9.15 8.90 13.55
4 2 2 6.45 6.10 8.75 11.70
5 4 2 7.65 9.60 5.50 10.55
6 1 3 7.40 6.05 8.30 12.30
7 2 3 11.90 6.65 7.20 11.95
9 4 1 6.35 7.80 7.95 13.60
10 3 1 6.30 6.35 7.15 12.35
11 1 2 4.30 6.95 7.20 10.75
12 3 2 6.85 8.30 8.10 11.90
13 4 3 7.00 2.80 5.20 9.95
14 3 3 5.65 13.00 9.35 13.30
22 2 4 5.30 7.30 7.60 13.90
23 4 4 9.80 5.10 6.70 11.50
24 1 5 9.30 5.60 6.65 13.20
25 4 5 9.80 6.80 7.05 10.05
26 3 6 5.55 6.60 8.45 11.95
27 4 6 4.85 4.75 5.45 10.90
29 1 4 4.90 2.80 7.05 11.95
30 3 4 8.50 4.35 6.25 9.60
31 2 5 7.40 10.15 9.40 15.05
32 3 5 8.80 4.85 7.60 12.80
33 2 6 6.90 5.25 10.00 9.80
34 1 6 5.55 9.80 9.60 15.00
Trt 1: 0% SBa and 0 ppm L-camitine
Trt 2: 0% SBa and 50 ppm L-camitine
Trt 3: 5% SBa and 0 ppm L-camitine
Trt 4: 5% SBa and 50 ppm L-camitine
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Appendix Table 75
Analysis of variance for blood urea nitrogen levels - Experiment 3.
Source d.f. DO
Mean Squares
D 10 D 24 038
Total
Error
Repetition
Treatment
SBO
L-camitine
Interaction
C.V.,%
23
15
5
3
1
1
1
3.0809097
5.7728512
1.7631597
3.7209375
1.4259375
0.1426042
25.0229
6.8555556
3.8735000
2.9168056
0.0600000
0.0504167
8.6400000
38.8618
180
1.3279444
0.9176667
5.6023611
0.2604167
6.4066667
10.1400000
15.2044
2.4080556
1.7980000
3.2168056
1.0837500
7.2600000
1.3066667
12.8380
Appendix Table 76
Pen means for C-reactive protein levels - Experiment 3.
C-reactive protein levels, mg/L
Pen Trt Rep DO D 10 D24 D 38
2 1 1 1.10 4.36 7.02 6.44
3 2 1 1.10 3.53 4.19 4.63
4 2 2 1.85 2.18 4.29 3.54
5 4 2 1.10 1.74 3.67 5.11
6 1 3 1.10 2.30 4.67 2.47
7 2 3 1.50 4.58 11.36 4.83
9 4 1 1.10 2.94 3.76 4.20
10 3 1 4.26 5.61 11.38 7.66
11 1 2 1.10 2.41 4.57 3.62
12 3 2 1.10 2.39 2.97 4.50
13 4 3 1.10 1.66 5.82 3.53
14 3 3 2.46 4.37 3.36 3.80
22 2 4 7.63 3.08 5.73 6.59
23 4 4 1.83 1.85 5.68 4.14
24 1 5 1.10 5.14 4.67 4.80
25 4 5 2.60 1.92 4.55 6.39
26 3 6 1.25 1.10 3.28 2.86
27 4 6 2.96 2.11 3.02 2.42
29 1 4 1.59 1.31 11.46
30 3 4 1.78 1.39 1.89 8.79
31 2 5 3.48 2.61 4.87 6.70
32 3 5 1.72 3.00 2.43
33 2 6 6.92 6.42 6.95 4.89
34 1 6 1.10 6.19 2.71 4.43
Trt 1: 0% SBO and 0 ppm L-camitine
Trt 2: 0% SBO and 50 ppm L-camitine
Trt 3: 5% SBO and 0 ppm L-camitine
Trt 4: 5% SBO and 50 ppm L-carnitine
Dashes indicate data for this variable not included in analysis due to poor pig
performance.
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Appendix Table 77
Analysis of variance for C-reactive protein levels - Experiment 3.
Mean Squares
Source d.f. DO d.f. D 10 D24 D 38
Total 21 23
Error 13 2.92690 15 2.05548 5.97092 3.48845
Repetition 5 2.57430 5 3.13783 6.84560 9.88343
Treatment 3 6.21393 3 3.90838 5.68719 1.63740
SBO 1 1.61297 1 10.12700 4.13340 3.06020
L-camitine 1 5.34668 1 0.65010 7.10682 1.64850
Interaction 1 10.44810 1 0.94804 5.82135 0.20350
C.V., % 76.0057 47.0128 51.1202 37.2833
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Appendix Table 78
Pen means for glucose levels - Experiment 3.
Glucose levels, mg/dL
Pen Trt Rep DO o 10 024 038
2 1 1 132.0 95.0 106.5 120.0
3 2 1 131.5 103.5 93.0 123.0
4 2 2 123.0 106.0 107.5 129.0
5 4 2 151.5 98.0 135.5 113.0
6 1 3 127.0 120.0 113.5 128.5
7 2 3 136.0 115.5 108.0 107.5
9 4 1 142.5 88.0 83.0 119.5
10 3 1 120.5 93.5 112.0 114.5
1I 1 2 129.0 108.5 115.0 118.5
12 3 2 120.5 96.0 126.0 131.0
13 4 3 234.5 128.0 108.5 136.5
14 3 3 128.5 93.5 104.0 113.5
22 2 4 151.0 96.5 113.0 118.5
23 4 4 124.0 108.5 95.0 121.5
24 I 5 131.0 108.0 88.5 107.5
25 4 5 I 10.5 102.5 116.5 115.5
26 3 6 123.5 101.5 106.5 137.5
27 4 6 149.0 113.5 108.5 134. (J
29 1 4 149.0 111.0 119.0 110.5
30 3 4 157.5 81.0 100.5 108.0
31 2 5 124.5 88.5 104.5 102.0
32 3 5 123.0 116.0 116.5 126.5
33 2 6 130.0 113.0 103.5 174.0
34 1 6 123.5 80.5 100.0 127.0
Trt 1: 0% SBO and 0 ppm L-camitine
Trt 2: 0% SBO and 50 ppm L-camitine
Trt 3: 5% SBO and 0 ppm L-carnitine
Trt 4: 5% SBO and 50 ppm L-camitine
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Appendix Table 79
Analysis of vari ance for glucose levels - Experiment 3.
Source d.f. DO
Mean Squares
D 10 D 24 D 38
Total
Error
Repetition
Treatment
SBO
L-carnitine
Interaction
C.V.,%
23
15
5
3
1
1
1
553.61667
608.60000
666.79167
400.16667
852.04167
748.16667
17.2535
151.41389
165.07500
99.63889
28.16667
135.37500
135.37500
11.9757
184
122.67431
217.16875
36.98264
68.34375
41.34375
1.26042
10.2852
161.84722
473.32500
51.59722
1.04167
108.37500
45.37500
10.3959
Appendix Table 80
Pen means for Don-esterified fatty acid levels - Experiment 3.
Non-esterified fatty acid levels, mmollL
Pen Trt Rep DO D 10 D 24 D 38
2 1 1 0.405 0.085 0.140 0.070
3 2 1 0.315 0.070 0.090 0.055
4 2 2 0.260 0.110 0.100 0.055
5 4 2 0.380 0.080 0.190 0.085
6 1 3 0.355 0.045 0.105 0.065
7 2 3 0.455 0.050 0.165 0.065
9 4 1 0.310 0.170 0.150 0.080
10 3 1 0.525 0.175 0.125 0.160
11 1 2 0.235 0.125 0.045 0.040
12 3 2 0.485 0.120 0.095 0.065
13 4 3 0.160 0.080 0.070 0.045
14 3 3 0.125 0.220 0.10U 0.070
22 2 4 0.360 0.075 0.120 0.040
23 4 4 0.240 0.065 0.090 0.105
24 1 5 0.385 0.050 0.085 0.090
25 4 5 0.405 0.095 0.095 0.170
26 3 6 0.285 0.160 0.105 0.080
27 4 6 0.355 0.130 0.085 0.070
29 1 4 0.170 0.085 0.055 (J.030
30 3 4 0.275 0.130 U.125 0.155
31 2 5 0.260 0.160 0.180 0.070
32 3 5 0.470 0.220 0.090 0.095
33 2 6 0.260 0.090 0.070 0.055
34 1 6 0.625 0.190 0.105 0.060
Trt 1: 0% SBO and 0 ppm L-camitine
Trt 2: 0% SBO and 50 ppm L-camitine
Trt 3: 5% SBO and 0 ppm L-camitine
Trt 4: 5% SBO and 50 ppm L-camitine
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Appendix Table 81
Analysis of variance for non-esterified fatty acid levels - Experiment 3.
Source d.f. DO
Mean Squares
D 10 D 24 D 38
--.-
Total
Error
Repetition
Treatment
SBO
L-camitine
Interaction
C.V" %
23
15
5
3
1
1
1
0.017110
0.012985
0.004775
0.000204
0.014017
0.000104
38.7571
0.002046
0.001687
0.008186
0.010838
0.007704
0.006017
39.0509
186
0.001638
0.000598
0.001097
0.000150
0.002204
0.000938
37.6492
0.000953
0.001354
0.003409
0.009801
0.000301
0.000126
39.5085
Appendix Table 82
Pen means for protein levels - Experiment 3.
Protein levels, g/dL
Pen Trt Rep DO D 10 D 24 D 38
2 1 1 5.40 4.80 5.05 4.70
3 2 1 5.40 5.00 4.60 4.50
4 2 2 5.35 4.80 4.65 4.70
5 4 2 5.70 5.10 4.95 4.80
6 1 3 5.30 4.70 4.95 4.85
7 2 3 5.85 4.55 5.05 5.65
9 4 1 4.75 4.80 4.50 4.45
10 3 1 5.75 5.00 4.80 4.90
11 1 2 5.20 4.45 4.65 4.25
12 3 2 5.15 4.70 4.45 4.35
13 4 3 5.30 4.65 4.80 4.60
14 3 3 5.90 5.15 5.05 4.60
22 2 4 5.50 4.45 5.00 4.60
23 4 4 5.00 4.35 4.30 4.60
24 1 5 5.00 4.20 3.35 4.60
25 4 5 5.20 4.75 4.20 4.55
26 3 6 5.20 4.40 4.15 4.70
27 4 6 5.30 4.30 3.50 4.20
29 1 4 4.60 4.25 4.25 5.20
30 3 4 5.60 4.30 3.90 4.60
31 2 5 4.85 4.50 4.30 4.80
32 3 5 5.00 4.50 4.00 4.75
33 2 6 5.50 4.65 4.80 5.15
34 1 6 5.00 4.45 3.40 4.80
Trt 1: 0% SBO and 0 ppm L-cami tine
Trt 2: 0% SBO and 50 ppm L-carnitine
Trt 3: 5% SBO and 0 ppm L-camitine
Trt 4: 5% SBO and 50 ppm L-camitine
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Appendix Table 83
Analysis of variance for protein levels - Experiment 3.
Source d.f. DO
Mean Squares
D 10 D 24 D 38
..
Total
Error
Repetition
Treatment
SSO
L-camitine
Interaction
C.V.,%
23
15
5
3
1
1
1
0.0917500
0.1479167
0.1675000
0.0337500
0.0150000
0.4537500
5.7332
0.0363889
0.1961667
0.0538889
0.0600000
0.0416667
0.0600000
4.1320
0.1385486
0.7029375
0.2395486
0.0876042
0.2926042
0.3384375
8.3763
0.0952222
0.0706667
0.1426389
0.3037500
0.0037500
0.1204167
6.5597
Appendix Table 84
Pen means for triglyceride levels - Experiment 3.
Triglyceride levels, mg/dL
Pen Tn Rep DO D 10 D 24 D 38
2 1 1 154.5 38.0 40.0 44.5
3 2 1 104.0 27.0 35.0 18.0
4 2 2 88.5 28.5 34.5 27.5
5 4 2 175.0 26.5 37.5 38.5
6 1 3 121.5 31.5 32.5 34.5
7 2 3 80.5 34.0 35.0 53.0
9 4 1 139.5 36.0 55.5 55.0
10 3 1 73.5 37.0 20.5 35.0
11 1 2 60.5 29.5 29.5 26.5
12 3 2 89.0 26.0 41.5 40.5
13 4 3 84.0 57.0 35.0 32.5
14 3 3 60.5 52.5 35.5 45.5
22 2 4 50.0 31.0 44.5 45,0
23 4 4 99.5 39.5 40.0 57.0
24 1 5 103.0 34.5 40.0 71.5
25 4 5 76.5 41.0 36.0 53.5
26 3 6 90.5 38.0 44.0 4(>.5
27 4 6 98.0 32.5 33.5 58.0
29 1 4 45.0 39.5 57.5 24.0
30 3 4 86.0 28.0 50.0 36.5
3] 2 5 65.5 38.5 36.0 32.5
32 3 5 158.0 37.5 43.0 46.5
33 2 6 72.0 35.0 48.0 40.5
34 1 6 104.5 26.0 30.0 59.0
Trt 1: 0% SBQ and 0 ppm L-camitine
Tn2: 0% SBQ and 50 ppm L-camitine
Tn3: 5% SBQ and 0 ppm L-camitine
Tn4: 5% SBQ and 50 ppm L-camitine
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Appendix Table 85
Analysis of variance for triglyceride levels - Experiment 3.
Source d.f. DO
Mean Squares
D 10 D 24 D 38
Total
Error
Repetition
Treatment
SBO
L-camitine
Interaction
c.Y., %
23
15
5
3
1
1
1
1155.4132
1061.8854
1278.5382
1357.5104
7.5938
2470.5104
35.7882
41.79653
115.21875
53.28819
142.59375
3.01042
14.26042
18.3731
190
74.96042
90.74375
1.84375
3.76042
1.76042
0.01042
22.2356
151.7188
203.1688
171.5104
195.5104
0.0104
319.0104
28.9396
Appendix Table 86
Pen means for average daily gain, average daily feed intake, and gain:feed for
Phases 1 and 2 - Experiment 4 (Room A).
Phase 1 Phase 2
ADG ADFI ADG ADFI
Pen Trt Rep (g) (g) G:F (g) (g) G:F
IA 2 5 61 97 .627 249 284 .878
2A 2 3 172 204 .844 347 480 .724
3A 5 3 123 149 .826 346 402 .860
4A 4 3 179 196 .915 296 397 .746
SA 3 3 203 228 .893 392 507 .773
6A 1 3 86 128 .672 343 436 .787
7A 4 5 119 130 .911 330 387 .855
8A 3 5 150 138 1.088 293 387 .757
9A 1 4 122 156 .785 307 421 .729
lOA 2 4 102 119 .854 320 400 .801
llA 4 4 184 200 .923 369 476 .775
12A 5 4 57 101 .563 321 360 .892
13A 3 4 139 172 .806 261 374 .698
14A 5 5 105 104 1.011 271 321 .845
15A 5 1 75 107 .699 442 505 .876
16A 2 1 122 183 .668 429 551 .779
17A 4 1 105 167 .628 455 568 .801
18A 3 1 100 145 .693 413 483 .855
19A 1 1 75 135 .555 445 603 .737
20A 1 2 117 140 .840 414 498 .832
21A 3 2 166 196 .847 383 472 .810
22A 4 2 120 198 .609 319 441 .725
23A 5 2 177 202 .883 461 533 .867
24A 2 2 165 186 .891 415 486 .853
Trt 1: Control diet
Trt 2: Control diet + 5% SBO and 0 ppm L-camitine
Trt 3: Control diet + 5% SBO and 50 ppm L-camitine
Trt 4: Control diet + 5% CO and 0 ppm L-camitine
Trt 5: Control diet + 5% CO and 50 ppm L-camitine
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Appendix Table 87
Analysis of variance for average daily gain, average daily feed intake, and gain:feed
for Phases 1 and 2 - Experiment 4 (Room A).
Mean Squares
Phase 1 Phase 2
Source d.f. ADG ADFI G:F ADG ADFI G:F
Total 23
Error 15 1115.25 685.76 0.0175 1660.50 2337.15 0.0025
Repetition 4 3362.50 3868.76 0.0382 17047.8 24219.6 0.0024
Treatment 4 2513.56 2524.07 0.0097 297.88 1070.17 0.0073
Fat 1 4355.68 3367.01 0.0161 57.05 1991.21 0.0031
L-camitine 1 56.68 953.99 0.0096 135.41 793.04 0.0044
Interaction 1 4723.20 5123.52 0.0010 413.69 1429.74 0.0168
Fat Source 1 918.69 651.74 0.0030 585.36 66.69 0.0049
C.V.,% 26.49 16.64 16.66 11.34 10.77 6.24
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Appendix Table 88
Pen means for average daily gain, average daily feed intake, and gain :feed for Phase
3 and overall- Experiment 4 (Room A).
Phase 3 Overall
ADG ADFI ADG ADFI
Pen Trt Rep (g) (g) G:F (g) (g) G:F
lA 2 5 369 524 .705 230 306 .752
2A 2 3 501 782 .640 344 496 .694
3A 5 3 474 637 .745 319 402 .794
4A 4 3 476 665 .716 321 425 .755
5A 3 3 554 815 .680 387 524 .740
6A 1 3 534 807 .661 327 465 .703
7A 4 5 512 715 .716 325 417 .779
8A 3 5 462 691 .669 305 412 .742
9A 1 4 369 604 .612 270 399 .675
lOA 2 4 474 688 .689 290 389 .746
llA 4 4 553 800 .691 373 499 .748
12A 5 4 486 666 .729 294 383 .767
13A 3 4 417 613 .681 276 392 .704
14A 5 5 438 585 .749 275 342 .805
15A 5 1 575 870 .661 371 503 .737
16A 2 1 549 869 .632 372 543 .686
17A 4 1 468 785 .596 348 515 .677
18A 3 1 596 919 .649 376 524 .717
19A 1 1 606 997 .608 383 589 .649
20A 1 2 580 839 .692 377 501 .752
21A 3 2 452 763 .592 338 484 .698
22A 4 2 423 723 .584 292 460 .634
23A 5 2 544 794 .684 400 517 .773
24A 2 2 612 861 .711 403 519 .777
Trt 1: Control diet
Trt 2: Control diet + 5% SSO and 0 ppm L-camitine
Trt 3: Control diet + 5% SBO and 50 ppm L-camitine
Trt 4: Control diet + 5% CO and 0 ppm L-camitine
Trt 5: Control diet + 5% CO and 50 ppm L-camitine
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Appendix Table 89
Analysis of variance for average daily gain, average daily feed intake, and gain:feed
for Phase 3 and overall- Experiment 4 (Room A).
Mean Squares
Phase 3 Overall
Source d.f. ADG ADFI G:F ADG ADFI G:F
Total 23
Error 15 4848.38 6709.36 0.0015 1640.98 2010.83 0.0013
Repetition 4 9556.80 45640.2 0.0042 6506.21 18795.8 0.0028
Treatment 4 346.16 3299.19 0.0031 65.56 1255.62 0.0035
Fat 1 518.21 6772.86 0.0019 81.93 737.63 0.0035
L-camitine 1 194.50 170.47 0.0013 88.20 360.49 0.0026
Interaction 1 600.28 2248.68 0.0069 90.65 3162.36 0.0057
Fat Source 1 71.63 4004.73 0.0025 1.44 762.00 0.0023
C.V., % 13.90 10.91 5.76 12.16 9.78 5.01
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Appendix Table 90
Pen means for average daily gain, average daily feed intake, and gain:feed for
Phases 1 and 2 - Experiment 4 (Room B).
Phase 1 Phase 2
ADG ADFI ADG ADFI
Pen Trt Rep (g) (g) G:F (g) (g) G:F
IB 4 10 90 109 .825 310 390 .794
2B 1 8 117 122 .955 356 453 .787
3B 4 8 116 153 .758 348 437 .796
4B 5 8 145 162 .894 356 472 .755
5B 3 8 122 168 .730 328 407 .806
6B 2 8 73 152 .476 380 477 .797
7B 3 10 152 188 .812 316 414 .764
8B 2 10 132 164 .801 259 379 .084
9B 3 9 112 141 .794 319 404 .790
lOB 2 9 129 159 .812 314 396 .794
11B 4 9 122 143 .848 297 373 .798
12B 5 9 114 142 .808 333 447 .745
13B 1 9 136 153 .887 373 467 .799
14B 5 10 104 142 .733 341 427 .798
15B 3 6 145 190 .766 370 482 .767
16B 5 6 154 174 .886 402 520 .772
17B 1 6 87 13] .667 413 511 .808
18B 4 6 125 ]79 .700 392 540 .726
19B 2 6 115 173 .665 3R6 472 .818
20B 4 7 117 168 .697 445 527 .844
21B 5 7 93 141 .658 340 455 .746
22B 1 7 127 169 .752 386 487 .791
23B 2 7 103 158 .649 374 484 .772
24B 3 7 170 229 .742 383 499 .767
Trt 1: Control diet
Trt 2: Control diet + 5% SBQ and 0 ppm L-camitine
Trt 3: Control diet + 5% SBQ and 50 ppm L-camitinc
Trt 4: Control diet + 5% CO and 0 ppm L-camitine
Trt 5: Control diet + 5% CO and 50 ppm L-camitine
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Appendix Table 91
Analysis of variance for average daily gain, average daily feed intake, and gain:feed
for Phases 1 and 2 - Experiment 4 (Room B).
Mean Squares
Phase 1 Phase 2
Source d.f. ADG ADFI G:F ADG ADFl G:F
Total 23
Error 15 606.52 441.71 0.0091 837.11 910.83 0.0013
Repetition 4 82.80 739.72 0.0133 5721.84 8789.13 0.0004
Treatment 4 695.70 1173.56 0.0136 609.08 701.25 0.0007
Fat 1 90.84 1362.90 0.0168 1507.80 993.35 0.0008
L-carnitine 1 1832.46 684.68 0.0175 14.78 141.09 0.0006
Interaction 1 602.58 488.86 0.0042 27.19 162.68 0.0015
Fat Source 1 256.90 2157.80 0.0157 886.58 1507.89 0.0001
C.V., % 20.39 13.24 12.54 8.15 6.63 4.69
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Appendix Table 92
Pen means for average daily gain, average daily feed intake, and gain:feed for Phase
3 and overall- Experiment 4 (Room B).
Phase 3 Overall
ADG ADFI ADG ADFI
Pen Trt Rep (g) (g) G:F (g) (g) G:F
IB 4 10 426 614 .694 295 398 .739
2B 1 8 440 713 .617 324 462 .702
3B 4 8 457 677 .675 327 451 .725
4B 5 8 494 735 .671 351 488 .720
5B 3 8 451 707 .638 319 455 .702
6B 2 8 484 778 .623 339 498 .680
7B 3 10 400 654 .612 304 443 .687
8B 2 10 480 694 .691 307 439 .69<)
9B 3 9 422 618 .683 302 414 .731
lOB 2 9 447 636 .703 314 422 .745
lIB 4 9 461 662 .696 311 419 .743
12B 5 9 464 688 .675 311 436 .713
DB 1 9 469 736 .637 346 484 .716
14B 5 10 451 666 .677 319 440 .725
15B 3 6 530 810 .654 370 526 .703
16B 5 6 558 779 .716 394 525 .751
17B 1 6 468 810 .578 348 521 .667
18B 4 6 597 993 .601 397 612 .649
19B 2 6 517 810 .638 351 495 .709
20B 4 7 501 757 .662 379 517 .733
21B 5 7 528 757 .698 344 483 .712
22B 1 7 542 864 .627 375 542 .692
23B 2 7 489 741 .660 345 493 .700
24B 3 7 511 787 .649 374 534 .700
Trt 1: Control diet
Trt 2: Control diet + 5% SBO and 0 ppm L-camitine
Trt 3: Control diet + 5% SBO and 50 ppm L-camitine
Trt 4: Control diet + 5% CO and 0 ppm L-camitine
Trt 5: Control diet + 5% CO and 50 ppm L-carnitine
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Appendix Table 93
Analysis of variance for average daily gain, average daily feed intake, and gain :feed
for Phase 3 and overall- Experiment 4 (Room B).
Mean Squares
Phase 3 Overall
Source d.f. ADG ADFI G:F ADG ADFI G:F
Total 23
Error 15 920.68 3420.60 0.0008 327.92 1044.41 0.0006
Repetition 4 8080.75 27081.8 0.0013 3749.24 10030.3 0.0008
Treatment 4 1036.39 1391.95 0.0031 147.19 287.96 0.0006
Fat 1 692.55 3852.53 0.0081 22.70 898.34 0.0012
L-camitine 1 120.49 1288.98 0.0001 28.54 0.04 0.0001
Interaction 1 1232.29 1.43 0.0018 0.59 123.01 0.0001
Fat Source 1 2100.23 424.86 0.0023 536.96 130.46 0.0012
C.V., % 6.29 7.94 4.25 5.33 6.75 3.38
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Appendix Table 94
Analysis of variance for average daily gain, average daily feed intake, and gain:feed
for Phases 1 and 2 - Experiment 4 (Rooms A and B pooled).
Mean Squares
Phase 1 Phase 2
Source d.f. ADG ADFI G:F ADG ADFI G:F
Total 47
Error 34 875.45 594.29 0.0132 1129.86 1529.12 0.0024
Repetition 9 1519.73 2027.96 0.0250 10110.9 14783.9 0.0021
Treatment 4 2224.53 2874.43 0.0101 669.21 953.84 0.0020
Fat 1 2852.30 4507.13 0.0001 1075.73 2898.68 0.0004
L-camitine 1 622.28 11.14 0.0266 30.38 132.57 0.0008
Interaction 1 4349.94 4388.82 0.0136 114.38 313.94 0.0042
Fat Source 1 1073.61 2590.65 0.0025 1456.37 470.18 0.0027
C.V.,% 23.97 15.42 14.78 9.41 8.65 6.19
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Appendix Table 95
Analysis of variance for average daily gain, average daily feed intake, and gain:feed
for Phase 3 and overall- Experiment 4 (Rooms A and B pooled).
Mean Squares
Phase 3 Overall
Source d.f. ADG ADFI G:F ADG ADFI G:F
Total 47
Error 34 2634.73 4621.05 0.0011 881.54 ]405.57 0.00] 0
Repetition 9 8307.91 32628.0 0.0026 4602.90 13376.2 0.0021
Treatment 4 621.28 3399.53 0.0056 103.02 1053.40 0.0032
Fat 1 6.31 10420.8 0.0089 9.19 1632.0] 0.0044
L-camitine 1 4.41 1198.48 0.0009 108.54 184.26 0.0016
Interaction 1 1776.36 1068.43 0.0078 52.92 2266.38 0.0036
Fat Source 1 698.06 910.40 0.0048 241.42 130.94 0.0034
C.V., % 10.44 9.14 4.93 8.23 8.00 4.28
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